Studies and Synthesis of Syringolin A, Functionalized Thiadiazines, and Thiol Additions to Enones by Rosenker, Christopher J
 STUDIES AND SYNTHESIS OF SYRINGOLIN A, FUNCTIONALIZED 
THIADIAZINES, AND THIOL ADDITIONS TO ENONES 
 
 
 
 
 
 
 
 
by 
Christopher Joseph Rosenker 
B.S., Juniata College, 2007 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
The Kenneth P. Dietrich School of Arts and Sciences in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2013 
 
 ii 
UNIVERSITY OF PITTSBURGH 
THE KENNETH P. DIETRICH SCHOOL OF ARTS AND SCIENCES  
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Christopher Joseph Rosenker 
 
 
 
It was defended on 
December 10th 2012 
and approved by 
Billy W. Day, Professor, Department of Chemistry 
Scott G. Nelson, Professor, Department of Chemistry 
Barry Gold, Professor, Department of Pharmaceutical Sciences 
Dissertation Advisor: Peter Wipf, Distinguished University Professor, Department of 
Chemistry 
 
 
 iii 
Copyright © by Christopher Joseph Rosenker 
2013 
 iv 
 
Part one of this dissertation describes the formal synthesis of syringolin A.  Syringolin A 
contains a unique 12-membered dipeptide core and has been shown to be a potent irreversible 
proteasome inhibitor.  Completion of the formal synthesis of syringolin A was facilitated by the 
rapid access to non-proteinogenic α,β-unsaturated-γ-amino acid and α-amino acid fragments with 
complete stereochemical control utilizing the stereoselective addition of alkenylorganometallic 
reagents to chiral N-tert-butanesulfinylimines. 
Part two discusses the development of a robust strategy for the preparation and selective 
functionalization of heterocyclic thiadiazines with four points of diversity.  Hydrolysis of the 
pendant C-4 ester and functionalization of the resulting acid provided access to a small library of 
highly substituted thiadiazine analogues that exhibit favorable physicochemical properties for 
drug-like compounds. 
Part three describes the investigation of the equilibria of thiophenol conjugate additions 
to enone-containing indole scaffolds.  Our studies indicate that mono-β-substituted enones form 
thermodynamically favorable adducts with thiophenol.  We also found that thiol eliminations to 
form enones are favorable in the presence of DBU but not Et3N.  These experiments suggest that 
mono-β-substituted enones could be used as irreversible covalent protein modifiers. 
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1.0  FORMAL TOTAL SYNTHESIS OF SYRINGOLIN A 
1.1 INTRODUCTION 
1.1.1 Isolation and Structure 
Syringolin A (1-1) was isolated from the bacterial plant pathogen Pseudomonas syringae pv. 
syringae (Pss) and initially shown to elicit the release of the defense-related Pir7b gene 
(encoding for an α/β hydrolase fold protein)1 in rice plants.2 The structure was deduced via mass 
spectrometry and 1D/2D homo- and hetero-nuclear NMR experiments.  The central 12-
membered ring contains two non-proteinogenic amino acids, 5-methyl-4-amino-2-hexenoic acid 
(an α,β-unsaturated-γ-amino acid) and 3,4-dehydrolysine (an α-amino acid), both containing (E)-
olefins.  The olefin configuration was assigned by 1H NMR coupling constant analysis (J = 16 
Hz).  The α-amino acid is appended with a valine-urea-valine side chain.  Further analysis of the 
Pss culture found structurally related natural products which differ from syringolin A by 
substitution of isoleucine for valine and lysine for 3,4-dehydrolysine (Figure 1).3 Syringolin A 
accounts for over 60% of the relative abundance of the syringolins isolated from the culture 
broth.  Interesting to note is that two expected minor variants of syringolin B (1-2), where the 
valine proximal to the core is replaced by isoleucine (syringolin H) and where both valines in the 
side chain are replaced by isoleucines (syringolin G), were not isolated.  However, in 2012 
 2 
Müller and coworkers cloned a syringolin biosynthetic gene (sylCDE) and expressed it in E. coli, 
which led to the discovery and isolation of the previously expected but not isolated natural 
products syringolin G and H.4 
 
 
Figure 1. Structures of the syringolin family of natural products. 
 
Syringolin A and a number of structurally similar, bioactive, peptide-based natural 
products have been collectively called syrbactins.5 This family of natural products includes the 
glidobactins, isolated from bacterium Polyangium brachysporum sp. nov.,6 cepafungins, isolated 
from the bacterium Pseudomonas sp.,7 and luminmycin A, generated by heterologous expression 
of silent biosynthetic gene clusters in Photorhabdus luminescens (Figure 2).8 The major 
differences between the glidobactins/luminmycin A and cepafungins are found in the fatty acid 
side chains; however, compared to syringolin A, they lack the 3,4-dehydrolysine moiety and 
contain either an alanine or serine based α,β-unsaturated-γ-amino acid. 
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Figure 2.  Structures of glidobactin A (1-3)/cepafungin II, glidobactin G, and luminmycin A of the 
syrbactin family of natural products. 
1.1.2 Biological Activity 
The initial discovery and isolation of syringolin A from the culture extracts of Pss was prompted 
by a marked increase of the defense-related Pir7b gene (encoding for an α/β hydrolase fold 
protein)1 in rice plants inoculated with Pss.2-3, 9 Later, it was found that syringolin A (1-1) 
completely eliminated powdery mildew in wheat plants, and, furthermore, protected wheat plants 
against future inoculation.10 Interestingly, syringolin A, unlike the glidobactins and cepafungins, 
does not exhibit fungicidal activity, and therefore its mechanism of action against powdery 
mildew was hypothesized to be a result of an increase in pathogenesis-related gene transcripts 
which decline after an untreated infection.10-11 In human neuroblastoma and ovarian cancer cell 
lines, syringolin A has been shown to induce apoptosis and increase the tumor suppressor protein 
p53 at µM concentrations.12 In 2008, syrbactins syringolin A and glidobactin A (1-3) were 
shown to be potent irreversible proteasome inhibitors.5 The proteasome plays a central role in the 
degradation of proteins via the ubiquitin-proteasome pathway and represents a significant 
regulatory checkpoint in many biological processes, including cell division, immune and 
inflammatory responses, embryonic development, and apoptosis.13 Bortezomib (Velcade®, PS-
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341), a reversible covalent proteasome inhibitor, is currently the only proteasome inhibitor 
approved by the FDA (since 2003) and is used for the treatment of relapsed multiple myeloma.13h  
The 20S proteasome is composed of three catalytic subunits, caspase-like (β1), trypsin-like (β2), 
and chymotrypsin-like (β5) proteolytic activities.  Syringolin A exhibits inhibition (Ki) at high 
nM concentrations for the chymotrypsin-like subunit and at low μM concentrations for the 
trypsin-like subunit.  Glidobactin A shows similar activity for the trypsin-like subunit; however, 
inhibition of the chymotrypsin-like subunit was seen at 49 nM. 
In order to gain more understanding of the binding mode of syringolin A (1-1), a crystal 
structure of syringolin A bound to the yeast 20S proteasome was obtained.5 This structure 
revealed a unique covalent binding mode resulting from a conjugate addition of the N-terminal 
threonine oxygen (Thr 1 O) onto the α,β-unsaturated-γ-amino acid, confirming that syringolin A 
was acting as an irreversible proteasome inhibitor (Scheme 1, Figure 3).  Groll and coworkers 
proposed that the conjugate addition was facilitated, among other factors, by the stabilization of 
the enol intermediate by the oxyanion hole of a glycine adjacent to the binding site (Gly 47 N).  
Thermodynamically, conjugate addition releases some ring strain in the 12-membered ring by 
eliminating the two sp2-hybridized carbons of the (E)-olefin.  Additionally, the covalent binding 
is entropically favored, compared to more flexible ligands, based upon the initial rigidity of the 
12-membered ring.5 Furthermore, the dipeptide moiety containing the 3,4-dehydrolysine and 
proximal valine (blue in Scheme 1) creates an antiparallel β-sheet interaction in the substrate 
binding channel, thus effectively increasing binding pocket residence time and thereby 
facilitating covalent binding. 
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Scheme 1.  Syringolin A and a schematic of the mechanism of irreversible proteasome binding (α,β-
unsaturated carbonyl (red), active site specificity determinants (green), and dipeptide binding site stabilizing moiety 
(blue)). 
 
 
Figure 3.  Details of the crystal structure of syringolin A (1-1) covalently bound to the proteasome via Thr 
1 O (Figure was prepared in Pymol (Delano Scientific, Inc.) using PDB code 2ZCY). 
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1.1.3 Biosynthesis of Syringolin A 
A model for the biosynthetic pathway of syringolin A was proposed after functional analysis of 
the genes in Pss which encode for proteins consisting of three distinct non-ribosomal peptide 
synthetase (NRPS) modules and one polyketide synthetase (PKS) module (Figure 4).14 The 
NRPS are large modular enzymes that activate, condense and transfer amino acids according to 
the thiotemplate mechanism.15 The exact biosynthetic pathway for formation of the valine-urea-
valine side chain was initially unclear; however, isotopic labeling studies indicated that the 
carbon of the urea comes from bicarbonate/carbon dioxide.16 Recent in vitro studies by Walsh 
and co-workers show that biosynthetic gene SlyC is responsible for the formation of the valine-
urea-valine side chain.17 Successive condensation/activation (C/A) of the valine fragment in 
module 1 provides the dehydrolysine fragment in module 2.  The second non-proteinogenic 
amino acid is formed by coupling with valine (module 3), transfer to the polyketide synthetase 
(PKS)18 module followed by condensation of malonate (β-ketoacyl synthase, KS), acyl transfer 
(acyl transferase, AT), dehydration (dehydratase, DH), and reduction (β-ketoreductase, KR).  
The acyl carrier protein (ACP) carries the natural product precursor to a cyclization step, 
presumably occurring via thioesterase (TE), to produce syringolin A (module 4).14, 16, 19 
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Figure 4.  Biosynthetic gene cluster for the formation of syringolin A through NRPS modules 1-3 and PKS 
module 4.  Condensation (C), activation (A), and peptide carrier protein (PCP) domains are indicated as boxes and 
the β-ketoacyl synthase (KS), acyl transferase (AT), dehydratase (DH), β-ketoreductase (KR), acryl carrier protein 
(ACP) and thioesterase (TE) domains are indicated as circles.14, 16, 19 
1.1.4 Syntheses of Glidobactin A and Syringolin A 
While Nature can complete the final macrolactamization to form syringolin A and similar 
members of the syrbactin family, synthetic endeavors towards members of the syrbactin family 
demonstrate that a macrolactamization approach is difficult to achieve.  Several energetic factors 
need to be considered when performing a cyclization: Pitzer strain (imperfect staggering or 
overlapping torsional angles); Baeyer strain (deformation of ring bond angles); and transannular 
strain.  The rate of cyclization can be estimated from two factors, activation energy and 
probability of end-to-end encounters.  Activation energy is directly related to the thermodynamic 
factors noted above, because the transition state of the cyclization is product-like.  The 
probability of end-to-end encounters is related to the entropy of the transition state, which is 
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controlled by reducing the freedom of rotation (or ordering) around the single bonds during ring 
formation. 
 Synthetically, macrolactamization appears to be challenging due to the build up in 
transannular ring strain across the 12-membered macrocycle.  While investigating the structure 
of glidobactin A, Oka and coworkers synthesized the natural product from the degradation 
fragments of the natural compound;6c however, cyclization of 1-4 using DCC and HOBt at high 
dilution afforded glidobactin A in only 2.3% yield as the only reported product (Scheme 2). 
 
 
Scheme 2.  Cyclization of amino acid 1-4 confirms the structure of glidobactin A (1-3). 
 
Several years later, in 1991, Hesse and Meng attempted to synthesize the 
unfunctionalized core of glidobactin A, lacking the hydroxy group and the fatty acid side chain.20 
Their route differed from Oka and coworkers in that they chose to form the 12-membered ring 
using the lysine side chain amine; however, they were unable to close the ring using several 
different conditions,21 even when employing high dilution conditions (Scheme 3).  Failure to 
close the macrocyclic ring was rationalized by the absence of bulky substituents on the 
cyclization precursor.  In general, the presence of bulky groups decreases the relative energy 
differences between the linear and bent conformations of an acyclic precursor, and thus 
facilitates cyclization.20, 22 
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Scheme 3. Failed cyclization of 1-5 to form the protected core scaffold of glidobactin A (1-6). 
 
The inability to complete the macrolactamization led Hesse and Meng to develop another 
approach, which utilized a ring expansion strategy.20-21, 23 This approach used the reductive 
cleavage of the N-N bond of the bicyclic hydrazide 1-7 to provide the unfunctionalized core 1-8 
in promising yield (Scheme 4).  Retrosynthetically, it was envisioned that glidobamine (1-9) 
could be synthesized from hydrazide 1-10; however, the preparation of the desired hydrazinde 1-
10 from 1-11 and lactone 1-12 was not described.20-21 
 
Scheme 4.  Reductive ring opening of bicyclic hydrazides as an approach to the core of glidobamine (1-9). 
 
Meanwhile, Schmidt and coworkers utilized a similar approach to Oka and coworkers, 
forming the macrolactam from the free amine of the alanine-derived α,β-unsaturated-γ-amino 
acid fragment.24 Macrolactamization was achieved in 20% yield over three steps using a 
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pentafluorophenyl ester as the activated intermediate.  While this methodology eventually 
provided access to glidobactin A (1-3), the yield was also lower than desirable (Scheme 5). 
 
 
Scheme 5.  Macrolactamization of 1-13 through an activated pentafluorophenyl ester towards the total 
synthesis of glidobactin A (1-3). 
 
The apparent synthetic challenge to affect the desired macrolactamization in reasonable 
yields led Trost and Machajewski to investigate the application of a palladium catalyzed allylic 
alkylation.25 After significant experimentation with activated amide pronucleophiles, allylic 
leaving groups, and cyclization conditions, a suitable substrate and reaction conditions were 
found.  Treatment of 1-15 under the optimized Pd-conditions led to the formation of the desired 
macrocycle 1-16 in 65% yield (Scheme 6).  The yield of the macrocyclization was 
irreproducible; however, Trost and Machajewski found that pretreatment of hydroxamate ester 1-
15 with Pd/C before cyclization appeared to rectify the problem.  Unfortunately, reduction of the 
hydroxamate ester 1-16 to the amide could not be optimized and led to deprotection of the silyl 
ether to give alcohol 1-17, resulting in lactonization to provide 1-18.25 
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Scheme 6.  Palladium catalyzed allylic alkylation approach towards the core macrocycle 1-16 of 
glidobactin A. 
 
In 2009, Kaiser and coworkers completed a synthesis of syringolin A (1-1) and B (1-2).26 
The valine-derived α,β-unsaturated-γ-amino acid 1-18 was prepared by a Wittig reaction of the 
corresponding α-amino aldehyde with the requisite ester.  Formation of the linear dipeptide 1-19 
occurred by coupling of the lysine- and valine-based α,β-unsaturated-γ-amino acid 1-18.  
Subsequently, macrolactamization proceeded in 30% yield followed by deprotection of the 
valine-urea-valine side chain to provide syringolin B (1-2) in an overall 9 steps and 7.8% yield 
from N-Boc-valine methyl ester (Scheme 7). 
 
 
Scheme 7. Synthesis of syringolin B (1-2) by the macrolactamization of linear dipeptide 1-19. 
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Kaiser and coworkers had hoped to use syringolin B as a model system for the synthesis 
of syringolin A; however, macrolactamization of the requisite linear dipeptide 1-20 afforded 
none of the desired product 1-21 (Scheme 8).  Presumably, the failure in this step was due to the 
increase in strain energy associated with the macrolactam of syringolin A compared to syringolin 
B, stemming from the increased torsional strain and transannular interactions due to the presence 
of the second (E)-olefin.  Thus, an alternate route to close the strained 12-membered ring utilized 
the RCM of 1-24 to provide the natural product precursor 1-25.  The RCM precursor could be 
obtained from valine-derived α,β-unsaturated-γ-amino acid 1-2327 and selenide 1-22, generated 
by ring opening of homoserine lactone with phenylselenide.  It should be noted that, although not 
explicitly stated, masking of the olefin in the α,β-unsaturated-γ-amino acid fragment 1-23 was 
necessary and eliminated the possibility of forming a smaller ring during the RCM process.  
Additionally, it also pre-organized the RCM transition state, biasing toward the geometry for 
localizing the reactive termini in proximity to one another (Thorpe-Ingold effect).  Coupling to 
the side chain, deprotection of the diol and thiocarbonate formation, followed by a Corey-Winter 
reaction provided syringolin A in 16 steps and 9.1% yield from Boc-valine methyl ester. 
During our synthetic endeavors in the total synthesis of syringolin A, both Pirrung and 
coworkers28 and Stephenson and Dai29 disclosed efficient syntheses of syringolin A.  Pirrung and 
coworkers oxidized alcohol 1-26 with Dess-Martin periodinane (DMP) and cyclized the resulting 
aldehyde under Horner-Wadsworth-Emmons (HWE) olefination conditions developed by 
Helquist and Schauer30 to provide 1-27, the core of syringolin A, in good yield (Scheme 9).  In 
four steps, the core 1-27 was functionalized to finish the total synthesis of syringolin A in a total 
of 10 steps and 22% overall yield.28  Stephenson and Dai used a macrolactamization strategy to 
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close the core of syringolin A (Scheme 10).  Undeterred by reports describing the difficult nature 
of the macrolactamization,26, 31 they were able to access the natural product core 1-27 by 
cyclization of the amino acid with BOP and HOAt, albeit in low yields.  Using the 
macrolactamization strategy, the natural product could be obtained in 13 steps and a 3.5 % 
overall yield.29 
 
 
Scheme 8.  Failure of the macrolactamization approach led to the use of RCM to close 1-21, forming the 
syringolin A precursor 1-22. 
 
 
Scheme 9.  Pirrung and coworkers’ synthetic strategy for the preparation of syringolin A. 
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Scheme 10.  Synthesis of syringolin A by Stephenson and Dai. 
1.1.5 Synthetic Analogues of Syringolin and Glidobactin 
While completing the first total synthesis of syringolin A, Kaiser and coworkers prepared a 
lipophilic analogue of syringolin A, SylA-LIP (Figure 5).26, 31 SylA-LIP exhibited 9 nM activity 
for chymotrypsin-like proteasome inhibition, which is two orders of magnitude more active than 
syringolin A.  Encouraged by the increase in biological activity by appending a fatty acid side 
chain on syringolin A, Kaiser and coworkers prepared a hybrid of syringolin A and glidobactin 
A, SylA-GlbA (Figure 5).32 The hybrid molecule contained the syringolin A core macrocycle 
with the glidobactin A fatty acid side chain.  This hybrid exhibited increased proteasome 
inhibition compared to SylA-LIP and its parent natural products.32 In 2012, the same group was 
able to obtain a crystal structure of SylA-GlbA covalently bound to the proteasome.33  In 
addition, they found that the hybrid molecule exhibits proteasome inhibition on par with the 
approved drug bortezomib. 
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Figure 5.  Structures of SylA-LIP and SylA-GibA, analogues of syringolin A. 
 
SAR analysis of the syrbactins and syringolin A analogues revealed some key structural 
features that impacted the biological activity (Figure 6).34  The macrocyclic core of syringolin A, 
R1, and R3 impact the proteasome subsite selectivity.  The addition of a lipophilic group at R4 
increases the inhibitor activity.  During the SAR it also became apparent that changes to the 
configuration of the amino acids were detrimental to the biological activity. 
 
 
Figure 6.  A summary of the SAR of syringolin A analogues. 
1.1.6 Retrosynthetic Approach to Syringolin A 
Initially, we were intrigued by syringolin A (1-1) not only because of its unique biological 
activity but also by its two (E)-alkenes, which we envisioned to be accessible using methodology 
previously developed in our group.  A retrosynthetic analysis of 1-1 led us to the known 
protected valine-urea-valine 1-3726 and peptide fragments 1-35 and 1-36 that can be joined 
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together via peptide coupling and RCM to give the core structure.  Fragment 1-36 can be further 
derived from allylic amine 1-34 which could be attained through protecting group and oxidation 
state adjustments followed by an amine coupling.  Allylic amines 1-34 and 1-35 could be formed 
by utilizing our methodology involving hydrozirconation of an alkyne, transmetalation, and 
addition to a suitable imine electrophile (Scheme 11).35 
 
 
Scheme 11. Retrosynthetic analysis of syringolin A (1-1). 
 
The endgame formation of the macrolactam core via RCM and coupling of the valine-
urea-valine moiety are identical to the previously reported synthesis of syringolin A; however, as 
illustrated above in similar examples, macrolactamization appears to be quite low yielding and 
therefore this obvious disconnection was avoided.26 Our proposed synthetic route differs from 
the other syntheses of glidobactin A and syringolin A in the generation of the non-proteinogenic 
amino acids.  The core precursors, 1-34 and 1-35, were synthesized from α-amino acids, valine 
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and homoserine, respectively.26 We envisioned the synthesis of these fragments to showcase our 
methodology and expand its utility in the synthesis of non-proteinogenic α-amino- and α,β-
unsaturated-γ-amino acids. 
1.1.7 Hydrozirconation-Transmetalation Methodologies 
Alkyl- and alkenylzirconocenes can be easily prepared by the hydrozirconation36 of alkenes and 
alkynes using Schwartz reagent (Cp2ZrHCl).  In general, Schwartz reagent is moderately air-, 
moisture-, and light-sensitive, but can be conveniently prepared in situ37 or on large scale38 and 
stored for several months.  Hydrozirconation has considerable functional group compatibility, 
greatly exceeding that of the preparation of lithium and magnesium reagents, and can therefore 
provide access to various functionalized organometallic compounds.  However, the lack of 
reactivity of the resulting sterically shielded alkyl39 and alkenyl36e zirconium species with 
organic electrophiles often necessitates transmetalation in order to gain utility for organic 
synthesis (Scheme 12). 
In 1970, Wailes and Weigold first prepared zirconocene hydrochloride (Cp2ZrHCl),
40 and 
later used it for the hydrozirconation of alkenes41 and alkynes.42 Thereafter, Schwartz and 
coworkers reacted alkyl-43 and alkenylzirconocenes44 with various halide electrophiles providing 
selective access to terminally halogenated alkanes and (E)-vinyl halides.  Subsequently, 
Schwartz and Carr utilized transmetalation (from Zr to Al) to increase the reactivity of the 
resulting organometallic intermediates towards organic electrophiles.45 
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Scheme 12.  Hydrozirconation of alkynes and addition to electrophiles provides access to various 
functionalized compounds. 
 
The functional group tolerance to certain esters, carbamates, acetals, epoxides, ethers, 
halides and sulfides during the hydrozirconation process allows for the generation of relatively 
functionalized organometallic reagents, compared to the corresponding Mg or Li organometallic 
reagents.  Amides, ketones, aldehydes, and nitriles are not compatible with hydrozirconation 
conditions due to the reducing ability of the hydride.  Interestingly, alcohols undergo an acid-
base reaction with one equivalent of Schwartz reagent, but subsequently do not interfere with 
hydrozirconation. 
After hydrozirconation, the resulting C-Zr bond (EN = 1.33) has a similar ionic character 
to that of C-Mg (EN = 1.31); however, the zirconium organometallic species has a much lower 
propensity as a nucleophile.  This is due to the steric shielding at the Zr metal center by the two 
cyclopentadienyl ligands.  Some electrophiles, such as halogens, protons, dioxygen, CO, and 
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isocyanides, have been added directly into the C-Zr bond.  The hydrozirconation of allenes 
results in the formation of highly reactive allylzirconocenes, which are the only class of 
organozirconium reagents that will react directly with organic electrophiles such as aldehydes.46 
Two general strategies have been investigated to increase the nucleophilicity of alkyl- 
and alkenylzirconocenes towards synthetically useful and interesting organic electrophiles.  One 
way to increase the nucleophilicity is to reduce the steric shielding around the zirconium by 
chloride abstraction.  Treatment of alkenylzirconocenes with catalytic AgClO4 has been used to 
generate a cationic zirconocene capable of rapidly reacting with aldehydes46b, 47 and epoxides.48 
The oxophilic nature of the Ag salts activate the electrophiles and further promote nucleophilic 
attack of the cationic zirconocene.  Alternatively transmetalation strategies49 from Zr to Pd,50 
Ni,51  Rh,52 Cu, 53 Zn,54 and Al45, 55 have been used. 
In general, the transmetalation approach provides access to a wide range of 
functionalized organometallic compounds from easily prepared organozirconocenes.  To a first 
approximation, the relative electronegativity of an organometallic precursor can be used to 
predict the equilibrium of the ligand transfer process, which generally is shifted toward the more 
electronegative metal complex (EN for Pd = 2.20, Ni = 1.91, Rh = 2.28, Cu = 1.90, Zn = 1.65, Al 
= 1.61).  The rate of ligand transfer is usually fastest for alkenyl groups followed by alkyl, 
methyl, and alkynyl groups; however, exceptions to this generalization can occur. 
The transmetalation strategy from Zr to Pd50a, b and Ni51 has been used for the cross-
coupling of alkenylzirconocenes to aryl and alkenyl halides.  In 2003, Fu and coworkers 
expanded the Pd-catalyzed coupling of alkenylzirconocenes to alkyl halides.56 
Hanzawa and coworkers demonstrated the Rh(I)-catalyzed addition of alkenylzirconium 
compounds to N-tosyl aldimines.52b Substrate scope included both aryl and alkyl aldimines.  The 
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authors propose a transmetalation of the alkenylzirconium to an alkenylrhodium species that then 
adds into the N-tosyl aldimine.  Additionally, Hanzawa and coworkers52a and Inoue and 
coworkers57 were able to demonstrate the Rh(I)-catalyzed conjugate additions to various α,β-
unsaturated carbonyl compounds. 
Transmetalation from Zr to Cu blends the ease of formation of organozirconocenes with 
the vast chemistry performed by organocopper reagents.58 Wipf and coworkers showed that the 
Cu-catalyzed addition of organozirconocenes to acid chlorides59 and enones36d, 60 provided access 
to ketones.  Lipshutz and Kato showed that cyanocuprates generated from a hydrozirconation-
transmetalation sequence could be added efficiently to activated (benzylic and allylic) halides, 
epoxides, and enol triflates61  Lipshutz and Wood applied the Zr-Cu transmetalation 
methodology to the three-component coupling for the synthesis of prostaglandin-like 
compounds.62 Additionally, in an interesting extension to heterocyclic chemistry, Hanzawa and 
coworkers utilized zirconium/copper transmetalation to perform asymmetric 1,2-additions of 
alkenylzirconocenes to 3,4-dihydroisoquinoline.63 
Wipf and Xu reported the hydrozirconation of alkynes and transmetalation to alkenylzinc 
species using Me2Zn and subsequent addition to aldehydes in 54-94% yield.
54 This methodology 
was developed into an enantioselective variant using chiral amino thiol catalyst64 and has been 
used in various natural product total syntheses.65 The methodology was expanded further by 
Wipf and coworkers by adding alkenylzinc reagents to N-diphenylphosphinoylimines.35a, 35c N-
Diphenylphosphinoylimines are attractive electrophiles because they are almost as reactive as the 
corresponding N-tosylimines but can be easily deprotected under acidic conditions.66 Performing 
the hydrozirconation-transmetalation protocol followed by imine addition in THF resulted in the 
formation of the expected allylic amine 1-41 (Scheme 13).  However, performing the same 
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reaction in CH2Cl2 at reflux provided cyclopropane 1-40 with high diastereoselectivity.  The 
cyclopropanation occurs through the formation of an N-bound zinc carbenoid that performs the 
Simmons-Smith cyclopropanation intramolecularly.  Cyclopropanes of type 1-40 have been used 
as precursors to α,β-cyclopropyl-γ-amino acids.67 
 
 
Scheme 13.  Alkenylzinc addition to N-diphenylphosphinoylimine 1-39 to form cyclopropane 1-40 or 
allylic amide 1-41. 
 
Initial attempts by Wipf and Stephenson to perform catalytic asymmetric additions of 
alkenylzinc reagents on α-ketoesters using chiral catalysts did not proceed to give 
enantiomerically enriched products; however, enantiomerically enriched products could be 
obtained by performing alkenylzinc additions to the 8-phenylmenthol derived α-ketoester 1-
42.35d In addition, Wipf and Stephenson expanded the hydrozirconation-transmetalation 
approach to the synthesis of enantiomerically enriched allylic amines via 1,2-additions to chiral 
α-N-diphenylphosphinoylimino esters.  These imines could be synthesized in moderate yield by 
the condensation of N-diphenylphosphinamide with ketoester 1-42 in the presence of Et3N and 
TiCl4 (Scheme 14).  Treatment of the pre-complexed mixture of α-imino ester 1-43 and  
TiCl(O-i-Pr)3 with 1.5 equivalents of alkenylzinc species, generated by hydrozirconation of 
alkyne 1-44 followed by transmetalation with Me2Zn, resulted in tertiary allylic amides 1-45 in 
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7-8:1 dr.  The transition state model 1-46 provides a rational of the stereochemistry observed and 
the necessity of the Lewis acid.68 This approach provided access to α,α-disubstituted α-amino 
acids. 
 
Scheme 14.  Alkenylzinc addition to α-N-diphenylphosphinoylimino ester 1-43. 
 
Wipf and Xiao utilized the hydrozirconation-transmetalation-imine addition methodology 
in an approach to synthesize hemigramicidin conjugates as therapeutic agents to target reactive 
oxygen species (ROS).69 Hydrozirconation of alkyne 1-47, followed by transmetalation and 
addition to imine 1-48 afforded the allylic amide 1-49 as a 1:1 mixture of diastereomers (Scheme 
15).  The mixture of diastereomers could be separated after desilyation and oxidation to the acid.  
The desired diastereomer was further functionalized to provide nitroxides 1-50 and 1-51. 
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Scheme 15. Application of hydrozirconation-transmetalation-imine addition in the synthesis of 
hemigramicidin conjugates by Xiao and Wipf. 
 
While alkenylzinc reagents have been used to generate allylic amides by the methodology 
described above, a general route to a variety of enantioenriched allylic amines has not been 
realized; however, work performed by Wipf and coworkers on the zirconium catalyzed 
carboalumination of alkynes provided alkenylalanes which were subsequently added with high 
diastereoselectivity to chiral N-tosylsulfinylimines (Scheme 16).35b Diastereoselective addition of 
the alkenylalane, obtained from the water-accelerated carboalumination70 of 1-hexyne, to chiral 
N-tosylsulfinylimine 1-53 provided allylic amide 1-54.  The configuration can be explained by a 
four-membered chelate Felkin-Anh-type transition state model.71 Interestingly, organolithium 
and -magnesium additions to similar sulfinylimines are thought to proceed through a six-
membered chelate transition state in non-coordinating solvents.72 
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Scheme 16.  Water accelerated carboaluminatation and addition to chiral sulfinylimine 1-56 to give allylic 
amide 1-54 in high diastereoselectivity. 
 
During the total synthesis of α-C-glycoside analogue 1-59 of the immunostimulant 
galactosylceramide (KRN7000) by Wipf and Pierce, a rapid and selective installation of the 
allylic amide was essential for a viable synthetic route.35e Initial attempts to apply the Zr-Zn 
transmetalation methodology did not provide the desired compound. However, inspired by the 
carboalumination/stereoselective addition to N-tosylsulfinylimines (Scheme 16),35b a 
hydrozirconation-transmetalation from Zr to Al45 followed by addition to a chiral sulfinylimine 
electrophile was investigated.  Fortunately, hydrozirconation of various alkynes 1-57 followed 
by transmetalation with Me3Al and addition to N-tert-butanesulfinylimine 1-56 provided the 
desired allylic amides 1-58 in 65-82% yield and high diastereomeric ratios (Scheme 17).73 The 
stereochemistry of the resulting additions could be rationalized using a four-membered chelate 
Felkin-Anh-type transition state model.35b Additionally, the N-tert-butanesulfinamides could be 
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easily deprotected under acidic conditions.  The development of this new methodology 
contributed to the expedient (10 linear steps) synthesis of the α-C-glycoside 1-59. 
 
 
Scheme 17.  Application of Zr-Al transmetalation to the diastereoselective addition of alkenylalanes to N-
tert-butanesulfinylimine 1-56 in the synthesis of α-C-glycoside 1-59. 
 
Wipf and Pierce utilized the Zr-Al transmetalation methodology again for the synthesis of 
the novel radioprotectant jp4_039 (1-63) (Scheme 17).73-74 The hydrozirconation of alkyne 1-38, 
transmetalation to form the alkenylalane, and addition to N-tert-butanesulfinylimine 1-60 yielded 
the expected allylic amide 1-61 in >95:5 dr.  Subsequently, deprotection provided the amine 
hydrochloride 1-62 in 74% yield over the two steps.  This amine could be further elaborated into 
jp4_039 (1-63). 
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Scheme 18.  Application of the Zr-Al transmetalation/imine addition methodology in the synthesis of 
radioprotectant jp4_039 (1-63). 
1.2 RESULTS AND DISCUSSION 
1.2.1 Studies Towards the Preparation of α-Amino Acid Fragment 1-35 
 
Scheme 19.  Amino acid fragments 1-34 and 1-35 from the core dipeptide macrocycle of syringolin A (1-
1). 
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Our initial investigations into the synthesis of syringolin A began with the synthesis of the α-
amino acid fragment 1-35 (Scheme 19), which will function as part of the dehydrolysine peptide 
fragment in the macrocyclic core.  We were inspired by the diastereoselective addition of 
alkenylzinc reagents to menthol derivatives of α-iminoesters performed by Wipf and Stephenson 
(Scheme 14).35d This methodology had only been tested on α-ketoimino esters substituted with 
aryl groups; the analogous substrate for the synthesis of fragment 1-35 was N-
diphenylphosphinoylimine 1-66 (Scheme 20).  Preparation of the desired imine 1-66 began with 
the acylation of 8-phenylmenthol (1-64)75 with acryloyl chloride followed by ozonolysis of the 
α,β-unsaturated ester to give glyoxylate 1-65.76 With this known glyoxylate in hand, imine 
formation was attempted under conditions used previously to generate the α-ketimino esters; 
however, none of the desired product could be isolated.  N-Diphenylphosphinoylimines have also 
been synthesized in a more general fashion from their corresponding oximes by treatment with 
chlorodiphenylphosphine and Et3N.
77 Work by Hudson and coworkers indicated that this 
reaction proceeds through a homolytic dissociation to a radical pair upon warming, followed by 
recombination to give the imine.78 The oxime 1-6779 was prepared; however, the radical 
rearrangement did not provide the desired product. 
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Scheme 20.  Attempted preparation of chiral N-diphenylphosphinoylimine 1-66. 
 
In order to investigate other conditions for the formation of the N-
diphenylphosphinoylimine, we decided to substitute the 8-phenylmenthol glyoxylate for a more 
easily prepared cyclohexanol glyoxylate 1-68.  This glyoxylate was obtained by oxidative 
cleavage of the corresponding tartrate.80 Several conditions for imine formation from 1-68 
(Entries 1-5) resulted in either partial decomposition and/or formation of complex mixtures 
where no product could be observed (Table 1).  Heating the glyoxylate 1-68 in benzene with 4 Å 
molecular sieves provided the desired N-diphenylphosphinoylimine 1-69 but only in a 3:1 (1-
69:1-68) mixture of starting material and product as measured by 1H NMR (decrease of the 
glyoxylate peak at δ 9.56 (s) and formation of the characteristic diphenylphosphinoylimine peak 
at δ 9.20 (d, J = 31.5 Hz)).  Attempts to push the reaction to completion by adding more 
molecular sieves and extending the reaction time were not successful, and we therefore shifted 
focus towards the in situ preparation of the imine. 
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Table 1.  Attempted condensation reactions to afford N-diphenylphosphinoyl imine 1-69. 
 
 
 
Inspired by work of Charette and coworkers,66a we set out to form the sulfinyl adducts of 
N-diphenylphosphinoyl imines, which would provide stable precursors that could undergo in situ 
elimination and formation of the desired imine.66a, 81 Even more encouraging was that Charette 
and coworkers subsequently added dialkylzinc reagents to these in situ generated imines.  
Unfortunately, a direct application of their conditions for the preparation of sulfinyl adducts on 
glyoxylates 1-65, 1-68, and 1-70 gave none of the desired compounds.  Further literature 
searching showed that sulfinyl adducts of the N-Cbz and N-Boc imines (1-71) have been 
synthesized and used as imine precursors.82 Hydrozirconation of two equivalents of 1-hexyne (1-
52), solvent swap and transmetalation followed by addition of one equivalent of sulfinyl adduct 
1-71 resulted in deprotonation and in situ generation of the imine (Scheme 21).  The second 
equivalent of alkenylzinc reagent added to the in situ generated acceptor to provide the allylic 
amide 1-72 in 77% yield. 
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Scheme 21.  Alkenylzinc addition to sulfinyl adduct 1-71 to access allylic amide 1-72. 
 
After the promising result obtained with the model system 1-72, we attempted to apply 
the analogous approach to glyoxylate 1-65 and perform a diastereoselective addition of 
alkenylzinc reagent to the in situ generated imine from sulfinyl adduct 1-73 (Scheme 22).  The 
addition of two equivalents of alkenyl zinc reagent and in situ imine generation followed by 
addition resulted in a complex mixture and low mass recovery. 
 
 
Scheme 22.  Alkenylzinc addition to sulfinyl aminal 1-73. 
 
After being met with limited success in the Zr-Zn transmetalation-alkenylzinc addition to 
imines, we turned our attention towards the Zr-Al transmetalation-alkenylalane addition to chiral 
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N-tert-butanesulfinylimines developed by Wipf and Pierce.35e, 83 We had envisioned that the 
carboxylic acid moiety of α-amino acid fragment 1-35 could be brought in as a furan and later 
unmasked by oxidation.84 N-tert-butanesulfinylimine 1-7785 could be synthesized from 2-furfural 
(1-75) and S-tert-butanesulfinamide (1-76) in good yield by stirring with titanium(IV) ethoxide 
(Scheme 23).  Hydrozirconation of 1.2 equivalents of 1-hexyne (1-53) followed by 
transmetalation with trimethylaluminum and addition to N-tert-butanesulfinylimine 1-77 resulted 
in the desired allylic amide 1-78 as a single diastereomer (1H NMR), however, the yield was only 
45%.  Increasing the amount of the alkenylalane to 2.3 equivalents provided 1-78 in 75% yield.  
In order to decrease the amount of Schwartz reagent and alkyne used, the N-tert-
butanesulfinylimine 1-77 was pre-complexed with 1.1 equivalents of trimethylaluminum for five 
minutes at room temperature, before being added to the alkenylalane.  This approach resulted in 
virtually identical yield.  The configuration shown in 1-78 is based on the four-membered chelate 
Felkin-Anh-type transition state model 1-79.35b 
 
Scheme 23.  Zr-Al transmetalation-alkenylalane addition to N-tert-butanesulfinylimine (1-77). 
 
With the desired allylic amide 1-78 in hand, we attempted the unmasking of the furan 
moiety to give a protected amino acid (Scheme 24).  We had realized that selective oxidation of 
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the furan in the presence of the olefin could be challenging.  Oxidation under catalytic RuCl3 and 
stoichiometric NaIO4 conditions did not provide 1-81 but resulted in over oxidation.
84a The 
oxidation conditions were also tested on the Boc-protected compound 1-80, obtained through 
acid hydrolysis of the N-tert-butane sulfinamide and protection using Boc-anhydride.  This 
reaction proceeded more slowly; however, 1H NMR analysis of aliquots from the reaction 
mixture indicated that the oxidative cleavage of the olefin was occurring before the furan. 
Presumably, the olefin could have been masked via the protected diol, then the furan could be 
selectively oxidized and the diol eliminated by a Corey-Winter reaction; however, because this 
strategy would result in an excessive number of steps for this segment, an alternative imine 
substrate was investigated. 
 
Scheme 24.  Attempted oxidations of furans 1-78 and 1-80 to the corresponding protected α-amino acids. 
 
In a different approach, hydrozirconation of 1-hexyne, transmetalation with 
trimethylaluminum, and addition to N-tert-butane sulfinyl imine 1-8386 pre-complexed with 
trimethylaluminum provided the allylic amide 1-84 in 61% yield as a single diastereomer (1H 
NMR) (Scheme 25).  Simultaneous deprotection of the tert-butanesulfinamide and silyl ether 
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moieties in acidic methanol followed by Boc protection of the crude amine hydrochloride 
resulted in the N-Boc protected amino alcohol 1-85 in 58% yield from N-tert-butanesulfinamide 
1-84.  Pretreating the crude amine hydrochloride with NaHCO3, to neutralize the excess HCl 
from the deprotection step, was essential to reproducibly obtain the Boc-protected compound.  
Furthermore, two step conversion of the alcohol to the corresponding carboxylic acid by DMP87 
and Pinnick oxidation88 provided the crude α-amino acid fragment 1-86 in high yield.  The Jones 
oxidation was also used to oxidize 1-85 to the corresponding α-amino acid 1-86, but the yield 
was only 35%.  These results provided a proof of concept that the Zr-Al transmetalation 
methodology could be used to synthesize 1-86; however, there was still opportunity for 
improvement in the alkenylalane addition to N-tert-butanesulfinylimine. 
 
 
Scheme 25. Alkenylalane addition to N-tert-butanesulfinyl imine 1-83 and functional group manipulation 
to provide α-amino acid fragment 1-86. 
 
After changing the silyl protecting group from TBS to TBDPS, the yield of the 
alkenylalane addition increased to 76-90% and still resulted in the formation of a single 
diastereomer, 1-88, as determined by 1H NMR of the crude reaction mixture (Scheme 26).  
Furthermore, the silyl ether and N-tert-butanesulfinamide of 1-88 could be deprotected 
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simultaneously resulting in the crude amine hydrochloride.  The amine was protected and the N-
Boc amino alcohol 1-85 was isolated in 64% yield over the two steps.  Similar amino alcohols 
have been prepared by aminopalladation of trichloroacetimidates89 and Wittig reactions on α-
amino aldehydes.90 
 
 
Scheme 26.  Alkenylalane addition to N-tert-butansulfinylimine 1-87 and subsequent protective group 
switch to give N-Boc amino alcohol 1-85. 
 
At this point, it was considered necessary to support the stereochemical assignment from 
the alkenylalane addition to N-tert-butanesulfinylimines 1-83 and 1-87, since the substrate is 
significantly different than the usual alkyl or aryl sulfinylimines previously investigated in the 
Wipf group.  We thought that N-Boc amino alcohol 1-85 could be converted to a derivative of 
Garner’s aldehyde 1-90 (Scheme 27).  The N-Boc protected amino alcohol 1-85 was protected as 
the acetonide 1-89 and subsequent reduction of the olefin resulted in alkane 1-90.  For 
comparison, commercially available Garner’s aldehyde was homologated by a Wittig reaction,91 
providing 1-92 as mixture of (E)- and (Z)-olefin isomers, which were reduced to arrive at 1-93.  
All spectroscopic data for 1-90 and 1-93 were identical; however, their optical rotations were of 
equal value and opposite sign, thus supporting the initial stereochemical assignment based on the 
four-membered chelate model.35b Attempts to separate 1-90 and 1-93 by chiral SFC and chiral 
HPLC to determine the er of 1-90 were unsuccessful.  With the α-amino acid fragment 1-86 in 
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hand, we set out to continue our synthetic efforts towards syringolin A by synthesizing the 
valine-derived α,β-unsaturated-γ-amino acid fragment 1-35. 
 
 
Scheme 27.  Synthesis of 1-90 and 1-93 to support the stereochemical assignment of N-Boc amino alcohol 
1-85. 
1.2.2 Synthesis of α,β-Unsaturated-γ-Amino Acid Fragment 1-35 
Encouraged by the high yield and high diastereocontrol of the alkenylalane addition to N-tert-
butansulfinylimine 1-88 in the synthesis of the α-amino acid fragment 1-86, we had hoped to 
apply the same approach for the synthesis of the α,β-unsaturated-γ-amino acid 1-35, the second 
fragment of the dipeptide macrolactam core of syringolin A.  The synthesis of N-tert-butane 
sulfinylimine 1-96 proceeded smoothly;92 however, hydrozirconation of alkyne 1-97, 
transmetalation with trimethylaluminum, and addition to the imine pre-complexed with 
trimethylaluminum showed no product 1-98 after 5 h (Scheme 28).  A model reaction with 1-
hexyne was allowed to proceed for 27 h, after which time it resulted in only 9% of the desired 
product.  These results were quite unexpected based on the success of the methodology in the 
synthesis of jp4_039 (1-63) shown in Scheme 18.  The major difference between the two 
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substrates is the lack of a methylene group in 1-96 compared to 1-60, which perhaps creates 
enough steric bulk to block the alkenylalane-zirconium metal complex from performing the 
addition.  Alkenylzinc additions to the corresponding sulfinyl adducts of N-
diphenylphosphinoylimines were also attempted, but met with little success. 
 
 
Scheme 28.  Alkenylalane additions to N-tert-butanesulfinylimine 1-96. 
 
At this point, we foresaw the possibility to expand the substrate scope of the 
methodology developed by Ellman and coworkers in which vinyl Grignard reagents are added 
diastereoselectively to N-tert-butansulfinylimines to arrive at allylic amides with predictable 
stereochemistry following the six-membered chelate transition state model 1-103 (Scheme 
29).84b, 93 Thus, the opposite N-tert-butanesulfinyl imine enantiomer 1-101 had to be prepared.  
Preparation of the requisite vinyl iodide 1-100 was achieved by hydrozirconation of alkyne 1-
9794 and quenching with iodine.95 With vinyl iodide 1-100 in hand, lithium-halogen exchange 
followed by transmetalation to magnesium and addition to N-tert-butanesulfinylimine 1-101 
provided the desired allylic N-tert-butanesulfinamide 1-102 as a mixture of diastereomers in 95% 
yield.  Fortunately, these diastereomers were easily separable by chromatography on SiO2. 
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Scheme 29.  Grignard reagent formation from vinyl iodide 1-100 followed by addition to N-tert-
butanesulfinylimine 1-101 to produce N-tert-butansulfinamide 1-102 via six-membered chelate transition state 
model 1-103. 
 
With N-tert-butanesulfinamide 1-102 in hand, deprotection in acidic hexanes allowed for 
the selective removal of the sulfinamide in the presence of the silyl ether and afforded the amine 
hydrochloride 1-104 as a colorless solid (Scheme 30).  N-Boc protection of the amine went 
smoothly, followed by diastereoselective dihydroxylation of 1-105 to provide diol 1-106 as a 
4.4:1 mixture of diastereomers that were conveniently separable by chromatography on SiO2.  In 
N-Boc amide 1-105, the conformation minimizing A1,3-strain has the iso-propyl group shielding 
the top face of the olefin, inducing high a dr for the diol 1-106 syn to the N-Boc amide.  
Protection of the diol as the acetonide 1-107 and subsequent cleavage of the silyl ether provided 
alcohol 1-108 in 87% yield over two steps. 
Initially, the Jones oxidation and coupling of amine 1-110 using PyBOP and HOAt 
provided the desired coupling product 1-111 in 29% yield from silyl ether 1-107 (Scheme 31).  
However, application of a two step oxidation of the alcohol to the corresponding carboxylic acid 
by DMP87 and Pinnick oxidation88 followed by the same PyBOP conditions provided terminal 
 38 
olefin 1-111 in a much improved 64% yield over the four steps.  At this point, our route 
intersects with the previous synthesis of syringolin A by Kaiser and coworkers.26 
 
Scheme 30.  Preparation of alcohol 1-108 from sulfinamide 1-102. 
 
 
Scheme 31.  Oxidation of alcohol 1-108 to the acid and coupling to provide terminal olefin 1-111. 
 
Mild deprotection of 1-111 with TMSOTf and 2,6-lutidine gave amine 1-112, which was 
coupled with the N-Boc amino acid 1-88 in moderate yield (Scheme 32).  RCM using modified 
conditions compared to those described by Kaiser and coworkers provided the 12-membered 
core 1-114 in comparable yield, successfully completing the formal synthesis of syringolin A.  
The spectral data obtained for carbamate 1-111 and the protected core 1-114 are consistent with 
the data published for the common intermediates in the synthesis by Kaiser and coworkers.26 
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Scheme 32.  Synthesis of RCM precursor 1-113 and subsequent RCM to arrive at the protected core of 
syringolin A 1-114. 
 
In order to complete the total synthesis of syringolin A (1-1), deprotection of 1-114 and 
coupling of the valine-urea-valine fragment would provide intermediate 1-115 (Scheme 33).  
Hydrolysis of the acetonide, thiocarbonate formation, and subsequent Corey-Winter reaction, 
followed by methyl ester cleavage will provide syringolin A (1-1). 
 
Scheme 33.  Steps to complete the total synthesis of syringolin A (1-1). 
The synthesis of macrocycle 1-111 was accomplished in 14 steps (longest linear 
sequence) from propargyl alcohol.  Following the route described by Kaiser and coworkers26, 31 
from the macrocyclic core 1-111 to syringolin A (1-1) would provide the natural product in 20 
steps.  These routes to syringolin A are significantly longer than the 13 step synthesis performed 
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by Stephenson and Dai29 in 3.5% overall yield and the 10 step synthesis executed by Pirrung and 
coworkers in 22% overall yield.28 The routes used by Kaiser, Stephenson, and Pirrung rely on the 
chiral pool for the preparation of the amino acid fragments.  While our approach is longer in 
comparison to the other reported syntheses, we successfully demonstrated the application of 
stereoselective additions of alkenylorganometallic reagents to N-tert-butanesulfinylimine, and 
this methodology provided enantiomerically pure α-amino acids and α,β-unsaturated-γ-amino 
acids in a manner not dependent on the chiral pool.  In addition, our approach is amenable to the 
preparation of syringolin A analogues by using different aldehyde or alkyne starting materials. 
1.2.3 Attempts to Streamline the Synthesis of Syringolin A 
After competing the formal total synthesis of syringolin A, we became interested in improving 
the efficiency of our current route.  Upon retrospective analysis of our synthesis we realized that 
the synthesis of the α,β-unsaturated amino acid fragment, particularly the masking/unmasking 
strategy of the double bond, could be improved.  We envisioned that a stereoselective 
alkenylzinc addition to glyoxylate 1-67 followed by an Overman rearrangement96 would rapidly 
provide the desired α,β-unsaturated-γ-amino acid fragment 1-116 (Scheme 34).  Preparation of 
racemic alcohol 1-118 was accomplished by hydrozirconation of alkyne 1-117, transmetalation 
to zinc, and addition to ethyl glyoxylate 1-67.  Unfortunately, attempts to reach the amino acid 
fragment 1-116 using this strategy failed, presumably due to the steric bulk of the iso-propyl 
group. 
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Scheme 34.  Proposed and attempted strategy to the α,β-unsaturated-γ-amino acid fragment 1-119. 
 
We also envisioned that masking the olefin 1-122 by a Diels-Alder/retro-Diels-Alder 
pathway97 would reduce the number of steps used to mask the olefin in the current approach.  
Attempts to obtain the Diels-Alder adduct 1-124 from the cycloaddition reaction between α,β-
unsaturated amino acid 1-122 and anthracene 1-123 were not met with success.  The lack of 
reactivity between 1-122 and 1-123 could be due to steric interactions.  In the A1,3-minimized 
conformation, the olefin is sterically shielded on both faces by the iso-propyl group and the tert-
butyl carbamate. 
 
Scheme 35.  Attempted Diels-Alder cycloaddition between 1-122 and 1-123 as an olefin masking strategy. 
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1.2.4 Work Towards a Cyclopropane Analogue of Syringolin A 
In addition to streamlining the synthesis, we were also interested in investigating the 
synthesis of cyclopropane derivatives (1-125 and 1-126) of syringolin A (Figure 7).  
Cyclopropanes have been shown to function as geometric and electronic bioisosteres for (E)-
alkenes, but unlike (E)-alkenes, they do not suffer from possible isomerization or oxidation 
pathways.98 They are also less susceptible to Michael addition and unspecific alkylation 
processes.  We envisioned that the cyclopropane analog could function as a more selective 
proteasome inhibitor and be less susceptible to degradation and off-target interactions, thereby 
limiting side effects.  In addition, the biological activity may increase due to the release of ring 
strain upon covalent binding via a cyclopropane opening.  Computational investigation of the 
core structures of syringolin A (1-1) and the cyclopropane analogs 1-125 and 1-126 revealed that 
the structures are nearly superimposable (Figure 8).  The global minimum of the core structure of 
cyclopropane analog 1-125 contains two (E)-amide configurations causing the backbone to 
deviate from the other core structures. 
 
 
Figure 7.  Cyclopropane analogs 1-125 and 1-126 of syringolin A (1-1) and precursor α,β-cyclopropane-γ-
amino acid 1-127. 
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Figure 8.  Superimposed structures of the core of syringolin A (1-1) and the core of cyclopropane analogs 
1-125 and 1-126 in red, green, and blue respectively.* 
 
Attempts to apply the addition of alkenylzinc reagents to N-diphenylphosphinoylimines 
and subsequent Simmons-Smith cyclopropanation35a, 35c, d, 99 were plagued with low yields and 
diastereoselectivities.  Unfortunately, attempts to prepare the cyclopropane containing building 
block 1-127 by a Simmons-Smith cyclopropanation of allylic alcohols 1-128 gave yields of less 
than 50% and poor diastereoselectivity (Scheme 36).  We believe the low yield is a result of the 
steric hindrance around the olefin, as described previously (Scheme 35).  A different approach 
using the addition of cyclopropyl magnesium bromides, derived from the corresponding 
                                                 
* Figure 8 was prepared using Molecular Operating Environment (MOE; Chemical Computing Group).  
The global minima shown were obtained using a stochastic conformer search with an MMFF94x force field, while 
fixing double bond geometry and allowing amide bond rotation. 
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iodocyclopropanes 1-130 and 1-131, to tert-butanesulfinyl imine 1-101 also suffered from low 
yields and diastereoselectivities (Scheme 36).  Due to the low yields and mixtures of 
diastereomers, this approach was abandoned. 
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Scheme 36.  Attempts towards the synthesis of cyclopropane 1-127. 
1.2.5 Conclusion 
The successful application of the Zr-Al transmetalation followed by the alkenylalane addition to 
N-tert-butanesulfinylimines provided a facile access to the α-amino acid fragment 1-86.  
Methodology developed by Ellman and co-workers utilizing vinyl Grignard additions to N-tert-
butanesulfinylimines proved useful for the synthesis of the α,β-unsaturated-γ-amino acid 1-109.  
We were able to complete the formal synthesis of syringolin A (1-1) by synthesizing 
macrolactam 1-114 in a longest linear sequence of 14 steps (4.1% yield), compared to 10 steps 
(15% yield) obtained by Kaiser and coworkers.26 Attempts to shorten our approach by 
incorporating an Overman rearrangement or an alternative olefin protecting group strategy were 
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unsuccessful.  The preparation of fragment 1-127 for the synthesis of the cyclopropane derivative 
of syringolin A (1-125) suffered from low yields and diastereoselectivties.  In our formal 
synthesis of syringolin A, we have demonstrated the addition of alkenylorganometallic reagents 
to N-tert-butanesulfinylimines to provide rapid access to non-proteinogenic amino acids similar 
to α,β-unsaturated-γ-amino acid 1-34 and α-amino acid 1-35 with complete stereochemical 
control. 
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2.0  SYNTHESIS AND SELECTIVE FUNCTIONALIZATION OF A 
HETEROCYCLIC THIADIAZINE SCAFFOLD 
2.1 INTRODUCTION 
2.1.1 Biological Importance of Sulfamide Containing Heterocycles 
Sulfamide containing heterocycles are attractive synthetic targets100 and have been shown to 
exhibit a wide variety of biological activities (Figure 9).  These activities include anti-bacterial 
(2-1, 2-2),101 colony stimulating factor-1 inhibition (CSF-1, implied in rheumatoid arthritis and 
metastatic bone cancer, 2-3),102 opioid receptor-like 1 receptor inhibition (nociception receptor, 
NOP, 2-4),103 and 11β-HSD1 inhibition (a target for type 2 diabetes, 2-5).104 A subclass of 
sulfamide containing heterocycles, 1,2,6-thiadiazine 1,1-dioxides (Figure 10), have been shown 
to act as cannabinoid agonists and antagonists (2-6),105 exhibit modest antimicrobial activity (2-
7),106 and display smooth muscle relaxation in rats and guinea pigs (2-8 and 2-9).107  The 
structurally related 2,1,3-benzothiadiazine-2,2-dioxides have demonstrated herbicidal activity 
(commercial pesticide bentazon, 2-10) and sedative effects.108  In addition to the varied 
biological activity, the sulfamide unit has also been shown to function as a urea bioisostere in 
which the tetrahedral nature of the sulfamide can increase receptor recognition.109 
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Figure 9.  Examples of biologically active sulfamide containing molecules. 
 
 
Figure 10.  Examples of biologically active thiadiazine containing molecules. 
2.1.2 Methods for the Synthesis of Thiadiazines 
The preparation of a 1,2,6-thiadiazine 1,1-dioxide (2-13) was first demonstrated in 1952, 
by Degering and Wilson.  Sulfamide 2-11 was condensed with pentanedione 2-12 in the presence 
of catalytic hydrogen chloride (Scheme 37, Equation 1).110 In order to expand upon the initial 
substrate scope of Degering and Wilson, Wright investigated the condensations of sulfamide 2-
11 with β-diketones 2-14 to give thiadiazines 2-15 (Scheme 37, Equation 2).111 At the same time, 
Moeller and Ouchi explored the preparation of thiadiazine 2-16 from sulfamide 2-11 and 
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monoketones (Scheme 37, Equation 3).112 It is interesting to note that thiadiazine 2-13 is acidic 
(pKa = 3.27) compared to 2-16 (pKa= 9.8), which can be explained by the stability of the 
diazapentadienyl anion (Scheme 38). 
 
Scheme 37.  Preparation of thiadiazines 2-13, 2-15, and 2-16. 
 
 
Scheme 38.  Deprotonation of thiadiazines 2-13 and 2-16 and resonance structures of the conjugate bases. 
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Building upon the initial reports, a number of methods have been developed to prepare 
functionalized thiadiazines.  Access to the C-5 hydroxy thiadiazine 2-25 has been achieved by a 
base-mediated condensation of sulfamide 2-11 and ethoxy methylene 2-23, followed by an 
intramolecular cyclization of sulfaminomethylene 2-24 (Scheme 39, Equation 1).113 Using a 
modified strategy, a 6-N-alkylated thiadiazine 2-29 was prepared from a monoalkylated 
sulfamoyl chloride 2-26 and amino methylene 2-27 (Scheme 39, Equation 2).114 Lee and Kohn 
generated thiadiazine 2-31 by treatment of sulfamide (2-11) and 3,3-diethoxypropane (2-30) with 
TFA (Scheme 39, Equation 3).115 A variation of this approach by the same group used sulfamide 
imines 2-32, prepared from sulfamide and the corresponding aldehyde, and acetal 2-30 to arrive 
at thiadiazine 2-33 (Scheme 39, Equation 4).116 Recently, Kang and coworkers developed an 
intramolecular Friedel-Crafts acylation of sulfamide iminium species 2-35 to assemble benzo-
fused thiadiazines 2-36 (Scheme 39, Equation 5).117  In 2010, Tong and co-workers prepared N-
benzylated thiadiazine 2-39 using a unique approach by joining substituted sulfamide 2-38 and 
allene 2-37 in the presence of catalytic DABCO (Scheme 39, Equation 6).118 
 
 50 
 
Scheme 39.  Methods for the synthesis of functionalized thiadiazines. 
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2.1.3 Wipf Group Methodology for Thiadiazine Preparation and Functionalization 
As a part of our group’s ongoing interest in heterocyclic compounds, Wipf and coworkers found 
1,2,6-thiadiazine 1,1-dioxides to be interesting structures wherein the core heterocycle could be 
synthesized and functionalized utilizing a streamlined synthetic strategy outlined in Scheme 40.  
They envisioned that various thiadiazines 2-41 would be prepared from sulfamide imine 2-40 
using conditions reported in the literature.115-116 Thiadiazines 2-41 would then be selectively N-
alkylated to give substituted thiadiazines 2-42.119 Unfortunately, initial attempts to access 2-41 in 
TFA required long reaction times and gave inconsistent yields.120 
 
 
Scheme 40.  Initial synthetic strategy to access functionalized thiadiazines 2-42. 
 
Access to alkylated thiadiazine 3-42 hinged on the successful and reliable preparation of 
the thiadiazine core 2-41.  After considerable experimentation, it was found that condensation of 
commercially available sulfamide 2-11 and 2-30 resulted in the formation of a stable 8-
membered ring dimer, 2-43 (Scheme 41).113, 121 Similar 8-membered sulfamide dimers have been 
reported.122 The structure of 2-43 was confirmed by X-ray analysis.123 Subsequent condensation 
of 2-43 with benzaldehyde in TFA:CH2Cl2 (1:1) provided the desired thiadiazine 2-44 in 61% 
yield.121 
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Scheme 41.  Synthesis of thiadiazine 2-44 and X-ray structure of 2-43. 
 
After their initial success with the formation of thiadiazines in TFA:CH2Cl2 (1:1), an 
investigation began to find alternative acidic conditions that were milder and would provide 2-44 
in a higher yield.  Polyphosphate ester (PPE),124 BF3Et2O, triflamide, methanesulfonic acid, and 
TFA:CH2Cl2 (1:5) yielded thiadiazine 2-44 in lower or comparable yields (Table 2, Entry 2-6).
121 
The amount of TFA could be reduced to 10 equivalents with no decrease in yield observed 
(Table 2, Entry 7).123 
With a general method for thiadiazine formation conditions identified by Wipf and 
coworkers, the scope of compatible aldehydes was investigated.  Alkyl (Table 3, Entry 1-2), 
electron deficient (Table 3, Entry 3-6), and electron rich (Table 3, Entry 7-8) aryl aldehydes were 
tolerated.121  Heterocyclic thiophene-3-carboxaldeyde provided 2-53 in modest yield (Table 3, 
Entry 9); however, other heterocyclic aldehydes (furans, quinolines, and pyridines) resulted in 
formation of complex mixtures. 
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Table 2.  Optimization of thiadiazine 2-44 formation. 
 
Entry Conditions Yield (%)a 
1 TFA:CH2Cl2 (1:1), rt, 30 min 61 
2 PPE, THF, reflux, 40 min 45 
3 BF3OEt2 (2 equiv), CH2Cl2, rt, 6 h 65 
4 10% Tf2NH, CH2Cl2, rt, 2.5 h 42 
5 MeSO3H (5.7 equiv), CH2Cl2, 0 C, 40 min 39 
6 TFA:CH2Cl2 (1:5), rt, 3 h 61 
7 TFA (10 equiv), CH2Cl2, rt, 60 h 59 
aisolated yield after SiO2 chromatography 
Table 3.  Substrate scope of thiadiazine formation. 
 
Entry R Product Yield (%)a 
1 Me 2-45 59 
2 Et 2-46 56 
3 4-CNC6H4 2-47 41 
4 4-CO2MeC6H4 2-48 57 
5 4-CF3C6H4 2-49 65 
6 2-BrC6H4 2-50 45 
7 4-OAcC6H4 2-51 48 
8 3-OMeC6H4 2-52 62 
9 3-thiophene 2-53 30 
aisolated yield after SiO2 chromatography 
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In order to complete the strategy to prepare functionalized thiadiazines, Wipf and 
coworkers explored the possibility of regioselective and sequential N-alkylation of the two 
sulfamide nitrogens by exploiting their inherent difference in acidity (sulfamide vs. vinylogous 
carbamate and sulfamide).  Thiadiazines 2-44 and 2-45 were subjected to NaH followed by allyl 
iodide, which led to a mixture of mono- and di-alkylated products;120 however, treatment of 
thiadiazines 2-44 and 2-45 with allyl alcohol under Mitsunobu125 conditions using DBAD gave 
selective 6-N-mono-alkylation in good yields to provide 2-54 and 2-55 (Scheme 42).121  The 
regiochemistry was determined by NOESY correlation between the methylene hydrogens of the 
allyl group and the hydrogen of the thiadiazine alkene.  A second alkylation at N-2 was achieved 
using NaH, TBAI, and benzyl bromide to yield compounds 2-56 and 2-57 (Scheme 42).  
Alternatively, the N-2 alkylation was accomplished using alkyl halides and K2CO3. 
 
 
Scheme 42.  Mono- and di-alkylation of thiadiazines. 
Using the strategy described above, Wipf and coworkers prepared an 87-membered 
library of functionalized thiadiazines that were submitted to the Molecular Libraries Small 
Molecule Repository (MLSMR).  The library (UPCMLD24A) was tested in approximately 230 
assays.  Several compounds exhibited ~10 μM activity for DNA rereplication in normal 
MCF10A breast cells (implicated as an anti-cancer therapy)126 and glucagon-like peptide-1 
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receptor inverse agonist activity (a potential target for diabetes and neurodegenerative 
disease).127 
 
Figure 11.  Structures of biologically active thiadiazine analogues from UPCMLD24A. 
2.2 RESULTS AND DISSCUSSION 
2.2.1 Optimization of Thiadiazine Formation 
Previous results in the Wipf group from a brief optimization study for the preparation of 
thiadiazine 2-44 showed that a variety of acid mediated conditions facilitated the formation of 
the heterocycle (Table 2).121  At the time, the optimal conditions used 10 equivalents of TFA at 
room temperature in CH2Cl2 to give 2-44 in 59% yield.  We sought to improve the reaction 
conditions by (1) decreasing the amount of TFA needed to obtain the thiadiazine product and (2) 
reducing the reaction time. 
Before tackling these problems, we felt it was important to consider a possible 
mechanism for the formation of 2-44. We propose the mechanism begins with protonation and 
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cleavage of the sulfamide dimer 2-43 to give iminium 2-58.  Proton transfer provides 2-59 and 
Mannich reaction with aldehyde 2-60 yields 2-61.  Sequential proton transfer and β-elimination 
of water from 2-62 produces the α,β-unsaturated iminium 2-63.  Intramolecular Michael addition 
of the sulfamide nitrogen in 2-63 followed by proton transfer gives the observed thiadiazine 2-
44.  Alternatively, a pathway that involves condensation of 2-59 and aldehyde 2-60 via the 
sulfamide nitrogen resulting in formation of iminium 2-65 could be envisioned.  Intramolecular 
aza-Mannich reaction forms iminum 2-66 that after proton transfer provides thiadiazine 2-44.  
Upon isolation of the desired product, specific byproducts could not be identified; however, 
oligomer formation via condensation of enamine 2-59 and iminium species 2-58, 2-61, 2-65, and 
2-66 are reasonable possibilities.  From the proposed mechanism, we envisioned that the reaction 
could be improved by changing the acid and/or by changing the solvent in order to facilitate the 
formation of and/or stabilize the cationic intermediates.  We suspected a slow step in the reaction 
sequence to be the break down of the sulfamide dimer 2-43, because 2-43 exhibited limited 
solubility in CH2Cl2.  This was further supported by the observation that the reaction mixture 
remained heterogeneous and became homogeneous only at the completion of the reaction. 
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Scheme 43.  Possible mechanisms for the acid mediated transformation of sulfamide dimer 2-43 to 
thiadiazine 2-44. 
 
In order find conditions to improve the formation of thiadiazine 2-44, a brief screen of 
reaction conditions was undertaken.  Changing the acid from TFA to anhydrous hydrogen 
chloride in 1,4-dioxane provided thiadiazine 2-44, but it could not be obtained pure (Table 4, 
Entry 2).  Increasing the concentration of the reaction mixture and decreasing the amount of TFA 
to 5 equivalents yielded no product at room temperature, but gave 55% of 2-44 upon heating to 
40 °C (Table 4, Entry 3-4).  Using 2.5 equivalents of TFA and increasing the concentration to 
0.51 M in CH2Cl2 resulted in the same yield (Table 4, Entry 5).  Due to the poor solubility of the 
sulfamide dimer 2-43 in CH2Cl2 coupled with our desire to increase the reaction rate and yield, 
the solvent was changed to hexafluoroisopropanol (HFIP).  It was envisioned the non-
 58 
nucleophilic alcohol and hydrogen bond donor/acceptor capabilities of HFIP would provide an 
increase in reaction rate and yield by increasing the dissolution of 2-43 and stabilizing 
carbocation intermediates shown in Scheme 43.  Unfortunately, the change in solvent provided a 
modest reduction of the reaction time and a comparable yield of 2-44 (Table 4, Entry 6).  To 
explore if the relatively acidic HFIP (pKa = 9.3 in H2O (17.9 in DMSO)) could promote the 
thiadiazine formation alone, a control reaction without TFA was performed and returned 81% of 
the sulfamide dimer starting material (2-43) (Table 4, Entry 7).  The small optimization screen 
showed that a reduction in TFA and reaction time was accomplished by increasing the reaction 
concentration and heating the reaction mixture to achieve similar yields.  The optimal conditions 
use 2.5 equivalents of TFA and HFIP as a solvent at 35-40 °C (Table 4, Entry 6). 
Table 4.  Optimization of conditions for the synthesis of thiadiazine 2-44. 
 
Entry Conditions Yield (%)a 
1 TFA (10 equiv), CH2Cl2 (0.13 M), rt, 60 h 59 
2 4 M HCl (10 equiv), 1,4-dioxane, rt, 14 h 47b 
3 TFA (5 equiv), CH2Cl2 (0.25 M), rt, 17 h SM 
4 TFA (5 equiv), CH2Cl2 (0.25 M), 40 °C, 18 h 55 
5 TFA (2.5 equiv), CH2Cl2 (0.51 M), 40 °C, 30 h 57 
6 TFA (2.5 equiv), HFIP (0.50 M), 35-40 °C, 17 h 66 
7 HFIP (0.51 M), 35-40 °C, 17 h SM (81%) 
aisolated yield after SiO2 chromatography bisolated 85% pure. 
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2.2.2 Functionalization of Thiadiazines 
We desired to develop a strategy to access a thiadiazine scaffold with four points of diversity 
(Scheme 44, 2-67).  We envisioned that the methods developed by our group could be used to 
prepare thiadiazine 2-41 and differentially alkylated thiadiazine 2-42, which in turn could be 
used to access compounds of type 2-67.  A conversion of the C-4 ester in 2-42 to the carboxylic 
acid would allow us to investigate Curtius rearrangements, amide bond formations, and reductive 
aminations. 
 
Scheme 44.  Approach to thiadiazines 2-67 with four points of diversity. 
 
To begin the preparation of functionalized thiadiazines of type 2-67, conditions to 
hydrolyze the C-4 ester to the carboxylic acid were needed.  Initial saponification of thiadiazine 
2-44 was attempted under a variety of conditions; however, the desired acid was not obtained.  
We envisioned this was due to the relatively acidic nature of the 6-NH as seen in Scheme 37 (2-
16).  Thus, we set out to explore hydrolysis conditions on alkylated thiadiazines.  The alkylated 
thiadiazines would be prepared using the alkylation strategy previously developed in our group.  
Thiadiazine 2-44 was selectively 6-N alkylated using Mitsunobu conditions to provide 2-68, 
which was subsequently treated with methyl iodide and K2CO3 to afford 2-69 in 75% over two 
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steps (Scheme 45).  Bis-alkylated thiadiazine 2-70 was also prepared quantitatively by treatment 
of 2-44 with excess methyl iodide and K2CO3. 
 
 
Scheme 45.  Alkylation of thiadiazine 2-44. 
 
With the alkylated thiadiazines 2-68, 2-69, and 2-70 in hand, we explored Lewis acid-
mediated transesterifications and mild hydrolysis with TMSOK or Bu3SnOH.  These 
transformations were not met with success, and we attributed the lack of reactivity under these 
mild conditions to the electron rich nature of the vinylogous carbamate at C-4.  Gratifyingly, 
hydrolysis of 2-68, 2-69, and 2-70 was cleanly completed under more vigorous conditions using 
2 M KOH in EtOH at elevated temperatures to give 2-71, 2-72, and 2-73, respectively, in good 
yields (Scheme 46).  The crude acids were stable at room temperature for weeks and could be 
used without purification. 
 
Scheme 46.  Saponification of esters 2-68, 2-69, and 2-70. 
 
Having developed reliable conditions to arrive at alkylated thiadiazines containing a 
carboxylic acid at C-4, we began to investigate transformations that could be used to introduce 
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other functional groups at C-4.  The first target we envisioned preparing was the tert-butyl 
carbamate.128 Attempts at the Curtius rearrangement129 of mono-alkylated thiadiazine 2-71 did 
not provide the desired product, presumably due to the presence of the free N-H.  However, the 
dialkylated thiadiazine 2-73 was treated with DPPA130 to evoke the Curtius rearrangement and 
afforded tert-butyl carbamate 2-74, in modest yield (Scheme 47).  In attempts to improve the 
yield, we performed a stepwise reaction to try to determine which step was responsible for the 
low yield.  There was clean conversion to the acyl azide intermediate but decomposition 
products appeared after formation of the vinylisocyanate. 
 
 
Scheme 47.  Curtius rearrangement of acid 2-73 to provide 2-74. 
 
Another approach to functionalize the C-4 carboxylic acid was amide bond formation.  
EDCI coupling conditions with monoalkylated thiadiazine 2-75 and pyridinylmethanamine 
proceeded in good yield.  PyBOP and DIPEA conditions were used to couple 
pyridylmethanamine, p-methoxybenzylamine, N,N-dimethylethylene diamine, and morpholine to 
give amides 2-76 – 2-79 (Scheme 48).  These conditions were also used to obtain Weinreb 
amides131 2-80 and 2-81 in high yields, which provide a convenient handle for further functional 
group manipulation. 
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Scheme 48.  Amidation of acids 2-71, 2-72, and 2-73 to give amides 2-75 – 2-81. 
 
With the Weinreb amide 2-81 in hand, selective reduction to aldehyde 2-82 was 
accomplished with lithium aluminum hydride (LAH, Scheme 49).  To avoid over reduction to 
the corresponding alcohol, the reaction was kept at -78 °C for two hours, warmed to 0 °C for 15 
minutes, and quenched at 0 °C.  Initial attempts to perform a reductive amination with aldehyde 
2-82 using a one-pot imine formation-reduction strategy were not successful.  Imine formation 
required aldehyde 2-82 to be treated with cyclopropylamine and p-methoxybenzylamine in the 
presence of Ti-Lewis acid.  The resulting imines were reduced using NaBH4 to provide amines 
2-83 and 2-84.  NaBH3CN and Curran’s N-heterocyclic carbene borane
132 were also explored as 
reducing agents, but amine formation was not observed.  We attribute the lack of reactivity of the 
aldehyde 2-82 and imine to the electron rich nature of the vinylogous formamide and formimide.  
This low electrophilicity necessitated the use of Lewis acid to promote imine formation and 
NaBH4 to afford the amine products.  
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Scheme 49. Reduction of Weinreb amide 2-81 and reductive amination sequence to yield 2-83 and 2-84. 
 
After developing a strategy to prepare the electron rich aldehyde 2-82, we saw an 
opportunity to access the corresponding hydrazone and explore a hetero-Diels-Alder reaction to 
provide a structurally unique fused thiadiazine-pyridine heterocyclic scaffold.  Hydrazone 2-86 
was obtained from aldehyde 2-82 and N,N-dimethylhydrazine (2-85).  The attempted 
cycloaddition reaction with DMAD did not produce the desired product 2-87.  However, nitrile 
2-88 and enamine 2-89 were isolated from the reaction mixture.  These by-products can be 
explained by the formation of intermediate 2-90 followed by intramolecular elimination.133  To 
circumvent the elimination side reaction, and in turn promote the desired pyridine formation, the 
less electron rich N,N-methylphenylhydrazone was used.  Unfortunately, pyridine 2-87 or 
cycloaddition intermediates were not observed. 
Additional efforts to arrive at the thiadiazine-pyridine scaffold were attempted with less 
electrophilic dieneophiles.  We believed that this strategy would avoid formation of 
intermediates of type 2-90.  Unfortunately, the cycloaddition reaction of hydrazone 2-86 with 
maleimide 2-92 and quinone 2-93 did not provide the desired products 2-91 and 2-94, 
respectively. 
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Scheme 50.  Hydrazone 2-86 synthesis and attempted cycloaddition to form pyridine 2-87. 
 
 
Scheme 51.  Attempted cycloaddition with hydrazone 2-86 and dienophilies 2-91 and 2-93. 
 
Since the intermolecular hetero-Diels-Alder reaction was not observed with substrate 2-
86, we set out to prepare thiadiazine 2-101, which we envisioned could undergo an 
intramolecular hetero-Diels-Alder reaction to access a structurally unique scaffold containing 
three fused rings.  We were encouraged to find that Markgraf and coworkers were able to 
perform an intramolecular cycloaddition on an electronically similar substrate to form 
pyridines.134  The preparation of the intramolecular cycloaddition precursor 2-101 began with the 
selective alkylation strategy previously developed in our group121 to give thiadiazine 2-97.  
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Hydrolysis of ester 2-97 followed by Weinreb amide formation proceeded smoothly to provide 
2-99.  Careful reduction of the Weinreb amide 2-99 using LAH was accomplished to give 
aldehyde 2-100 that was treated with N,N-dimethylhydrazine to afford hydrazone 2-101.  
Conventional heating of hydrazone 2-101 in xylenes for several days or microwave irradiation in 
o-DCB did not yield the desired cycloaddition product 2-102. 
 
 
Scheme 52.  Synthesis of intramolecular cycloaddition precursor 2-101 and attempted intramolecular 
cycloaddition reaction. 
2.2.3 Analysis of the Physicochemical Properties of Thiadiazine Analogues 
At this point, we have developed a robust strategy for the preparation of thiadiazines with four 
points of diversification.  We prepared analogues that contained a tert-butyl carbamate, amides, 
and amines at the C-4 position of the thiadiazine core.  With a small library of structurally unique 
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thiadiazines in hand, we were interested in evaluating their physicochemical properties. The 
physicochemical properties of C-4 functionalized thiadiazine analogues were calculated using 
Instant JChem135 (Table 5).  All of the compounds in Table 5 meet Lipinski’s rules for drug like 
compounds136 and Veber’s rules for good bioavailability in rats.137 The clogP and clogD for most 
of the compounds fall in the optimal range (0< log P <3); however, under physiological 
conditions (clogD) amines 2-78, 2-83, and 2-84 may suffer from poor lipid bilayer permeability.  
In general, the synthetic strategy allows for the strategic introduction of polar or lipophilic 
groups to achieve the desired physicochemical properties. 
 
Table 5.  Calculated physicochemical properties of thiadiazine analogues. 
Compound 
MW 
(g/mol) 
Log 
P 
Log 
D 
TPSA 
(Å2) 
H-Bond 
Acceptors 
H-Bond 
Donors 
Rotatable 
Bonds 
 
2-74 
353.44 1.0 - 79.0 4 1 4 
 
2-75 
372.44 0.39 - 91.4 5 2 5 
 
2-76 
386.47 0.61 - 82.6 5 1 5 
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Table 5 (continued). Calculated physicochemical properties of thiadiazine analogues. 
Compound 
MW 
(g/mol) 
Log 
P 
Log 
D 
TPSA 
(Å2) 
H-Bond 
Acceptors 
H-Bond 
Donors 
Rotatable 
Bonds 
 
2-77 
415.51 1.59 - 79.0 5 1 5 
 
2-78 
366.48 0.04 -1.10 73.0 5 1 6 
 
2-79 
365.45 0.03 - 70.2 5 0 3 
 
2-80 
339.41 0.40 - 70.2 5 0 4 
 
2-81 
325.38 0.04 - 70.2 5 0 3 
 
2-83 
307.41 0.57 -1.01 52.7 5 2 5 
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Table 5 (continued). Calculated physicochemical properties of thiadiazine analogues. 
Compound 
MW 
(g/mol) 
Log 
P 
Log 
D 
TPSA 
(Å2) 
H-Bond 
Acceptors 
H-Bond 
Donors 
Rotatable 
Bonds 
 
2-84 
387.50 1.67 0.18 61.9 5 1 6 
2.3 CONCLUSION 
We have developed a robust strategy for the preparation and selective functionalization of 
heterocyclic thiadiazines with four points of diversity.  Original thiadiazine preparation 
conditions were optimized, and the amount of TFA was reduced from 10 to 2.5 equivalents.  A 
method for the hydrolysis of the C-4 ester to install the requisite carboxylic acid was developed.  
The acid functional group handle was used to investigate Curtius rearrangements, amide bond 
formations, aldehyde formation, and reductive aminations, providing access to highly substituted 
thiadiazines.  The formation of structurally unique thiadiazines though an inter- and 
intramolecular hetero Diels-Alder reaction was studied, but the desired heterocyclic scaffolds 
were not obtained.  The prepared analogues exhibit favorable physicochemical properties for 
drug-like compounds and display some biological effects, including DNA rereplication, an anti-
cancer target, and glucagon-like peptide 1 receptor inverse agonist activity, a potential target for 
diabetes and neurodegenerative disease.126a, 127a 
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3.0  INFLUENCE OF BASE AND STRUCTURE IN THE REVERSIBLE 
CONJUGATE ADDITION OF THIOLS TO INDOLE SCAFFOLDS 
3.1 INTRODUCTION 
3.1.1 Background of covalent protein inhibitors 
Recently, a significant amount of research has focused on covalent protein inhibitors as potential 
therapeutics for a variety of diseases.138 As we gain knowledge of the mechanism of action,139 
strategies can be developed to modulate the reactivity of the functional groups through which 
covalent attachment occurs.  Many different functional groups and structural motifs have been 
used as the warhead for covalent protein modification in clinically approved drugs (Figure 
12).138a Compounds such as Orlistat (3-1) and Amoxicillin (3-2) covalently bind via opening of 
their strained β-lactone and β-lactam core.  The widely used drugs Aspirin (3-4),140 for pain 
relief, and Warfarin (3-5),141 an anticoagulant, function as acylation agents.  Bortezomib (3-3), 
which is used to treat multiple myeloma and mantle cell lymphoma, behaves as a covalent 
proteasome inhibitor, forming a covalent link between the active site threonine and the pendant 
boronic acid.142 The popular proton pump inhibitor, Omeprazole (3-6), behaves as a prodrug that 
upon exposure to the acidic conditions in the stomach rearranges to spirocycle 3-11 and forms a 
covalent disulfide enzyme adduct 3-13 (Scheme 53).143 The hepatitis C virus NS3 serine protease 
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is inhibited by telaprevir (VX-950, 3-7) through a reversible covalent hemiketal formation at the 
α-ketoamide.144 Another widely used class of electrophiles for covalent inhibitors are Michael 
acceptors.  Michael addition of a cysteine, of thymidylate synthase, to floxuridine (3-8) generates 
an enolate that subsequently reacts with the cofactor CH2FAH4 to give a covalently modified 
species.145 A similar mechanism of action is followed by finasteride (3-9), which is used to treat 
prostatic hyperplasia.146 PX-866 (3-10), an analogue of the natural product Wortmanin, functions 
as a covalent inhibitor of phosphoinositide-3-kinase (PI3K), and is in clinical trials as an anti-
cancer therapeutic.147 
A new approach to improve the selectivity or decrease off-target binding events of 
covalent inhibitors uses targeted covalent inhibitors (TCIs).138b, 148 TCIs involve improving the 
binding of an optimized lead compound by appending a weakly electrophilic functional group in 
the direction of a potential nucleophile in the protein binding pocket.  This approach can be very 
successful and has been used to develop the compounds shown in Figure 13.  Acrylamides and 
α-keto-amides are commonly used electrophiles because they are weakly electrophilic, thereby 
modulating off-target effects, but will react rapidly when in close proximity to a nucleophile.148b  
Prominent examples of TCIs are carfilzomib (3-14), a proteasome inhibitor that reacts through 
the terminal epoxide, and boceprevir (3-15), an HCV protease inhibitor, which reversibly forms a 
hemiketal.  A particularly useful strategy for TCI design is the use of a γ-amino-acrylamide 
functional group (as seen in neratinib (3-16) and Tovok (3-17)), which functions as an 
intramolecular catalyst of the nucleophilic addition of a cysteine via deprotonation.  A potential 
drawback for widespread application of TCIs is that it is imperative to have protein structure 
information, substrate-binding orientation, and a nucleophilic group (such as cysteine or serine) 
near the binding site. 
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Figure 12.  Clinically approved covalent inhibitors. Regions where covalent modification occurs are 
highlighted. 
 
 
Scheme 53.  Mechanism of covalent enzyme binding of Omeprazole (3-6). 
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Figure 13.  Approved drugs and candidate compounds that were developed using targeted covalent 
inhibitors (TCIs). 
 
In addition to the synthetic covalent inhibitors mentioned above, many natural products 
have been shown to exhibit biological activity through a covalent mechanism.139, 148b Two classic 
examples are the mitomycins and enediyne antibiotics.  Unlike many of the compounds that 
covalently modify proteins (Figure 12 and Figure 13), the biological activity of the mitomycins 
and enediyne natural products is a result of DNA modification.  Mitomycin C (3-19) was isolated 
from the bacterium Streptomyces lavendulae in 1958149 and has since proved to be a valuable 
anticancer therapeutic, especially for the treatment of bladder cancer.150 The anticancer activity 
of mitomycin C comes from its ability to covalently alkylate and crosslink DNA.151 
Mechanistically, the natural product is activated by reduction of the quinone moiety leading to 3-
20 (Scheme 54).152 Opening of the aziridine forms the conjugated enone 3-21, which is 
susceptible to nucleophilic attack from DNA (guanine (3-25)) to give 3-22.  Elimination of the 
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pendant carbamate gives iminum 3-23 which is attacked by DNA to give the dialkylated 
compound 3-24.151, 153 
 
 
Scheme 54.  Mechanism of action of mitomycin C. 
 
The enediyne family of natural products is characterized by a unique (Z)-1,5-diyne-3-ene 
structural unit and possesses nanomolar anticancer activities.154  Their mechanism of action 
involves a Bergman cycloaromatization and formation of a 1,4-benzenoid diradical 
intermediate.154c  The diradical abstracts a hydrogen from the ribose backbone of DNA, at C(5’), 
C(4’), or C(1’).  The resulting radical leads to DNA strand cleavage via oxidation, reduction, and 
elimination.154c Specifically, enediyne natural product, calicheamicin γ1
1 (3-26), accomplishes 
DNA double strand cleavage through the mechanism shown in Scheme 55.154a, 154c The trisulfide 
3-26 is cleaved by nucleophilic displacement, postulated to occur with glutathione, to give thiol 
3-27.  Conjugate addition of the thiol side chain provides 3-28, which undergoes a structural 
change and leads to spontaneous cycloaromatization to relieve strain and form diradical 3-29.  
The diradical induces DNA double strand cleavage to give 3-30. 
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Scheme 55.  Mechanism of action of calicheamicin γ1
1 leading to DNA double strand cleavage. 
 
Some more recent examples of covalently modifying natural products employ ring-
strained scaffolds and Michael acceptors to accomplish covalent modification of a protein target.  
Duocarmycin SA (3-32) contains a strained cyclopropane and azinomycin A (3-33) contains a 
strained aziridine that function as electrophilic targets.155  Syringolin A (3-34) inhibits the 20S 
proteasome by covalent attachment through a threonine residue (See Section 1.1.2).  The 
Michael acceptor ability of the cross-conjugated enone zerumbone (3-35) has suggested uses as a 
chemopreventive and anticancer agent.156 A biotinylated derivative of the anti-inflammatory 
natural product parthenolide (3-36) was revealed to be a covalent binder.157 The anti-proliferative 
activity of leptomycin B (3-50) has been attributed to Michael addition into the α,β-unsaturated 
lactone.158 Wortmannin (3-37) irreversibly inhibits PI 3-kinase by lysine addition into the 
activated furan.159 Other electrophilic groups that function as effective Michael acceptors are 
vinyl sulfones (methyldambullin, 3-38) and vinyl nitrones (avrainvillamide, 3-39).148b, 160 
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Figure 14.  Biologically active natural products that inhibit though covalent inhibition. 
3.1.2 Mechanistic Studies of Thiol Additions to Enones 
Understanding the mechanism and the influence of structural features on the rate and equilibrium 
of thiol additions to enones is paramount for the rational development of enones as covalent 
inhibitors.  To this end, several research groups have investigated the addition of thiols to simple 
enones using experimental and computational methods.  Bernardi and coworkers have 
investigated the kinetics and equilibria of the Et3N-catalyzed addition of thiophenol to enones 
using 1H NMR.161 The concentrations of enone, thiophenol, and adduct were determined at 
equilibrium by integration of the appropriate 1H NMR signals and used to calculate the 
equilibrium constant (Keq).  With the equilibrium constant known, ΔG (RTlnKeq) was calculated.  
Thiophenol addition to cyclopentenone 3-41 gave thioether adduct 3-42, which was favored by 
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−4.8 kcal/mol (Scheme 56, Equation 1).  Thiophenol addition to β-substituted enone 3-43 was 
slightly unfavorable by +0.1 kcal/mol (Scheme 56, Equation 2).  Interestingly, thiophenol 
addition to α-substituted enone 3-45 resulted in kinetic formation of the cis-substituted adduct 3-
46 (Scheme 56, Equation 3).  The cis-substituted adduct 3-46 is formed by rapid protonation of 
the intermediate enolate from the less sterically hindered face.  The initial formation of the cis-
substituted adduct 3-46 is −0.2 kcal/mol downhill in energy compared to enone 3-45.  Over 150 
h, equilibration of the cis-adduct 3-46 to the trans-substituted adduct 3-47 was observed, which 
was found to be favored by −0.9 kcal/mol.  The equilibration is thought to occur via enolization 
of ketones 3-46 and 3-47 followed by protonation give the more thermodynamic trans 
orientation between the thiophenyl and methyl group.  Kinetic measurements indicated 
thiophenol addition to enone 3-41 is two orders of magnitude faster than addition to α-substituted 
enone 3-45 and three orders of magnitude faster than addition to β-substituted enone 3-43.  The 
authors propose that the decrease in product formation for the thiol addition to enones 3-43 and 
3-45 is a result of both the electronic stabilizing effect of the methyl group on the π-bond and the 
increase of bond eclipsing interactions in the thiol adducts 3-44, 3-46, and 3-47. 
 
Scheme 56.  Kinetic and equilibrium studies of thiophenol additions to cyclopentenones 3-41, 3-43, and 3-
45. 
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In 2011, Houk and coworkers investigated the transition states and thermodynamics of 
the addition of thiols to α,β-unsaturated ketones using density functional theory (DFT) 
calculations.162  The general mechanism of thiol additions to enones begins with thiolate 
formation followed by addition to enone 3-48 (Scheme 57, Equation 1).  The resulting enolate 3-
49 is protonated to give enol 3-50 that tautomerizes to yield the ketone 3-51.  Transition states 3-
52 and 3-55 were identified by DFT calculations† for the addition of a thiolate to an enone 
(Scheme 57, Equation 2 and 3).  The energy of the unsubstituted enone transition state 3-52 is 
lower than the β-substituted enone transition state 3-55.  The authors propose this is due to the 
loss of hyperconjugation in the branched enone 3-54 and the weaker solvation of the more 
sterically crowded transition state 3-55 (Scheme 57, Equation 3). 
 
 
Scheme 57.  Computational evaluation of the mechanism of thiol additions to enones. 
                                                 
† Gas phase calculations using B3LYP/CBSB7 and solution phase calculations using CPCM water 
B3LYP/6-31+G(d) in Gaussian 03 
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3.1.3 Spectroscopic and Computational Methods for the Identification and Classification 
of Thiol Acceptors 
In order to better understand and use thiol acceptors as lead structures in drug discovery, several 
methods have been published to rapidly identify, classify, and predict the reactivity of thiol 
acceptor molecules.  Suzuki and coworkers investigated the rates and equilibria of thiol additions 
to enone-containing prostaglandins.163 Thiol addition to cross-conjugated enone 3-57 provided 3-
59 as the only observed product (Scheme 58).  They were able to rationalize the regiochemistry 
of the thiol addition to cross-conjugated enone 3-57 by calculating the LUMO orbital 
coefficients and atomic charges‡ for enone 3-60.  The thiol addition occurs at the endocyclic β-
position, which has a larger LUMO coefficient and a more positive atomic charge. 
Cusack and coworkers investigated the β-carbon chemical shift of α,β-unsaturated 
carbonyl compounds to estimate the reactivity of drug-like molecules.164 They examined small 
libraries of three scaffold families 3-61, 3-62, and 3-63 by 13C-NMR (Figure 15) and found that 
the chemical shifts for the β-carbon fell into three distinct groups.  Chemical shifts between 137-
139 ppm were observed for compounds 3-61 that exhibited Michael acceptor properties, while 
compounds 3-62 with chemical shifts of 135-128 ppm showed redox activity and are reduced by 
NADPH.  The chemical shift for scaffold 3-61 is slightly higher due to the presence of the 
conjugated indole, while the electron rich pyrrole in scaffold 3-62 causes the chemical shift to 
decrease slightly.  Compounds from the scaffold 3-63 have a much lower chemical shift range, 
between 122-118 ppm, due to the increase in electron density of the enamide from the 
benzothiazinone ring.  Enamide scaffold 3-63 was inactive as a Michael acceptor and an 
                                                 
‡ Calulations performed using STO-3G in Monstergaus 81 
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NADPH substrate, but did show a lack of olefin geometry photostability.  Compounds from 
scaffold 3-61 and 3-62 have better photostability of the olefin geometry due to the stabilizing 
nature of an intramolecular H-bond. 
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Scheme 58.  Calculated LUMO coefficients and atomic charges used to rationalize regioselectivity of thiol 
additions to cross-conjugated enones. 
 
 
Figure 15.  β-carbon enone chemical shifts used to predict enone reactivity. 
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In 2011, Appendino and coworkers developed a rapid NMR spectroscopic method to 
identify thiol acceptors.165 A variety of α,β-unsaturated carbonyl compounds were treated with 
cysteamine 3-65 followed by 1H NMR analysis to reveal if the thiol addition occurred.  Initial 
attempts to use N-acylcysteamine showed a lack of reactivity with enones while cysteamine 3-65 
performed much better.  The authors suggest the increase in reactivity of cysteamine compared 
to N-acylcysteamine is because of the ability of the amine to catalyze the thiol addition reaction 
to enones through an intramolecular proton transfer, seen in intermediate 3-66 (Scheme 59).  
Additionally, the nucleophilicity of cysteamine 3-65 has been explained by the charge-separated 
tautomer 3-68, which is stabilized by the polar aprotic solvent DMSO.  This method was able to 
identify parthenolide 3-36 and anhydroverlotorin 3-69 as mono- and di-thiol acceptors, 
respectively.  Dihydrovaltrate 3-70, containing the reactive epoxide moiety, showed no reaction 
under the assay conditions.  Structurally similar α,β-unsaturated ketones 3-71, 3-72, and 3-73 
were treated with cysteamine, but only umbellone 3-71 gave a positive assay result.  The authors 
speculate that 3-71 is reactive due to the cyclopropane of the cyclopentenone stabilizing a partial 
positive charge on the β-carbon.  In addition to the electronic effects, the steric interactions in the 
thiol adduct of the bridged system 3-73 are unfavorable. Curcumin 3-75 reacted with two 
equivalents of cysteamine, while cross-conjugated enone 3-74 (α-santonin) gave no reaction.  
The lack of reactivity of 3-74 under the assay conditions could be due to the electron rich nature 
of the cross conjugated enone and the sterics of the quaternary center next to the β-carbon of the 
enone.  α,β-Unsaturated aldehydes 3-76 and 3-77 were compatible with the assay conditions; 
however, 1,2-addition of cysteamine (kinetic product) into the carbonyl was observed. 
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Scheme 59.  1H NMR assay for the identification of thiol acceptors. 
 
In 2012, Taunton and coworkers explored the use of cyanoacrylates as reversible 
covalent inhibitors for non-catalytic cysteine residues.166 Initial investigations found a rapid 
formation of thiol adducts when cyanoacrylamides in Figure 16 were treated with β-
mercaptoethanol.  Upon dilution of the adduct mixtures, rapid thiol dissociation occurred.  These 
findings suggested that cyanoacrylamides could be used to reversibly target cysteine residues.  
Thus, a set of pyrrolopyrimidine-containing Michael acceptors (Figure 17) was tested in vitro 
and compound 3-86 exhibited nanomolar inhibition of p90 ribosomal protein S6 kinase RSK2, 
which has been implicated as a target to treat cancer.167 Compound 3-86 showed long enzyme 
 82 
residence time and was completely reversible over several hours.  A co-crystal structure was 
obtained with derivative 3-87, which showed that covalent attachment to RSK2 via Cys436 was 
stabilized by key hydrogen bonds to the pyrimidine core.  The design and application of 
reversible covalent inhibitors could be a useful approach to maintain potency and mitigate off-
target effects compared to traditional irreversible covalent inhibitors.165 
 
 
Figure 16.  Cyanoacrylamide-based reversible thiol acceptors with reported thiol dissociation constants. 
 
 
Figure 17.  Rationally designed reversible covalent p90 ribosomal protein S6 kinase RSK2 inhibitors. 
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3.1.4 Thiol Addition Chemistry in the Wipf Group 
The Wipf group has investigated the fundamental alkylating properties of epoxyketone-
containing natural products such as aranorosin, LL-C10037α, manumycin and dipoxin σ.168 Of 
particular relevance is the thiol capture pathway of the manumycin A core 3-88 (Scheme 60).168a 
In the presence of excess thiophenol, regioselective epoxide opening was observed to give 3-89 
with no Michael addition into the enone.  Interestingly, they found that thiophenol addition to 3-
90, a diastereomer of 3-88, provided 3-91 in which both epoxide opening and Michael addition 
was observed.  Kinetically favored addition of thiophenol in to the enone would form a chair 
shaped intermediate but would give a thiol addition diastereomer that was not observed.  Thus 
addition of the thiol to the enone must arise from equatorial attack and a boat shaped 
intermediate to arrive at a thermodynamically more stable diastereomer 3-91. 
 
Scheme 60.  Thiophenol addition reactions to manumycin A core enone 3-88 and 3-90. 
 
The Wipf group has also used a thiol addition to an enone as a protecting group strategy 
to differentiate the two olefins in 3-92 en route to the natural product tuberostemonine 3-96 
(Scheme 61).169 Conjugate addition of thiophenol in the presence of catalytic Et3N gave 
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thiophenol adduct 3-93.170 Reduction of the azepine was accomplished with Wilkinson’s catalyst 
under an atmosphere of H2 to afford 3-94, and the enone was regenerated by a DBU-mediated 
thiophenol elimination to provide 3-95.171 Enone 3-95 was then used to complete the synthesis of 
tuberostemonine 3-96. 
 
Scheme 61.  Thiol addition/elimination strategy used in the synthesis of tuberostemonine (3-96). 
3.2 RESULTS AND DISCUSSION 
3.2.1 Investigation of the Thermodynamics of Thiol Additions to Enones 
The ability to shift the equilibrium from 3-92 to 3-93 and 3-94 to 3-95 by changing the base was 
noteworthy; however we could only speculate how the equilibrium was affected by 
conformational changes of the tricycle (azepine (3-92) vs. azepane (3-95)) or base strength (Et3N 
vs. DBU).  As discussed previously, the ability to predictably influence the electrophilicity of 
Michael acceptors has a profound effect on their use in drug discovery.  It is also apparent that 
substitution, sterics, and electrophilicity of the Michael acceptor effect the kinetics and 
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thermodynamics of thiol additions.  Accordingly, we experimentally explored the equilibria of 
thiophenol addition and elimination reactions of several indole containing enones. 
We began our investigation of the equilibria of the thiol addition/elimination reactions 
using enone containing indole scaffolds that were reported in the synthesis of 
tuberostemonine.169 The enones 3-98 and 3-99 were prepared according to reported methods 
starting from Cbz-protected tyrosine (Scheme 62).169, 172 The enone 3-101 was obtained from a 
Ley oxidation173 of known alcohol 3-100. 
 
 
Scheme 62.  Preparation of enones 3-98, 3-99, and 3-101. 
 
In order to measure the equilibrium of the thiophenol addition reaction and investigate 
the effects of enone structure and base strength, NMR experiments were performed in the 
presence of an excess of thiophenol (1.15 equivalents) and catalytic base (0.09 equivalents of 
Et3N and DBU, Scheme 63, Equation 1).  The experiments for the measurement of the thiol 
elimination reactions equilibria were performed using stoichiometric base (1.06 equivalents of 
Et3N and DBU, Scheme 63, Equation 2).  The ratio of starting material to product was measured 
by the integration of diagnostic peaks in the 1H NMR and used to determine the equilibrium 
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constant (Keq).  In turn, the Keq was used to calculate the ΔG of the thiol addition/elimination 
reactions (Scheme 63).  From these observations, we expected the catalytic base to have no 
influence on the thiol addition reaction and thus measure the equilibrium between the enone 3-
102 and thiol adduct 3-103.  Although, in the thiol elimination reactions we expected to see a 
difference in the equilibrium constant with respect to the base because of the stoichiometric 
formation of a base-thiol ion pair complex (Scheme 63, Equation 2).  By comparing equilibrium 
constants from the thiol elimination reactions using Et3N and DBU we expected to calculate the 
difference in energy between the two base-thiol complexes (DBUH+PhS- vs. Et3NH
+PhS-).  The 
pKa values of thiophenol, DBUH
+, and TEAH+ (pKa values in DMSO of 10.3, 12, and 9, 
respectively)174 suggest that the formation of the DBUH+PhS- ion pair complex will be favored 
over the TEAH+PhS- ion pair complex. 
 
 
Scheme 63.  General reaction schemes for the (1) thiol addition and (2) thiol elimination reactions 
accompanied by equations for equilibrium constants.  [A]=thiol addition adduct; [T]=thiol; [E]=enone; [BT]=base 
thiol complex; [B]=base. 
 
With the enones in hand, we began investigating the equilibria of the thiol addition and 
elimination reactions.  The addition of thiophenol to enone 3-98 with either Et3N and DBU gave 
a ratio of 3-104:3-98 of ≥50:1 by 1H NMR (beyond the limit of detection by 1H NMR) and a ΔG 
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of ≤ −4.6 kcal/mol (Figure 18).  The equilibrium constant was determined by integration of the 
peaks for 3-98 (Ha δ 5.95 (dd)) and 3-104 (Hb δ 4.29 (app. t, minor diastereomer); 4.22 (app. t) 
and 4.17 (dd, major diastereomer)).  Thiol elimination of thioether 3-104 in the presence of Et3N 
resulted in a ΔG of +1.8 kcal/mol, while the thiol elimination of 3-104 using DBU yielded a ratio 
of 3-98:3-104 of ≥50:1 by 1H NMR and a ΔG of ≤ −3.8 kcal/mol. 
 
 
Reaction Base ΔG 
3-98 to 3-104 Et3N ≤ −4.6 kcal/mol 
3-98 to 3-104 DBU ≤ −4.6 kcal/mol 
3-104 to 3-98 Et3N +1.8 ± 0.03 kcal/mol 
3-104 to 3-98 DBU ≤ −3.8 kcal/mol 
Figure 18.  Thiol addition/elimination reactions with enone 3-98 using Et3N and DBU. 
 
On preparative scale, thiol adducts 3-104a and 3-104b were isolated in 79% yield as an 
inseparable ~2.3:1 mixture of diastereomers.  In the major diastereomer, coupling constant 
analysis of the methine proton highlighted in Figure 19 indicated the presence of a large and a 
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small coupling constant, which suggests an equatorial thiophenyl group.  Simple MMFF 
calculations§ agreed with the assignment of the major diastereomer to 3-104a. 
 
 
 3-104a 3-104b 
 0 kcal/mol +0.9 kcal/mol 
Figure 19.  Assignment of diastereomers of thiol addition products 3-104a and 3-104b. 
 
Next, we investigated the thiol addition reaction to O-benzoyl protected enone 3-99.  The 
equilibrium constant was determined by integration of the peaks for 3-99 (Ha δ 6.10 (app. t)) and 
3-105 (H o-OBz, δ 7.99-7.95 (m, 2 H, minor diastereomer) and 7.71-7.67 (m, 2 H, major 
diastereomer)).  The reaction was favored by a ΔG of −4.1 and −4.0 kcal/mol using catalytic 
Et3N and DBU, respectively (Figure 20).  Additionally, thiol elimination of the major 
diastereomer 3-105 to afford 3-99 was unfavorable by +1.0 kcal/mol using Et3N but favorable by 
≤ −3.8 kcal/mol in the presence DBU.  On preparative scale, the thiophenol addition to enone 3-
                                                 
§ Calculations performed using MMFF conformational search with Spartan 10’ 
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99 yielded adduct 3-105 as a separable ~2:1 mixture of diastereomers in 92% yield.  
Unfortunately, the relative configuration at C-4 could not be determined; however, MMFF 
calculations§ and analogy to 3-104 suggest the α-epimer to be the major diastereomer. 
 
 
Reaction Base ΔG 
3-99 to 3-105 Et3N −4.1 ± 0.06 kcal/mol 
3-105 to 3-105 DBU −4.0 ± 0.02 kcal/mol 
3-105 to 3-105 Et3N +1.0 ± 0.001 kcal/mol 
3-105 to 3-99 DBU ≤ −3.8 kcal/mol 
Figure 20.  Thiol addition/elimination reactions with enone 3-99 using Et3N and DBU. 
 
Although the ΔG of the base-catalyzed thiol addition reaction to enones should be 
independent with respect to the identity of the base catalyst, initial experiments for the 
thiophenol addition to enone 3-99 resulted in deviations of 0.4 kcal/mol when Et3N or DBU were 
used.  This deviation was initially attributed to the inherent basicity of DBU and the stability of 
the DBUH+PhS complex, both of which shift equilibrium toward enone 3-99.  However, upon 
close inspection of the data we realized that the diastereomers of 3-105 were observed in 1.9:1 
ratio in Et3N and a 2.3:1 ratio in DBU after 23 h.  This observation suggested that while the 
equilibration between enone 3-99 and 3-105 appeared to be complete, equilibration of the 
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diastereomers of 3-105 was comparably slower.  Literature precedent161a and repeating the enone 
addition reactions indicated that equilibration between the diastereomers occurs over 150 hours, 
however during the extended reaction only minor changes in the ΔG (0.3 kcal/mol) were 
observed to give a ΔG −4.0 to −4.1 kcal/mol for the thiol addition reaction. 
Enone 3-101 could be accessed via oxidation of an undesired byproduct in the synthesis 
of tuberostemonine.  We thought that the additional alkene could impact the equilibria of the 
thiol addition/elimination reactions due to the increase in conjugation and elimination of steric 
influence at the γ-carbon of the enone 3-101.  Base-catalyzed thiol addition to enone 3-101 and 
thiol mediated elimination of adduct 3-106 gave significant quantities of unidentifiable 
byproducts during the equilibration (Scheme 64); therefore, proper thermodynamic analysis of 
this substrate could not be completed.  We imagine a mixture of β- and δ-conjugate addition 
products could form in addition to epimerization or isomerization reactions. 
 
 
Scheme 64.  Attempted thiol addition to enone 3-101 and thiol elimination with adduct 3-106. 
 
After performing a preliminary analysis on simplified enones 3-98 and 3-99, we were 
poised to explore the equilibrium of the thiol addition reaction of tricyclic enone 3-92.  Enone 3-
92 was prepared in 8 steps from enone 3-99 following the literature procedure.169 The 
equilibrium constant was determined by integration of the peaks for 3-92 (Ha δ 6.96 (d)) and 3-
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93 (Hb δ 5.70-5.62 (m)).  Addition of thiophenol to enone 3-92 was favorable beyond the limits 
of detection for NMR (≤ −4.6 kcal/mol) using either catalytic Et3N or DBU (Figure 21).  Thiol 
elimination of thioether 3-93b was unfavorable by +3.4 kcal/mol in the presence of Et3N; 
however, the thiol elimination was favorable by −2.6 kcal/mol in the presence of DBU. 
 
 
Reaction Base ΔG 
3-92 to 3-93 Et3N ≤ −4.6 kcal/mol 
3-92 to 3-93 DBU ≤ −4.6 kcal/mol 
3-93b to 3-92 Et3N +3.4 ± 0.1 kcal/mol 
3-93b to 3-92 DBU ≤ −2.6 kcal/mol 
Figure 21.  Thiol addition/elimination reactions with enone 3-92 using Et3N and DBU. 
 
Preparation of thiol adducts 3-93a and 3-93b was accomplished in 86% yield as a 
separable ~2.7:1 mixture of diastereomers.  In the minor diastereomer, coupling constant 
analysis of the methine proton highlighted in Figure 22 indicated the presence of two large and 
one small coupling constant, which suggests an equatorial thiophenyl group.  MMFF 
calculations§ indicate a 1.1 kcal/mol preference for 3-93b, with the equatorial thiophenyl group, 
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however the parameters in the low level calculations may not properly account for the 6,7,6-ring 
system. 
 
 
Figure 22.  Assignment of diastereomers of thiol addition products 3-93a and 3-93b. 
 
After hydrogenation of the azepine 3-93a, the thiophenol addition/elimination reaction 
was performed with enone 3-95.  The equilibrium constant was determined by integration of the 
peaks for 3-95 (Ha δ 5.91 (dd)) and 3-94 (Hb δ 4.02 (dd, major diastereomer) and 3.98 (dd, minor 
diastereomer).  Et3N- and DBU-catalyzed thiophenol addition to enone 3-95 was favorable with 
a ΔG of ≤ −4.8 kcal/mol (Figure 23).  The thiol elimination reaction of 3-94a (major) was 
unfavorable by +2.3 kcal/mol using Et3N.  The thiol elimination reaction of 3-94b using DBU 
was favorable by −2.9 kcal/mol, although enone 3-95 was epimerized to a 2.5:1 (S:R) mixture of 
epimers at C-7 during the reaction.  It could not be determined if epimerization occurred in 3-94 
because of the small amount present at equilibrium. 
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Reaction Base ΔG 
3-95 to 3-94 Et3N ≤ −4.6 kcal/mol 
3-95to 3-94 DBU ≤ −4.6 kcal/mol 
3-94a to 3-95 Et3N +2.3 ± 0.03 kcal/mol 
3-94b to 3-95 DBU −2.9 ± 0.2 kcal/mola 
aduring reaction 3-94b to 3-95 with DBU enone 3-95 is 
observed as a 2.5:1 mixture of diastereomers (epimerization α to 
ketone). 
Figure 23.  Thiol addition/elimination reactions with enone 3-95 using Et3N and DBU. 
 
During our investigations, our data showed that Michael additions of thiophenol to 
enones are highly energetically favorable (≤ −4.6 kcal/mol) for enones 3-92, 3-95, and 3-98.  The 
thiol addition to enone 3-99 is slightly less favorable, −4.1 to −4.0 kcal/mol, which may be a 
result of the increased steric bulk of the benzoyl group on the tertiary alcohol.  The ΔG of the 
thiol additions to our enones compares well with the ΔG of −4.8 kcal/mol calculated for the 
addition of thiophenol to cyclopentenone by Bernardi and coworkers.161a Our results suggest that 
these enone containing indole scaffolds could function as covalent inhibitors through a thiol 
addition pathway. 
The thiol elimination reactions of thioethers in the presence of DBU were favored by ≤ 
−2.6 kcal/mol; however, in the presence of Et3N the thiol elimination reactions were unfavored 
by ≥ +1.0 kcal/mol.  The difference in ΔG between the thiol elimination reactions using Et3N and 
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DBU provides the difference in energy of the two base-thiol complexes (DBUH+PhS− vs. 
Et3NH
+PhS−).  The difference in ΔG between the thiol elimination reactions employing Et3N and 
DBU shows that the DBUH+PHS− is ≥ 4.8 kcal/mol lower in energy than Et3NH
+PHS−.  The 
stability of the DBUH+PhS− can be explained by the intrinsic basicity of DBU compared to Et3N 
(DBUH+ pKa 12.0 (DMSO) vs. Et3NH
+ pKa 9.0 (DMSO)).  This trend correlates with the acidity 
of PhSH (pKa 10.3 (DMSO)), which thermodynamically should be deprontated to a greater 
extent by DBU compared to TEA.  These thiol elimination experiments indicate that in the 
absence of strong base, equilibrium between the enone and thiol adduct favors the thiol adduct.  
This suggests that these enones would function as irreversible thiol trapping agents. 
3.3 CONCLUSIONS 
Our investigations of the equilibria of thiophenol additions to enones and base-mediated thiol 
eliminations reveal that the formation of thiol adducts is energetically favorable and that the 
elimination of thiophenol is dependent on the strength of the base used in the elimination 
reaction.  The difference in ΔG of the base-thiol ion pair complexes (DBUH+PhS− vs. 
Et3NH
+PhS−) acts as a ≥ 4.8 kcal/mol driving force for the thiol eliminations using DBU.  Our 
results show that structure and base strength are two factors that play an important role in the 
equilibrium between enone and thiol adducts.  In agreement with the literature, mono-β-
substituted enones form energetically favorable adducts with thiol nucleophiles, which suggests 
they could be used as covalent protein modifiers.  The thiol elimination reactions indicate that 
strongly basic conditions are required to reverse the equilibrium to favor the enone, which 
implies that these enones would function as irreversible covalent inhibitors.  The effect of base 
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on the thiol adduct and enone equilibrium should be considered when covalent protein 
modification occurs in the presence of basic amino acids, such as histidine, lysine, or arginine.  
The potential impact of these basic residues in the enone binding site may cause a shift in the 
equilibrium favoring the unbound enone over the thiol adduct. 
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4.0  EXPERIMENTAL 
4.1 GENERAL EXPERIMENTAL 
All glassware was flame dried and cooled under dry N2 or Ar prior to use.  All moisture 
sensitive reactions were performed under an atmosphere of dry N2 or Ar.  Reactions carried out 
below 0 °C employed an acetone/dry ice bath or a cyrocool and an isopropanol/ethanol bath.  
Reagents obtained from commercial sources were used as received unless otherwise specified.  
THF, Et2O, and 1,4-dioxane were distilled from sodium/benzophenone ketyl; DIPEA and Et3N 
were distilled from CaH2 and stored over KOH; t-BuOH was distilled over CaH2; HFIP was 
distilled from 4Å MS and stored over 4Å MS; and CH2Cl2 and toluene were purified by passage 
through an activated alumina filtration system or by distillation from CaH2.  Concentrating under 
reduced pressure refers to the use of a rotary evaporator connected to a membrane vacuum pump 
or a PIAB Lab Vac H40 to remove solvent. 
Melting points were determined using a Laboratory Devices Mel-Temp II in open 
capillary tubes and are uncorrected.  Infrared spectra were determined as neat solids or oils on a 
Smiths Detection IdentifyIR FT-IR spectrometer.  Mass spectra were obtained on a Micromass 
Autospec UK Limited double focusing instrument or a Q-TOF Ultima API a Thermo Scientific 
Exactive Orbitrap LC-MS.  Optical rotations were determined using a Perkin-Elmer 241 
polarimeter at 23 °C.  Microwave reactions were performed using a Biotage Initiator microwave 
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reactor.  1H and 13C NMR spectra were recorded on a Bruker Avance 300 MHz, 400 MHz, 500 
MHz, or 600 MHz instruments.  Chemical shifts (δ) were reported in parts per million with the 
residual solvent peak used as an internal standard δ 1H / 13C (Solvent); 7.26 / 77.16 (CDCl3); 
2.50 / 39.52 (DMSO-d6); 5.32 / 53.84 (CD2Cl2); 2.05 / 29.84 (acetone-d6) and are tabulated as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintet, sext = sextet, sept = septet, m = multiplet), number of protons, and coupling constant(s).  
13C NMR spectra were obtained using a proton-decoupled pulse sequence and are tabulated by 
observed peak.  Thin-layer chromatography was performed using pre-coated silica gel 60 F254 
plates (EMD, 250 μm thickness) and visualization was accomplished with a 254 nm UV light 
and by staining with a p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 
3.5 mL of conc. H2SO4 in 100 mL of 95% EtOH), a KMnO4 solution (1.5 g of KMnO4 and 1.5 g 
of K2CO3 in 100 mL of a 0.1% NaOH solution), or Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 
H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4 solution).  Flash chromatography on 
SiO2 (Silicycle, Silia-P Flash Silica Gel or SiliaFlash® P60, 40-63 μm) was used to purify crude 
reaction mixtures.  All desired products were placed under high vacuum (0.5-4 mmHg) to 
remove trace solvent. 
4.2 CHAPTER 1 EXPERIMENTAL PART 
 
1-71 
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Ethyl 2-(((benzyloxy)carbonyl)amino)-2-((p-tolylsulfinyl)oxy)acetate (1-71).82 To a 
solution of ethyl glyoxylate 1-70 (2.02 g, 9.89 mmol, 50% in toluene, freshly depolymerized by 
heating at ~50 °C for 1 min) in formic acid (4.85 mL, 128 mmol) was added benzylcarbamate 
(1.48 g, 9.79 mmol) and sodium p-toluensulfinate (2.62 g, 14.7 mmol).  The resulting slurry 
turned into a solution after 2 min and was stirred vigorously for 86 h at rt.  The mixture was 
poured onto ice water (50 mL) and the resulting colorless precipitate was filtered, washed with 
water and dried to give 1-71 (2.24 g, 58%) as a colorless solid of 90% purity that was used 
without further purification: 1H NMR (300 MHz, CDCl3) δ 7.78 (d, 2 H, J = 8.2 Hz), 7.39-7.26 
(m, 5 H), 7.31 (d, 2 H, J = 8.2 Hz), 6.00 (d, 1 H, J = 10.0 Hz), 5.61 (d, 1 H, J = 10 Hz), 5.03 (s, 2 
H), 4.31 (q, 2 H, J = 7.1 Hz), 2.44 (s, 3 H), 1.31 (t, 3 H, J = 7.1 Hz).  
 
 
1-72 
(E)-Ethyl 2-(((benzyloxy)carbonyl)amino)oct-3-enoate (1-72).  To a suspension of 
Cp2ZrHCl (0.172 g, 0.667 mmol) in CH2Cl2 (2 mL) was immediately added 1-hexyne 1-52 (65.0 
μL, 0.566 mmol).  The suspension was stirred for 10 min at rt and the solvent was removed in 
vacuo.  The residue was dissolved in toluene (2 mL), cooled to -78 °C, Me2Zn (280 μL, 0.532 
mmol, 1.90 M toluene) was added and the mixture was allowed to warm to rt.  The vinyl zinc 
reagent was added to a suspension of sulfinyl adduct 1-71 (0.100 g, 0.255 mmol) in toluene (2 
mL) at 0 °C and allowed to stir for 30 min, quenched with sat. aq. NH4Cl (1 mL), washed with 1 
M HCl (1 x 10 mL) and brine (1 x 10 mL), the organic phase was dried (MgSO4), filtered, and 
concentrated under reduced pressure.  The crude residue was purified by chromatography on 
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SiO2 (1:4; EtOAc:hexanes) to give 1-72 (0.0625 g, 77%) as a yellow oil: 
1H NMR (500 MHz, 
CDCl3) δ 7.36-7.30 (m, 5 H), 5.77 (dt, 1 H, J = 15.3, 6.7 Hz), 5.48-5.42 (m, 2 H), 5.12 (s, 2 H), 
4.83 (bt, 1 H, J = 6.5 Hz), 4.20 (q, 2 H, J = 7.1 Hz), 2.04 (aq, 2 H, J = 7.0 Hz), 1.37-1.25 (m, 7 
H), 0.88 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz) δ 171.2, 155.6, 136.4, 135.1, 128.6, 128.2, 
124.1, 67.1, 61.8, 55.8, 31.9, 31.0, 22.2, 14.2, 14.0; MS (EI) m/z 319 (M+, 9), 246 (94), 228 (14), 
91 (70); HRMS (EI) m/z calcd for C18H25NO4 M
+ 319.1784, found 319.1777. 
 
 
1-73 
(1R,2S,5R)-5-Methyl-2-(2-phenylpropan-2-yl)cyclohexyl 2-(((benzyloxy)carbonyl) 
amino)-2-((p-tolylsulfinyl)oxy)acetate (1-73).  To a solution of 8-phenylmethol glyoxylate 1-65 
(1.67 g, 5.77 mmol) in formic acid (4.50 mL) was added benzylcarbamate (0.874 g, 5.78 mmol), 
and sodium p-toluenesulfinate (1.61 g, 9.02 mmol).  The solution was stirred rapidly for 16 h 
upon which the mixture became gel like.  The mixture was allowed to stand for 25 h then diluted 
with water (5 mL), cooled on ice, filtered, and washed with water (2 x 50 mL).  The crude solid 
was recrystallized from Et2O (75 mL) and MeOH (5-10 mL) to give 1-73 (0.918 g, 28%) as a 
colorless solid: 1H NMR (500 MHz, DMSO-d6) δ 8.79 (d, 1 H, J = 10.0 Hz), 7.61 (d, 2 H, J = 8.0 
Hz), 7.48 (d, 2 H, J = 8.0 Hz), 7.41-7.34 (m, 5 H), 7.08-6.98 (m, 5 H), 5.06 (d of AB, 1 H, J = 
13.0 Hz), 5.03 (d of AB, 1 H, J = 13.0 Hz), 4.74 (td, 1 H, J = 10.8, 4.3 Hz), 4.67 (d, 1 H, J = 10.2 
Hz), 2.45 (s, 3 H), 1.91-1.86 (m, 1 H), 1.73-1.58 (m, 3 H), 1.41-1.39 (m, 1 H), 1.08 (s, 6 H), 
0.98-0.86 (m, 3 H), 0.87 (d, 3 H, J = 6.5 Hz); MS (EI) m/z 577 (M+, 0.1), 422 (88), 156 (100); 
HRMS (ESI+) m/z calcd for C33H39NO6SNa [M+Na]
+ 600.2396, found 600.2417. 
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1-77 
(S,E)-N-(Furan-2-ylmethylene)-2-methylpropane-2-sulfinamide (1-77).85 To a 
mixture of S-N-tert-butanesulfinamide (1-73) (0.637 g, 5.15 mmol) and furfural (1-75) (0.435 
mL, 5.20 mmol, freshly distilled from Na2CO3 and passed through basic alumina) was added 
Ti(EtO)4 (3.20 mL, 10.3 mmol) and the solution was stirred rapidly for 4 h at rt.  The resulting 
slurry was poured into a flask and diluted with CH2Cl2 (20 mL) and brine (10 mL), filtered 
through a pad of Celite®, and the filter cake was washed with CH2Cl2 (3 x 50 mL).  The aqueous 
phase was separated and extracted with CH2Cl2 (2 x 15 mL).  The combined organic layers were 
concentrated under reduced pressure and purified by chromatography on SiO2 (2:8; 
EtOAc:hexanes) to give 1-77 (0.895 g, 86%) as a yellow solid (upon refrigeration): 1H NMR 
(CDCl3, 300 MHz) δ 8.35 (s, 1 H), 7.61-7.60 (m, 1 H), 6.97 (dd, 1 H, J = 3.5, 0.6 Hz), 6.53 (dd, 
1 H, J = 3.5, 1.8 Hz), 1.21 (s, 9 H); 13C NMR (CDCl3, 75 MHz) δ 150.9, 149.9, 146.9, 118.8, 
112.3, 57.9, 22.6. 
 
 
1-78 
(S)-N-((S,E)-1-(Furan-2-yl)hept-2-en-1-yl)-2-methylpropane-2-sulfinamide (1-78).  A 
solution of 1-hexyne (1-52) (70.0 μL, 0.609 mmol) in CH2Cl2 (1.5 mL) was treated with 
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Cp2ZrHCl (0.187 g, 0.725 mmol) and allowed to stir for 10 min at rt.  A solution of imine 1-77 
(0.100 g, 0.502 mmol) in CH2Cl2 (1 mL) was treated with Me3Al (276 μL, 0.552 mmol, 2.0 M in 
CH2Cl2) and allowed to stir for 5 min at 0 °C.  The vinyl zirconium species was cooled to 0 °C, 
then Me3Al (301 μL, 0.602 mmol, 2.0 M in CH2Cl2) and the pre-complexed imine 1-77 were 
added.  The reaction mixture was allowed to warm to rt and stirred for 8 h, quenched with sat. 
aq. NH4Cl (1 mL), diluted with Et2O (50 mL) and stirred vigorously with sat. aq. Rochelle’s salt 
(100 mL) for 30 min.  The mixture was filtered through a short pad of Celite®, and the organic 
phase was dried (MgSO4), filtered, and concentrated under reduced pressure.  The crude mixture 
was purified by chromatography on SiO2 (1:5 to 2:3; EtOAc:hexanes) to give 1-78 (0.106 g, 
74%) as yellow oil and a single diastereomer by 1H NMR: 1H NMR (CDCl3, 300 MHz) δ 7.34 
(d, 1 H, J = 1.2 Hz), 6.28 (dd, 1 H, J = 1.8, 3.3 Hz), 6.19 (d, 1 H, J = 3.0 Hz), 5.76 (dt, 1 H, J = 
6.9, 15.3), 5.52 (ddt, 1 H, J = 1.2, 7.5, 15.3 Hz), 4.94 (dd, 1 H, J = 3.6, 7.5 Hz), 3.53 (d, 1 H, J = 
3.3 Hz), 2.06 (app q, 2 H, J = 6.6 Hz), 1.41-1.22 (m, 4 H), 1.19 (s, 9 H), 0.86 (t, 3 H, J = 6.9 Hz); 
13C NMR (CDCl3, 75 MHz) δ 154.4, 142.3, 135.7, 127.1, 110.3, 106.8, 55.7, 55.0, 31.9, 31.1, 
22.6, 22.2, 13.9; MS (EI) m/z 283 (M+, 0.3), 163 (100), 107 (87), 57 (88); HRMS (EI) m/z calcd 
for C15H25NO2S M
+ 283.1606, found 283.1600. 
 
 
1-80 
(S,E)-tert-Butyl (1-(furan-2-yl)hept-2-enyl)carbamate (1-80).  To a solution of 
sulfinamide 1-78 (0.475 g, 1.68 mmol) in MeOH (2.0 mL) was added HCl (2.00 mL, 4.00 mmol, 
2.0 M in Et2O).  The reaction mixture was allowed to stir for 30 min at rt and concentrated in 
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vacuo to give the crude amine hydrochloride (0.361 g, 100%) as a orange-red colored oil that 
was taken on without further purification: 1H NMR (CDCl3, 300 MHz) δ 8.87 (bs, 3 H), 7.41 (d, 
1 H, J = 1.5 Hz), 6.48 (d, 1 H, J = 3.3 Hz), 6.33 (dd, 1 H, J = 1.8, 3.3 Hz), 5.95 (dt, 1 H, J = 6.9, 
15.3 Hz), 5.74 (dd, 1 H, J = 7.5, 15.6 Hz), 4.90 (app t, 1 H, J = 5.7 Hz), 2.09 (app q, 2 H, J = 6.9 
Hz), 1.40-1.26 (m, 4 H), 0.88 (t, 3 H, J = 6.9 Hz); To a solution of the crude amine hydrochloride 
in CH2Cl2 (4.0 mL) was added Boc2O (0.427 g, 1.94 mmol), DMAP (0.203 g, 1.66 mmol), and 
Et3N (0.500 mL, 3.56 mmol).  The reaction mixture was allowed to stir a rt.  After 3.5 h, Boc2O 
(0.464 g, 2.13 mmol) was added and the solution was allowed to stir for 1 h at rt, then 
concentrated under reduced pressure and purified by chromatography on SiO2 (1:9; 
EtOAc:hexanes) to give 1-80 (0.225 g, 48%) as a yellow oil: [α]D -17.3 (c 0.77, CH2Cl2); IR 
(ATR) 3338, 2956, 2926, 2870, 1696, 1165, 1006, 967, 732 cm-1; 1H NMR (CDCl3, 500 MHz) δ 
7.35 (dd, 1 H, J = 0.6, 1.2 Hz), 6.30 (dd, 1 H, J = 1.8, 3.3 Hz), 6.15 (d, 1 H, J = 3.3 Hz), 5.66 (dt, 
1 H, J = 5.7, 15.3 Hz), 5.56 (dd, 1 H, J = 5.7, 15.5 Hz), 5.28 (bs, 1 H), 4.87 (bs, 1 H), 2.05 (app 
q, 2 H, J = 6.9 Hz), 1.44 (s, 9 H), 1.38-1.25 (m, 4 H), 0.88 (t, 3 H, J = 6.9 Hz); 13C NMR (CDCl3, 
75 MHz) δ 155.0, 154.4, 142.1, 133.3, 127.2, 110.3, 106.3, 79.9, 77.4, 32.0, 31.3, 28.5, 22.3, 
14.1; MS (EI) m/z 279 (M+, 0.7), 223 (49), 178 (17), 163 (28), 57 (59); HRMS (EI) m/z calcd for 
C16H25NO3 M
+ 279.1834, found 279.1830. 
 
 
1-83 
(S,E)-N-(2-((tert-Butyldimethylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide 
(1-83).86b, 175 To a solution of but-2-ene-1,4-diol (2.00 g, 1.87 mL, 22.0 mmol), imidazole (3.04 
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g, 44.2 mol) and DMAP (0.151 g, 1.22 mmol) in CH2Cl2 (46 mL) was added TBSCl (6.86 g, 
44.6 mmol).  The reaction mixture was stirred for 13.5 h at rt, concentrated, dissolved in Et2O 
(50 mL), washed with 1M HCl (1 x 50 mL), dried (MgSO4), filtered and concentrated under 
reduced pressure to give the protected diol as a crude mixture.  To a solution of the crude diol 
(6.67 g, 22.0 mmol) in CH2Cl2 (44 mL) was bubbled ozone at -78 °C until a blue color persisted 
(~25 min).  Nitrogen was bubbled through the solution until the blue color disappeared.  Me2S 
(9.25 mL, 123 mmol) was then slowly added at -78 °C.  The reaction mixture was slowly 
warmed to rt, stirred for 16 h, and concentrated under reduced pressure.  The residue was 
redissolved in Et2O (50 mL), washed with water (50 mL), and the organic layer was dried 
(MgSO4), filtered, and concentrated under reduced pressure to give the crude aldehyde as a 
colorless oil.  To a solution of the aldehyde (1.50 g, 8.61 mmol) in CH2Cl2 (15 mL) was added 
anhydrous copper sulfate (4.27 g, 26.8 mmol) followed by the S-N-tert-butanesulfinamide (1-76) 
(0.852 g, 7.03 mmol).  The heterogeneous mixture was stirred rapidly for 14 h at rt and filtered 
through a pad of Celite®. The filter cake was washed with CH2Cl2, and the filtrate was 
concentrated under reduced pressure.  The resulting oil was purified by chromatography on SiO2 
(15:85; EtOAc:hexanes) to give 1-83 (0.818 g, 34% from cis-butene-1,4-diol) as a light yellow 
oil containing ~15% of a silyl impurity (could be stored under dry N2 at -20 °C for several 
weeks, decomposition occurred at rt over several days): 1H NMR (CDCl3, 300 MHz) δ 8.05 (t, 1 
H, J = 3.1 Hz), 4.54 (d, 2 H, J = 3.1 Hz), 1.20 (s , 9 H), 0.91 (s, 9 H), 0.09 (s, 6 H). 
 
 
1-84 
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(S)-N-((S,E)-1-((tert-Butyldimethylsilyl)oxy)oct-3-en-2-yl)-2-methylpropane-2-
sulfinamide (1-84).  To a solution of 1-hexyne (1-52) (0.602 mL, 5.24 mmol) in CH2Cl2 (7.0 
mL) at 0 °C was added Cp2ZrHCl (1.48 g, 5.73 mmol).  The reaction mixture was warmed to rt, 
stirred for 10 min, cooled to 0 °C, and treated with Me3Al (2.20 mL, 4.04 mmol, 2.02 M in 
CH2Cl2).  To a separate flask containing imine 1-83 (1.12 g, 4.03 mmol) in CH2Cl2 (7.0 mL) 
cooled to 0 °C was added Me3Al (2.20 mL, 4.04 mmol, 2.02 M in CH2Cl2) and then this solution 
was cannulated into the solution of the vinyl alane and stirred at rt for 9 h.  The reaction mixture 
was transferred to a larger flask and diluted with Et2O (100 mL), quenched with sat. aq. NH4Cl 
(2 mL), and stirred vigorously with sat. aq. Rochelle’s salt (100 mL) for 30 min.  The mixture 
was filtered though a pad of Celite®, and the organic layer was dried (MgSO4), filtered, and 
concentrated under reduced pressure.  The crude residue was purified by chromatography on 
SiO2 (15:85; EtOAc:hexanes) to give 1-84 (0.884 g, 61%) as a light yellow oil: [α]D +111 (c 
0.99, CH2Cl2); IR (ATR) 3202, 3282, 2952, 2926, 2855, 1470, 1463, 1251, 1060, 833 cm
-1; 1H 
NMR (CDCl3, 300 MHz) δ 5.73 (dt, 1 H, J = 6.8, 15.3 Hz), 5.12 (ddt, 1 H, J = 1.2, 7.8, 15.3 Hz), 
3.90-3.82 (m, 2 H), 3.61 (AB dd, 1 H, JAB = 4.2, 9.9 Hz), 3.41 (AB dd, 1 H, JAB = 8.7, 9.6 Hz), 
2.00 (app q, 2 H, J = 6.6 Hz), 1.37-1.26 (m, 4 H), 1.17 (s, 9 H), 0.86 (s, 12 H), 0.03 (s, 6 H); 13C 
NMR (CDCl3, 75 MHz) δ 136.2, 126.7, 66.5, 57.8, 55.1, 32.1, 31.2, 25.9, 22.7, 22.1, 18.2, 13.9, -
5.3, -5.4; MS (EI) m/z 361 (M+, 7), 304 (43), 241 (30), 185 (92), 142 (73); HRMS (ESI+) m/z 
calcd for C18H39NO2SiS M
+ 361.2471, found 361.2463. 
 
 
1-85 
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(S,E)-tert-Butyl (1-hydroxyoct-3-en-2-yl)carbamate (1-85).176 To a solution of 
sulfinamide 1-84 (0.644 g, 1.78 mmol) in MeOH (2.0 mL) cooled to 0 °C was added HCl (9.00 
mL, 18.0 mmol, 2.0 M in Et2O).  The mixture was warmed to rt and stirred for 1.5 h then 
concentrated in vacuo and to yield the crude amino alcohol hydrochloride.  To a solution of the 
crude amino alcohol hydrochloride in CH2Cl2 (6.0 mL) was added NaHCO3 (0.747 g, 8.89 
mmol) and stirred rapidly for 5 min.  Et3N (0.750 mL, 5.34 mmol), DMAP (0.0423 g, 0.346 
mmol), and Boc2O (0.253 g, 2.71 mmol) were added and the mixture was allowed to stir for 19 h 
at rt, quenched with water (3 mL), and extracted with CH2Cl2 (2 x 10 mL).  The combined 
organic layers were washed with brine (1 x 7 mL), dried (Na2SO4), filtered, and concentrated 
under reduced pressure.  The resulting residue was purified by chromatography on SiO2 (1:9 to 
2:8; EtOAc:hexanes) to give 1-85 (0.433 g, 58%) as a light yellow oil: [α]D +4.2 (c 1.02, 
CH2Cl2); IR (ATR) 3332, 2956, 2924, 1685, 1165, 1051 cm
-1; 1H NMR (CDCl3, 300 MHz) δ 
5.66 (ddt, 1 H, J = 1.2, 6.9, 15.3 Hz), 5.35 (dd, 1 H, J = 6.3, 15.3 Hz), 4.88 (d, 1 H, J = 7.5 Hz), 
4.15 (bs, 1 H), 3.67-3.52 (m, 2 H), 2.02 (app q, 2 H, J = 6.9 Hz), 1.43 (s, 9 H), 1.36-1.29 (m, 4 
H), 0.87 (t, 3 H, J = 6.9 Hz); 13C NMR (CDCl3, 75 MHz) δ 156.3, 133.7, 126.8, 79.9, 66.6, 54.5, 
32.1, 31.3, 28.5, 22.3, 14.0; MS (EI) m/z 212 ([M-CH3O]
+, 60), 156 (100), 112 (96), 96 (65); 
HRMS (EI) m/z calcd for C12H22NO2 [M-CH3O]
+ 212.1651, found 212.1648. 
 
 
1-86 
(S,E)-2-((tert-Butoxycarbonyl)amino)oct-3-enoic acid (1-86).176 To a solution of 1-85 
(0.219 g, 0.900 mmol) in CH2Cl2 (8.0 mL) was added NaHCO3 (0.232 g, 2.76 mmol) and DMP 
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(0.575 g, 1.36 mmol).  The reaction mixture was allowed to stir at rt for 1.5 h, quenched with sat. 
aq. Na2S2O3 (3 mL) and sat. aq. NaHCO3 (3 mL), diluted with Et2O (5 mL), and stirred rapidly 
until the solids dissolved.  The organic layer was separated and the aqueous layer was extracted 
with Et2O (2 x 10 mL).  The combined organic layers were washed with brine (1 x 10 mL), dried 
(Na2SO4), filtered, and concentrated under reduced pressure.  To a solution of the crude aldehyde 
in THF (4.0 mL) and water (2.0 mL) was added NaH2PO4•H2O (0.376 g, 2.72 mmol), 2-methyl-
2-butene (0.950 mL, 8.97 mmol), followed by NaClO2 (0.243 g, 2.69 mmol).  The mixture was 
allowed to stir at rt for 3.75 h, extracted with EtOAc (3 x 10 mL), washed with brine (1 x 10 
mL), and concentrated under reduced pressure.  The oily residue was dissolved in CH2Cl2, 
filtered through a pad of Celite®, washed with brine (1 x 10 mL), dried (Na2SO4), filtered and 
concentrated under reduced pressure to give 1-86 (0.214 g, 92%) as a crude yellow oil of 
approximately 85% purity based on 1H NMR analysis: 1H NMR (CDCl3, 300 MHz) δ 10.25 (bs, 
1 H), 7.18 (bs, 1 H), 5.83-5.76 (m, 1 H), 5.49-5.44 (m, 1 H), 5.19 (d, 1 H, J = 6.9 Hz), 2.04 (app 
q, 2 H, J = 6.6 Hz), 1.42 (s, 9 H), 1.38-1.25 (m, 4 H), 0.87 (t, 3 H, J = 6.6 Hz). 
 
 
1-87 
(S,E)-N-(2-((tert-Butyldiphenylsilyl)oxy)ethylidene)-2-methylpropane-2-sulfinamide 
(1-87).177 To a solution of 2-cis-1,4-butenediol (1.00 mL, 12.2 mL), in CH2Cl2 (30 mL) was 
added TBDPSCl (6.32 mL, 24.3 mmol), imidazole (2.51 g, 36.5 mmol) and DMAP (0.0743 g, 
0.608 mmol) at 0 °C.  The reaction mixture was warmed to rt and stirred for 15 h, concentrated, 
redissolved in Et2O (30 mL) and washed with 1 M HCl (30 mL).  The organic layer was dried 
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(MgSO4), filtered, and concentrated under reduced pressure.  To a solution of the crude protected 
diol (6.87 g, 12.17 mmol) in CH2Cl2 (30 mL) was bubbled ozone at -78 °C until a blue color 
persisted (~20 min).  Nitrogen was bubbled through the blue solution until it turned colorless and 
Me2S (32.0 mL, 433 mmol) was then slowly added.  The reaction mixture was slowly warmed to 
rt, stirred for 17 h, and concentrated under reduced pressure.  The residue was partitioned 
between Et2O (30 mL) and water (30 mL).  The organic layer was washed with water (1 x 30 
mL) and brine (1 x 30 mL), dried (Na2SO4), filtered and concentrated under reduced pressure.  
To a solution of the crude aldehyde (1.06 g, 3.55 mmol) in THF (6 mL) was added S-N-tert-
butanesulfinamide (1-76) (0.485 g, 4.00 mmol) and Ti(EtO)4 (1.50 mL, 7.15 mmol).  The 
mixture was stirred for 20 h at rt.  The resulting slurry was diluted with EtOAc (10 mL), 
quenched with brine (5 mL), stirred for 5 min, and filtered through a pad of Celite®.  The filtrate 
was washed with brine (1 x 10 mL), dried (MgSO4), filtered and concentrated.  The crude oil was 
purified by chromatography on SiO2 (1:9, EtOAc:hexanes) to give 1-87 (0.680 g, 48% from 2-
cis-1,4-butenediol) as a light yellow oil: 1H NMR (CDCl3, 300 MHz) δ 8.11 (t, 1 H, J = 2.9 Hz), 
7.72-7.67 (m, 4 H), 7.45-7.37 (m, 6 H), 4.57 (d, 2 H, J = 2.9 Hz), 1.20 (s, 9 H), 1.10 (s, 9 H); 13C 
NMR (CDCl3, 75 MHz) δ 168.3, 135.6, 132.9, 130.1, 127.9, 66.2, 56.9, 26.8, 22.4, 19.3. 
 
 
1-88 
(S)-N-((S,E)-1-((tert-Butyldiphenylsilyl)oxy)oct-3-en-2-yl)-2-methylpropane-2-
sulfinamide (1-88).  To a solution of 1-hexyne (1-52) (0.205 mL, 1.78 mmol) in CH2Cl2 (2.25 
mL) was adde Cp2ZrHCl (0.498 g, 1.93 mmol) and the suspension was stirred at rt for 10 min, 
 108 
cooled to 0 °C and treated with Me3Al (0.750 mL, 1.50 mmol, 2.0 M in CH2Cl2).  To a solution 
of imine 1-87 (0.549 g, 1.37 mmol) in CH2Cl2 (2.25 mL) in a separate flask at 0 °C was added 
Me3Al (0.750 mL, 1.50 mmol, 2.0 M in CH2Cl2).  The mixture was stirred for 5 min and the 
vinyl alane was added via cannula.  The reaction mixture was warmed to rt, stirred for 4 h, 
diluted with Et2O (50 mL), quenched with sat. aq. NH4Cl (5 mL), and stirred rapidly with sat. aq. 
Rochelle’s salt (100 mL) for 10 min.  The mixture was filtered through a pad of Celite®, 
separated, the aqueous layer was extracted with Et2O (2 x 10 mL), and the organic layers were 
combined, washed with brine (1 x 20 mL), dried (Na2SO4), filtered, and concentrated under 
reduced pressure.  Analysis of the crude mixture by 1H NMR showed a single diastereomer 
before purification by chromatography on SiO2 (2:8; EtOAc:hexanes) to give 1-88 (0.503 g, 
76%) as a colorless oil: [α]D +68.3 (c 1.03, CH2Cl2); IR (ATR) 3280, 2952, 2926, 1109, 1073, 
969 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.69-7.65 (m, 4 H), 7.47-7.36 (m, 6 H), 5.72 (dt, 1 H, J 
= 15.4, 6.7 Hz), 5.10 (dd, 1 H, J = 15.4, 8.0 Hz), 4.10 (bs, 1 H), 4.04-3.97 (m, 1 H), 3.67 (dd, 1 
H, J = 9.9, 4.2 Hz), 3.53 (app t, 1 H, J = 9.6 Hz), 1.99 (app q, 2 H, J = 6.7 Hz), 1.36-1.26 (m, 4 
H), 1.24 (s, 9 H), 1.06 (s, 9 H), 0.86 (t, 3 H, J = 7.0 Hz); 13C NMR (CDCl3, 75 MHz) δ 136.7, 
135.7, 135.7, 133.2, 133.0, 130.0, 130.0, 127.9, 127.9, 126.4, 67.2, 57.8, 55.2, 32.2, 31.2, 26.9, 
22.8, 22.2, 19.3, 14.0; MS (ESI+) m/z 508 ([M+Na]+, 100), 486 ([M+H]+, 4), 387 (48); HRMS 
(ESI+) m/z calcd for C28H44NO2SSi [M+H]
+ 486.2862, found 486.2870. 
 
 
1-89 
(S,E)-tert-Butyl 4-(hex-1-en-1-yl)-2,2-dimethyloxazolidine-3-carboxylate (1-89).  To a 
solution of 1-85 (0.036 g, 0.15 mmol) in toluene (0.5 mL) was added 2,2-dimethoxypropane 
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(0.037 mL, 0.30 mmol) and PTSA (0.0010 g, 0.0058 mmol).  The reaction mixture was stirred at 
reflux for 6 h, cooled to rt, quenched with sat. aq. NaHCO3 (5 mL) and extracted with Et2O (2 x 
10 mL).  The combined organic layers were washed with brine (1 x 10 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure. The resulting residue was purified by 
chromatography on SiO2 (5:95; EtOAc:hexanes) to give 1-89 (0.027 g, 66%) as a colorless oil: 
1H NMR (CDCl3, 300 MHz) δ 5.55 (bs, 1 H), 5.40 (dd, 1 H, J = 7.8, 15.3 Hz), 4.33-4.21 (m, 1 
H), 4.00 (AB dd, 1 H, JAB = 6.0, 8.7 Hz), 3.70 (AB dd, 1 H, JAB = 2.1, 8.7 Hz), 2.02 (app q, 2 H, 
J = 6.6 Hz), 1.59 (bs, 3 H), 1.49 (s, 3 H), 1.43 (bs, 9 H), 1.36-1.24 (m, 4 H), 0.88 (t, 3 H, J = 6.9 
Hz); 13C NMR (CDCl3, 75 MHz) δ 152.1, 132.8, 129.2, 93.8, 79.5, 68.7, 59.4, 31.9, 31.5, 28.6, 
26.8, 23.9, 22.3, 14.0; MS (EI) m/z 268 ([M-CH3]
+, 73), 212 (20), 168 (80), 57 (100); HRMS 
(EI) m/z calcd for C15H26NO3 [M-CH3]
+
 268.1913, found 268.1910. 
 
 
1-90 
(S)-tert-Butyl 4-hexyl-2,2-dimethyloxazolidine-3-carboxylate (1-90).  To a solution of 
olefin 1-89 (0.020 g, 0.072 mmol) in EtOH (0.42 mL) was added 10% Pd/C (0.012 g, 0.011 
mmol) and H2 was bubbled through the reaction mixture at rt for 3.75 h.  The mixture was 
filtered through a pad of Celite®, washed with CH2Cl2, and concentrated under reduced pressure.  
The crude residue was purified by chromatography on SiO2 (3:97; EtOAc:hexanes) to give 1-90 
(0.018 g, 89%) as a colorless oil: [α]D +27 (c 0.95, CH2Cl2); IR (ATR) 2928, 2857, 1694, 1385, 
1375 cm-1; 1H NMR (DMSO-d6, 60 °C, 300 MHz) δ 3.90 (ddd, 1 H, J = 8.7, 5.9, 0.6 Hz), 3.77 
(dddd, 1 H, J = 8.8, 5.7, 3.8, 1.8 Hz), 3.67 (dd, 1 H, J = 8.7, 1.8 Hz), 1.69-1.56 (m, 1 H), 1.48 (s, 
3 H), 1.43 (s, 9 H), 1.41 (s, 3 H), 1.28 (bs, 9 H), 0.88 (t, 3 H, J = 6.7 Hz); 13C NMR (DMSO-d6, 
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60 °C, 75 MHz) δ 150.9, 92.3, 66.2, 56.5, 32.6, 30.7, 28.1, 27.7, 26.5, 24.9, 23.4, 21.5, 13.3; MS 
(EI) m/z 285 (M+, 0.5), 270 (75); HRMS (EI) m/z calcd for C16H31NO3 M
+
 285.2304, found 
285.2312. 
 
 
1-93 
(R)-tert-Butyl 4-hexyl-2,2-dimethyloxazolidine-3-carboxylate (1-93).  To a solution of 
pentylphosphoniumbromide (0.136 g, 0.330 mmol) in THF (1.0 mL) cooled to -78 °C was added 
dropwise KHMDS (0.610 mL, 0.305 mmol, 0.5 M in toluene).  The solution was warmed to rt, 
stirred for 5 min, cooled to -78 °C and treated dropwise with a solution of Garner’s aldehyde 1-
91 (0.051 g, 0.22 mmol) in THF (0.6 mL).  After dropwise addition of MeOH (1.6 mL), the 
mixture was warmed to rt, stirred for 3 h, diluted with CHCl3, washed with water, dried 
(MgSO4), filtered through a pad of Celite
®, and concentrated under reduced pressure.  The crude 
residue was purified by chromatography on SiO2 (5:95; EtOAc:hexanes) to give 1-92 (0.0365 g, 
58%) as a colorless oil and ~92:8 E:Z mixture of olefin isomers.  Major isomer: 1H NMR 
(CDCl3, 300 MHz) δ 5.54 (bs, 1 H), 5.39 (dd, 1 H, J = 15.3, 7.5 Hz), 4.32-4.21 (m, 1 H), 3.99 
(dd of AB, 1 H, J = 8.7, 6.0 Hz), 3.69 (dd of AB, 1 H, J = 8.7, 2.1 Hz), 2.01 (app q, 2 H, J = 6.6 
Hz), 1.58 (bs, 3 H), 1.48 (s, 3 H), 1.42 (bs, 9 H), 1.36-1.24 (m, 4 H), 0.87 (t, 3 H, J = 6.9 Hz).  
To a solution of the olefin mixture 1-92 (0.0365 g, 0.129 mmol) in EtOH (0.75 mL) was added 
10% Pd/C (0.0186 g, 0.0175 mmol) and H2 was bubbled through at rt for 3.5 h.  The reaction 
mixture was filtered through a pad of Celite®, washed with CH2Cl2, concentrated under reduced 
pressure, and the crude residue was purified by chromatography on SiO2 (3:97; EtOAc:hexanes) 
to give 1-93 (0.0317 g, 86%) as a colorless oil: [α]D -26 (c 0.99, CH2Cl2); IR (ATR) 2924, 2857, 
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1692, 1385, 1374 cm-1; 1H NMR (DMSO-d6, 60 °C, 300 MHz) δ  3.90 (dd of AB, 1 H, J = 8.7, 
5.7, Hz), 3.78-3.72 (m, 1 H), 3.67 (dd of AB, 1 H, J = 8.7, 1.8 Hz), 1.69-1.56 (m, 2 H), 1.56 (s, 3 
H), 1.43 (s, 9 H), 1.41 (s, 3 H), 1.28 (bs, 8 H), 0.87 (t, 3 H, J = 6.6 Hz); 13C NMR (DMSO-d6, 60 
°C, 75 MHz) δ 150.9, 92.3, 78.4, 66.2, 56.5, 32.6, 30.8, 28.1, 27.8, 26.5, 24.9, 23.4, 21.5, 13.3; 
MS (EI) m/z 285 (M+, 0.6), 214 (55); HRMS (EI) m/z calcd for C16H31NO3 M
+
 285.2304, found 
285.2312. 
 
 
1-96 
(R,E)-2-Methyl-N-(2-methylpropylidene)propane-2-sulfinamide (1-96).92 To a 
solution of isobutyraldehyde (1-94) (1.20 mL, 13.0 mmol) in CH2Cl2 (40 mL) was added MgSO4 
(3.66 g, 30.4 mmol), (R)-tert-butanesulfinamide (1-95) (0.753 g, 6.09 mmol), and PPTS (0.0813 
g, 0.324 mmol).  The resulting suspension was stirred for 20 h at rt, filtered through a pad of 
Celite®, washed with CH2Cl2 (50 mL), and concentrated under reduced pressure to give 1-96 
(0.800 g, 75%) as a light yellow oil that was used without purification: 1H NMR (CDCl3, 300 
MHz) δ 7.97 (d, 1 H, J = 4.4 Hz), 2.70 (dqq, 1 H, J = 6.9, 6.9, 4.4 Hz), 1.17 (s, 9 H), 1.16 (d, 3 
H, J = 6.9 Hz), 1.15 (d, 3 H, J = 6.9 Hz). 
 
 
1-97 
tert-Butyldiphenyl(prop-2-ynyloxy)silane (1-97).94 To a solution of propargyl alcohol 
(10.3 mL, 178 mmol) in CH2Cl2 (100 mL) was added TBDPSCl (52.5 mL, 197 mmol) and 
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imidazole (13.5 g, 196 mmol).  The reaction mixture was stirred for 16 h at rt, diluted with Et2O 
(100 mL), washed with brine (2 x 50 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure.  The resulting oil was cooled in the freezer (-20 °C) then placed under high 
vacuum, resulting in a light yellow solid that was recrystallized (Et2O:hexanes) to give 1-97 
(42.1 g, 80 %) as a light yellow crystalline solid.  The filtrate was concentrated and purified by 
chromatography (1:99; Et2O:hexanes) to give 1-97 (10.9 g, 21%) as a colorless solid: 
1H NMR 
(CDCl3, 300 MHz) δ 7.76-7.74 (m, 4 H), 7.50-7.40 (m, 6 H), 4.34 (d, 2 H, J = 2.3 Hz), 2.41 (t, 1 
H, J = 2.3 Hz) 1.10 (s, 9 H); 13C NMR (CDCl3, 75 MHz) δ 135.7, 133.1, 130.0, 127.9, 82.1, 
73.2, 52.6, 26.8, 19.3. 
 
 
1-100 
(E)-tert-Butyl((3-iodoallyl)oxy)diphenylsilane (1-100).95 To a suspension of Cp2ZrHCl 
(5.25 g, 20.4 mmol) in THF (48 mL) at 0 °C was added 1-97 (5.00 g, 17.0 mmol).  The reaction 
mixture was warmed to rt, stirred for 1.5 h while protected from light, cooled to -78 °C, and 
treated with iodine (5.33 g, 21.0 mmol).  The mixture was warmed to rt and stirred for 30 min, 
then quenched with 1 M HCl (50 mL).  The mixture was extracted with Et2O (3 x 25 mL), and 
the combined organic layers were washed with sat. aq. Na2S2O3 (2 x 20 mL), sat. aq. NaHCO3 (1 
x 20 mL), and brine (1 x 20 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure.  The crude oil was purified by chromatography on SiO2 (hexanes) to give 1.17 g (68%) 
of 1-100 as light orange oil: 1H NMR (CDCl3, 300 MHz) δ 7.67-7.65 (m, 4 H), 7.48-7.37 (m, 6 
H), 6.60 (dt, 1 H, J = 4.5, 14.4 Hz), 6.36 (dt, 1 H, J = 1.8, 14.4 Hz), 4.13 (dd, 2 H, J = 1.8, 4.5 
Hz), 1.07 (s, 9 H); 13C NMR (CDCl3, 75 MHz) δ 144.6, 135.6, 133.2, 130.0, 127.9, 76.1, 66.2, 
26.9, 19.4. 
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1-101 
(S,E)-2-Methyl-N-(2-methylpropylidene)propane-2-sulfinamide (1-101).92 To a slurry 
of (S)-tert-butanesulfinamide (1-77) (3.00 g, 24.8 mmol), MgSO4 (14.9 g, 123 mmol), and PPTS 
(0.314 g, 1.25 mmol) in CH2Cl2 (90 mL) was added isobutyraldehyde (4.75 mL, 52.0 mmol). 
The reaction mixture was stirred for 24 h at rt, filtered through a pad of Celite®, washed 
thoroughly with CH2Cl2, and concentrated under reduced pressure.  The resulting oil was 
purified by chromatography on SiO2 (1:9; EtOAc:hexanes) to give 1-101 (3.96 g, 91%) as a 
colorless oil: 1H NMR (CDCl3, 300 MHz) δ 7.98 (d, 1 H, J = 4.4 Hz), 2.71 (dqq, 1 H, J = 6.9, 
6.9, 4.4 Hz), 1.18 (s, 9 H), 1.16 (d, 3 H, J = 7.1 Hz), 1.16 (d, 3 H, J = 6.9 Hz). 
 
 
1-102 
(S)-N-((S,E)-6-((tert-Butyldiphenylsilyl)oxy)-2-methylhex-4-en-3-yl)-2-
methylpropane-2-sulfinamide (1-102).  To a solution of 1-100 (1.78 g, 4.21 mmol) in Et2O (4.0 
mL) cooled to -78 °C was added t-BuLi (5.00 mL, 8.45 mmol, 1.69 M in pentane) dropwise.  
The reaction mixture was allowed to stir for 15 min, treated dropwise with MgBr2 (4.21 mL, 4.21 
mmol, 1.0 M in benzene:Et2O; 1:4), and stirred for 15 min.  A solution of imine 1-101 (0.568 g, 
3.24 mmol) in CH2Cl2 (5 mL) was added via cannula.  The mixture was warmed to rt, and stirred 
for 14 h, quenched with sat. aq. NH4Cl (5 mL) and water (5 mL), and extracted with CH2Cl2 (3 x 
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10 mL).  The combined organic layers were washed with brine (1 x 10 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure.  The crude residue was purified by 
chromatography on SiO2 (2:8 to 4:6; EtOAc:hexanes) to give 1-102 (1.24 g, 81%) as a light 
yellow oil along with a minor diastereomer (0.208 g, 14%).  Major diastereomer: [α]D +38.7 (c 
1.00, CH2Cl2); IR (ATR) 3211, 2956, 2930, 2855, 1470, 1428, 1109, 1057, 701 cm
-1; 1H NMR 
(CDCl3, 300 MHz) δ 7.70-7.66 (m, 4 H), 7.45-7.34 (m, 6 H), 5.82 (dt, 1 H, J = 15.6, 3.6 Hz), 
5.75 (ddt, 1 H, J = 15.6, 6.3, 0.9 Hz), 4.24 (d, 2 H, J = 3.0 Hz), 3.67 (app q, 1 H, J = 5.7 Hz), 
3.05 (d, 1 H, J = 5.7 Hz), 1.95 (dqq, 1 H, J = 6.6, 6.6, 4.8 Hz), 1.23 (s, 9 H), 1.06 (s, 9 H), 0.90 
(d, 3 H, J = 6.6 Hz), 0.89 (d, 3 H, J = 6.6 Hz); 13C NMR (CDCl3, 75 MHz) δ 135.6, 133.8, 133.8, 
132.6, 129.8, 128.7, 127.8, 63.9, 62.9, 56.0, 32.3, 26.9, 22.8, 19.4, 18.8, 17.5; MS (EI) m/z 472 
([M+H]+, 30), 394 (22), 351 (47), 337 (63), 295 (37), 280 (51), 121 (23), 77 (35); HRMS (EI) 
m/z calcd for C27H42NO2SSi [M+H]
+
 472.2706, found 472.2695.  Minor diastereomer: [α]D +45.8 
(c 1.00, CH2Cl2); IR (ATR) 3209, 2953, 2928, 1470, 1105, 1052 cm
-1; 1H NMR (CDCl3, 300 
MHz) δ 7.70-7.67 (m, 4 H), 7.45-7.34 (m, 6 H), 5.77 (dt, 1 H, J = 15.3, 4.2 Hz), 5.62 (ddt, 1 H, J 
= 15.3, 8.1, 1.8 Hz), 4.24 (dd, 2 H, J = 3.9, 1.5 Hz), 3.70 (ddd, 1 H, J = 8.1, 4.8, 3.0 Hz), 3.15 (d, 
1 H, J = 2.7 Hz), 1.79 (dqq, 1 H, J = 6.6, 6.6, 4.8 Hz), 1.21 (s, 9 H), 1.05 (s, 9 H), 0.94 (d, 3 H, J 
= 6.6 Hz), 0.92 (d, 3 H, J = 6.6 Hz); 13C NMR (CDCl3, 75 MHz) δ 135.6, 135.6, 133.9, 133.8, 
133.2, 129.8, 127.8, 127.7, 63.8, 62.1, 55.5, 33.8, 26.9, 22.8, 19.4, 19.1, 17.6; MS (EI) m/z 472 
([M+H]+, 3), 351 (24), 337 (28), 295 (21), 280 (94), 121 (34); HRMS (EI) m/z calcd for 
C27H42NO2SSi [M+H]
+
 472.2706, found 472.2722. 
 
 
1-104 
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(S,E)-6-((tert-Butyldiphenylsilyl)oxy)-2-methylhex-4-en-3-amine hydrochloride (1-
104). To a solution of sulfinamide 1-102 (0.187 g, 0.396 mmol) in hexanes (1.8 mL) was added 
HCl (2 M in Et2O, 0.400 mL, 0.800 mmol).  The resulting slurry was stirred at rt for 30 min, 
filtered, and washed with hexanes (2 x 5 mL) to give amine hydrochloride 1-104 (0.140 g, 88%) 
as a colorless solid: Mp 171.3-172.1 °C (hexanes); [α]D -2.84 (c 1.00, CH2Cl2); IR (ATR) 3008, 
2954, 2889, 1599, 1109, 971 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.59 (bs, 3 H), 7.66-7.63 (m, 4 
H), 7.38-7.37 (m, 6 H), 5.95 (dt, 1 H, J = 15.5, 3.6 Hz), 5.83 (dd, 1 H, J = 15.5, 7.2 Hz), 4.20 (d, 
1 H, J = 2.5 Hz), 3.56-3.55 (m, 1 H), 2.13 (app sext., 1 H, J = 6.4 Hz), 1.05 (s, 9 H), 0.98 (d, 3 H, 
J = 6.4 Hz), 0.96 (d, 3 H, J = 6.4 Hz); 13C NMR (CDCl3, 75 MHz) δ 135.8, 135.6, 133.5, 133.5, 
129.8, 127.9, 127.9, 122.3, 63.3, 59.0, 31.4, 26.9, 19.4, 19.3, 17.5; MS (EI) m/z 324 ([M-C3H7]
+, 
13), 310 (18), 199 (100); HRMS (EI) m/z calcd for C20H26NOSi [M-C3H7]
+
 324.1784, found 
324.1780. 
 
 
1-105 
(S,E)-tert-butyl (6-((tert-butyldiphenylsilyl)oxy)-2-methylhex-4-en-3-yl)carbamate 
(1-105). To a solution of amine hydrochloride 1-104 (0.150 g, 0.371 mmol) in CH2Cl2 (2.5 mL) 
was added Boc2O (0.100 mL, 0.435 mL) and Et3N (0.155 mL, 1.10 mmol).  The reaction mixture 
was stirred at rt for 17.75 h, quenched with sat. aq. NH4Cl (5 mL) and water (5 mL), separated, 
and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers 
were washed with brine (1 x 10 mL), dried (Na2SO4), filtered, concentrated under reduced 
pressure, and purified by chromatography on SiO2 (1:9; EtOAc:hexanes) to give 0.180 g (100%) 
of 1-105 as a colorless oil: [α]D -12.2 (c 1.00, CH2Cl2); IR (ATR) 3338, 2959, 2930, 1700, 1497, 
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1111 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.69-7.66 (m, 4 H), 7.45-7.34 (m, 6 H), 5.72-5.59 (m, 
2 H), 4.50-4.46 (m, 1 H), 4.21 (dd, 2 H, J = 2.3, 0.9 Hz), 4.00 (bs, 1 H), 1.77 (app sext., 1 H, J = 
6.6 Hz), 1.45 (s, 9 H), 1.06 (s, 9 H), 0.89 (d, 3 H, J = 6.8 Hz), 0.88 (d, 3 H, J = 6.8 Hz); 13C 
NMR (CDCl3, 75 MHz) δ 155.8, 135.8, 134.2, 130.3, 129.8, 129.5, 127.8, 79.3, 64.3, 32.8, 28.7, 
27.7, 27.1, 19.5, 18.7, 18.4; MS (ESI+) m/z 490 ([M+Na]+, 100), 351 (15); HRMS (ESI+) m/z 
calcd for C28H41NO3SiNa [M+Na]
+
 490.2753, found 490.2744. 
 
 
1-106 
tert-Butyl ((3S,4R,5R)-6-((tert-butyldiphenylsilyl)oxy)-4,5-dihydroxy-2-methylhexan-
3-yl)carbamate (1-106).  To a biphasic solution of carbamate 1-105 (1.86 g, 3.98 mmol) in 
acetone (17 mL) and water (8 mL) was added NMO (0.806 g, 5.96 mmol) and OsO4 (2.50 mL, 
0.200 mmol, 0.08 M in n-BuOH).  The reaction mixture was vigorously stirred for 20.5 h, 
quenched with sat. aq. NaHSO3 (20 mL), and the acetone was removed under reduced pressure.  
The aqueous mixture was diluted with water (10 mL) and EtOAc (15 mL), separated, and the 
aqueous layer was extracted with EtOAc (3 x 10 mL).  The combined organic layers were dried 
(Na2SO4), filtered through a pad of Celite
®, and concentrated.  The crude residue was composed 
of a 4:1 mixture of diastereomers that were purified by chromatography on SiO2 (10:90 to 15:85; 
EtOAc:hexanes) to give the major diastereomer 1-106 (1.18 g, 59%) as a colorless solid: Mp 
45.6-47.9 °C (CHCl3); [α]D -2.5 (c 1.00, CH2Cl2); IR (ATR) 3360, 2956, 2928, 1679, 1170, 1111 
cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.70-7.66 (m, 4 H), 7.45-7.37 (m, 6 H), 4.59 (d, 1 H, J = 9.3 
Hz), 3.81-3.80 (m, 2 H), 3.73 (app q, 1 H, J = 5.0 Hz), 3.59-3.54 (m, 2 H), 3.51 (dt, 1 H, J = 9.2, 
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3.9 Hz), 2.56 (d, 1 H, J = 7.9 Hz), 2.24 (dqq, 1 H, J = 6.9, 6.9, 4.3 Hz), 1.45 (s, 9 H), 1.07 (s, 9 
H), 0.96 (d, 3 H, J = 6.9 Hz), 0.89 (d, 3 H, J = 7.0 Hz); 13C NMR (CDCl3, 75 MHz) δ 157.7, 
135.7, 135.7, 133.4, 133.2, 129.9, 127.9, 80.2, 70.8, 70.1, 65.4, 57.0, 28.5, 27.1, 27.0, 20.4, 19.3, 
16.1; MS (ESI+) m/z 524 ([M+Na]+, 55), 387 (100); HRMS (ESI+) m/z calcd for C28H45NO5SiNa 
[M+Na]+ 524.2808, found 524.2825. 
 
 
1-107 
tert-Butyl ((S)-1-((4R,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)-2-methylpropyl)carbamate (1-107).  To a solution of diol 1-106 (0.031 g, 0.061 
mmol) in CH2Cl2 (0.25 mL) was added 2,2-dimethoxypropane (0.25 mL, 2.0 mmol) and PPTS 
(0.0010 g, 0.0040 mmol).  The reaction vessel was sealed and heated at 60 °C for 10.5 h, 
concentrated under reduced pressure, and purified by chromatography on SiO2 to give dioxolane 
1-107 (0.029 g, 87%) as a colorless oil:  [α]D -27.3 (c 1.00, CH2Cl2); IR (ATR) 2958, 2930, 
1716, 1700, 1167, 1111 cm-1; 1H NMR (CDCl3, 300 MHz) δ 7.72-7.68 (m, 4 H), 7.47-7.36 (m, 6 
H), 4.17 (d, 1 H, J = 10.4 Hz), 4.08 (dt, 1 H, J = 6.7, 3.5 Hz), 3.97 (dd, 1 H, J = 9.4, 6.8 Hz), 
3.88 (dd, 1 H J = 11.1, 3.7 Hz), 3.70 (dd, 1 H, J = 10.0, 3.1 Hz), 3.63 (dd, 1 H, J = 11.2, 3.3 Hz), 
2.11 (dqq, 1 H, J = 6.8, 6.8, 3.2 Hz), 1.41 (s, 3 H), 1.36 (s, 9 H), 1.08 (s, 9 H), 0.93 (d, 3 H, J = 
6.9 Hz), 0.83 (d, 3 H, J = 6.9 Hz); 13C NMR (CDCl3, 75 MHz) δ 156.1, 135.8, 133.5, 133.4, 
129.9, 129.8, 127.9, 127.9, 109.3, 80.6, 79.4, 64.1, 57.6, 28.7, 28.4, 27.6, 27.5, 27.0, 20.0, 19.4, 
15.7; MS (ESI+) m/z 564 ([M+Na]+ (100); HRMS (ESI+) m/z calcd for C31H47NO5SiNa [M+Na]
+
 
564.3121, found 564.3119. 
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1-111 
tert-Butyl ((S)-1-((4R,5S)-5-(but-3-en-1-ylcarbamoyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)-2-methylpropyl)carbamate (1-111).26 To a solution of silyl ether 1-107 (1.20 g, 2.21 mmol) 
in THF (19 mL) was added TBAF (3.00 mL, 3.00 mmol, 1.0 M in THF).  The resulting yellow 
solution was stirred at rt for 2 h, quenched with sat. aq. NH4Cl (5 mL) and water (2 mL), 
separated and the aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic 
layers were washed with brine (1 x 10 mL), dried (MgSO4), filtered through a pad of Celite
®, 
concentrated under reduced pressure and purified by chromatography (3:7; EtOAc:hexanes) to 
give 1-108 (0.674 g, 101%) as a colorless oil.   
To a solution of alcohol 1-108 (0.0923 g, 0.304 mmol) in CH2Cl2 (3.0 mL) was added 
NaHCO3 (0.0790 g, 0.940 mmol) followed by Dess-Martin periodinane (0.197 g, 0.460 mmol).  
The resulting colorless slurry was stirred at rt for 2 h, quenched with sat. aq. Na2S2O3 (2 mL) and 
sat. aq. NaHCO3 (2 mL), and diluted with Et2O (5 mL).  The organic phase was separated and 
the aqueous phase was extracted with Et2O (3 x 5 mL).  The combined organic phases were 
washed with brine (1 x 10 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure to give crude aldehyde as a colorless oil that was taken on without further purification. 
To a solution of the crude aldehyde partitioned between THF (1.33 mL) and water (0.67 
mL) was added NaH2PO4•H2O (0.125 g, 0.909 mmol), 2-methyl-2-butene (0.290 mL, 2.74 
mmol), followed by NaClO2 (0.0802 g, 0.887 mmol).  The reaction mixture was allowed to stir 
at rt for 3.75 h, extracted with EtOAc (3 x 10 mL), washed with brine (1 x 10 mL), and 
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concentrated under reduced pressure.  The oily residue was dissolved in CH2Cl2 (10 mL), filtered 
through a pad of Celite®, washed with brine (1 x 10 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure to give 1-109 as a colorless oil that was used without 
further purification. 
To a slurry of crude acid 1-109, PyBOP (0.238 g, 0.457 mmol), HOAt (0.105 g, 0.464 
mmol), and amine 1-110 (0.0398 g, 0.370 mmol) in CH2Cl2 (0.350 mL) at 0 °C was added 
dropwise DIPEA (0.106 mL, 0.609 mmol).  The resulting yellow solution was warmed to rt and 
stirred for 13 h, quenched with 1 M citric acid (5 mL), and diluted with CHCl3 (5 mL).  The 
organic layer was separated and the aqueous layer was extracted with CHCl3 (3 x 5 mL).  The 
combined organic layers were dried (Na2SO4), decanted, and concentrated.  The crude residue 
was purified by chromatography on SiO2 (2:8; EtOAc:hexanes) to give 1-111 (0.0718 g, 64% 
over 4 steps) as colorless solid:  Mp 90.3-91.0 °C (EtOAc); [α]D -25.5 (c 1.00, CH2Cl2); IR 
(ATR) 3314, 2972, 2961, 1700, 1662 cm-1; 1H NMR (CDCl3, 300 MHz) δ 6.63 (bs, 1 H), 5.74 
(ddt, 1 H, J = 16.9, 10.4, 6.8 Hz), 5.20 (d, 1 H, J = 9.5 Hz), 5.12-5.05 (m, 2 H), 4.28 (d, 1 H, J = 
6.0 Hz), 4.05 (dd, 1 H, J = 9.2, 6.0 Hz), 3.67 (dt, 1 H, J = 9.4, 3.2 Hz), 3.40 (dq, 1 H, J = 13.3, 
6.6 Hz), 3.27 (dq, 1 H, J = 13.1, 6.7 Hz), 2.26 (app q, 2 H, J = 6.8 Hz), 2.05 (dqq, 1 H, J = 6.9, 
6.9, 3.6 Hz) 1.44 (s, 3 H), 1.41 (s, 9 H), 1.34 (s, 3 H), 0.94 (d, 3 H, J = 6.9 Hz), 0.85 (d, 3 H, J = 
6.9 Hz); 13C NMR (CDCl3, 75 MHz) δ 171.4, 156.6, 135.1, 117.6, 111.4, 79.2, 79.1, 78.3, 58.1, 
38.0, 33.8, 29.6, 28.5, 27.3, 26.3, 19.8, 16.2; MS (ESI+) m/z 393 ([M+Na]+, 100); HRMS (ESI+) 
m/z calcd for C19H34N2O5Na [M+Na]
+ 393.2365, found 393.2338. 
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1-113 
tert-Butyl ((S,E)-1-(((S)-1-((4R,5S)-5-(but-3-en-1-ylcarbamoyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)-2-methylpropyl)amino)-1-oxooct-3-en-2-yl)carbamate (1-113). To a solution 
of amide 1-111 (5.1 mg, 14 μmol) in CH2Cl2 (0.1 mL) was added 2,6-lutidine (3.2 μL, 28 μmol) 
followed by freshly distilled TMSOTf (3.7 μL, 21 μmol).  The solution was stirred for 30 min at 
rt and quenched with sat. aq. NH4Cl (1 mL).  The aqueous phase was basified (pH 9) by addition 
of 2 M KOH (3 drops) and the aqueous phase was extracted with CH2Cl2 (3 x 3 mL).  The 
combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced pressure 
to give free amine 1-102 (2.6 mg, 70%) as a yellow oil.26 
To a suspension of amine 1-102 (2.6 mg, 9.6 μmol), acid 1-87 (3.8 mg, 14 μmol), PyBOP 
(8.1 mg, 15 μmol), and HOAt (2.3 mg, 17 μmol) in CH2Cl2 (0.075 mL) was added DIPEA (3.4 
μL, 19 μmol).  The suspension became a yellow solution and was stirred at rt for 12 h.  The 
reaction was quenched with 1 M citric acid (2 mL) and the mixture was extracted with CHCl3 (3 
x 3 mL).  The combined organic layers were dried (Na2SO4), decanted, concentrated, and 
purified by chromatography on SiO2 (1:4; EtOAc:hexanes) to give 1-113 (2.7 mg, 55%) as 
colorless film:  1H NMR (CDCl3, 500 MHz) δ 6.93 (d, 1 H, J = 8.8 Hz), 6.66 (t, 1 H, J = 5.4 Hz), 
5.81-5.71 (m, 2 H), 5.48 (dd, 1 H, J = 15.3, 6.8 Hz), 5.41 (bs, 1 H), 5.12 (dq, 1 H, J = 6.0, 1.5 
Hz), 5.09 (t, 1 H, J = 1.2 Hz), 4.58 (bs, 1 H), 4.14 (d, 1 H, J = 6.7 Hz), 4.07 (dd, 1 H, J = 9.0, 6.8 
Hz), 3.98 (dt, 1 H, J = 9.0, 3.5 Hz), 3.43 (dq, 1 H, J = 13.4, 6.7 Hz), 3.26 (dq, 1 H, J = 13.1, 6.6 
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Hz) 2.28 (dq, 2 H, J = 6.8, 1.0 Hz), 2.08 (dqq, 1 H, J = 6.9, 6.9, 3.5 Hz), 2.01 (app q, 2 H, J = 6.7 
Hz), 1.45 (s, 3 H), 1.43 (s, 9 H), 1.36 (s, 3 H), 1.35-1.27 (m, 4 H), 0.94 (d, 3 H, J = 6.9 Hz), 0.89 
(d, 3 H, J = 6.9 Hz), 0.86 (t, 3 H, J = 7.1 Hz). 
 
 
1-114 
tert-Butyl ((3aR,4S,7S,13aS,E)-4-isopropyl-2,2-dimethyl-6,13-dioxo-
3a,4,5,6,7,10,11,12,13,13a-decahydro-[1,3]dioxolo[4,5-c][1,6]diazacyclododecin-7-
yl)carbamate (1-114).26 To a solution of 1-113 (3 mg, 5 μmol) in degassed toluene (5.0 mL) 
was added Grubbs 2nd generation catalyst (0.7 mg, 0.8 μmol).  The reaction flask was evacuated 
and back filled with ethylene gas (6 x), then heated at 90 °C under an atmosphere of ethylene.  
After 14.5 h, a second batch of Grubbs 2nd generation catalyst (0.8 mg, 0.8 μmol) was added and 
the reaction flask was purged with ethylene (3 x).  The reaction mixture was heated at 90 °C for 
6 h, cooled to rt, and concentrated under reduced pressure.  The crude residue was purified by 
chromatography on SiO2 (1:1; EtOAc:hexanes) to give of 1-114 (1.1 mg, 49%) as a light brown 
solid in about 90% purity.  A second purification was needed to eliminate traces of impurities, 
providing 1-114 (0.5 mg, 22%): 1H NMR (CDCl3, 500 MHz) δ 5.79-5.68 (m, 2 H), 5.59-5.55 (m, 
2 H), 5.17 (dd, 1 H, J = 15.0, 9.7 Hz), 4.53 (app t, 1 H, J = 9.1 Hz), 4.41 (t, 1 H, J = 7.9 Hz), 
4.00-3.91 (m, 2 H), 3.75 (d, 1 H, J = 8.3 Hz), 2.93 (app d, 1 H, J = 13.8 Hz), 2.47 (app d, 1 H, J 
= 13.1 Hz), 2.07 (dqq, 1 H, J = 6.9, 6.9, 3.3 Hz), 1.98-1.90 (m, 1 H), 1.42 (s, 9 H), 1.41 (s, 3 H), 
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1.40 (s, 3 H), 0.95 (d, 3 H, J = 6.9 Hz), 0.93 (d, 3 H, J = 6.9 Hz); MS (EI) m/z 425 (M+, 1), 369 
(23), 325 (5); HRMS (EI) m/z calcd for C21H35N3O6 M
+ 425.2526, found 425.2538. 
 
 
1-121 
(E)-Ethyl 2-hydroxy-5-methylhex-3-enoate (1-121).  To a solution of alkyne 1-120 
(0.150 mL, 1.47 mmol) in CH2Cl2 (3.5 mL) was added Cp2ZrHCl (0.347 g, 1.72 mmol).  The 
reaction mixture was stirred for 20 min at rt.  The solvent was removed in vacuo and the 
resulting light yellow oil was dissolved in toluene (3.0 mL), cooled to -78 °C for 5 min, and 
treated with Me2Zn (1.54 mL, 3.08 mmol, 2 M in toluene).  The solution was warmed to rt, 
stirred for 10 min, then cooled to -78 °C for 5 min.  Freshly cracked ethyl glyoxylate (0.270 mL, 
1.23 mmol, 45% in toluene by 1H NMR) was added to the vinyl zinc reagent at -78 °C, warmed 
to rt, and stirred for 5 h.  The reaction was quenched with sat. aq. NH4Cl (5 mL) at rt, stirred for 
30 min, diluted with EtOAc (25 mL), filtered though a pad of Celite®, and the aqueous layer was 
extracted with EtOAc (2 x 10 mL).  The combined organic layers were washed with brine (1 x 
20 mL), dried (MgSO4), filtered, and concentrated under reduced pressure to give a yellow oil.  
The crude residue was purified by chromatography on SiO2 (1:9; EtOAc:hexanes) to give 1-121 
(0.118 g, 56%) as a yellow oil:  IR (ATR) 3468, 2956, 1729 cm-1; 1H NMR (CDCl3, 300 MHz) δ 
5.86 (ddd, 1 H, J = 15.5, 6.6, 1.5 Hz), 5.45 (ddd, 1 H, J = 15.5, 5.9, 1.4 Hz), 4.58 (d, 1 H, J = 5.6 
Hz), 4.25 (q, 2 H, J = 7.1 Hz), 2.90 (s, 1 H), 2.32 (app. sext, 1 H, J = 6.7 Hz), 1.29 (t, 3 H, J = 
7.1 Hz), 1.00 (d, 6 H, J = 6.8 Hz); 13C NMR (CDCl3, 75 MHz) δ 174.1, 141.5, 123.5, 71.5, 62.0, 
30.8, 22.2, 22.1, 14.3; MS (ESI+) m/z 195 ([M+Na]+, 100); HRMS (ESI+) m/z calcd for 
C9H16O3Na [M+Na]
+195.0997, found 195.0992. 
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4.3 CHAPTER 2 EXPERIMENTAL PART 
 
2-43 
Diethyl 2,2'-(1,1,5,5-tetraoxido-1,5,2,4,6,8-dithiatetrazocane-3,7-diyl)diacetate (2-
43).113 To a suspension of sulfamide (2-11) (11.00 g, 113.3 mmol) in CH2Cl2 (217 mL) and TFA 
(44.0 mL, 586 mmol) was added diethyoxypropionate (2-30) (25.5 mL, 125 mmol) over 5 min.  
The solution was stirred for 4 h at rt, filtered through a medium glass fritted funnel, washed with 
CH2Cl2 (~60 mL), MeOH (~50 mL), and Et2O (~50 mL), and dried under high vacuum to give 
2-43 (21.2 g, 96%) as a colorless solid:  Mp 182.9-183.4 C (CH2Cl2); IR (ATR) 3318, 2990, 
1717, 1348, 1335, 1048 cm-1; 1H NMR (DMSO-d6, 400 MHz) δ 7.52 (d, 4 H, J = 9.4 Hz), 5.18 
(ddt, 2 H, J = 9.2, 9.2, 7.3 Hz), 4.06 (q, 4 H, J = 7.1 Hz), 2.64 (d, 4 H, J = 7.2 Hz), 1.18 (t, 6 H, J 
= 7.1 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 168.5, 62.1, 60.2, 41.1, 14.0; HRMS (ESI
+) m/z 
calcd for C10H21N4O8S2 [M+H]
+ 389.0801, found 389.0779. 
 
 
2-44 
Ethyl 3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylate 1,1-dioxide (2-44).116 
To a suspension of sulfamide 2-43 (9.76 g, 25.1 mmol) and benzaldehyde (5.20 mL, 51.2 mmol) 
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in HFIP (100 mL) was added dropwise TFA (9.65 mL, 126 mmol).  The solution was stirred 
between 35-40 °C in a round bottom flask capped with a glass stopper for 17 h.  The solvent was 
evaporated under reduced pressure to give a yellow oil that was purified by chromatography on 
SiO2 (2:8 to 4:6; EtOAc:hexanes) to give the thiadiazine 2-44 (9.33 g, 66%) as a colorless solid:  
Mp 143.8-144.9 C (CHCl3); IR (ATR) 3269, 3176, 2980, 1655, 1150, 1100 cm
-1; 1H NMR 
(DMSO-d6, 400 MHz) δ 10.82 (s, 1 H), 7.93 (d, 1 H, J = 7.2 Hz), 7.49 (s, 1 H), 7.31-7.21 (m, 5 
H), 5.33 (d, 1 H, J = 7.2 Hz), 4.01, 3.96 (AB dq, 2 H, JAB = 10.9, 7.1 Hz), 1.04 (t, 3 H, J = 7.1 
Hz); 13C NMR (DMSO-d6, 100 MHz) δ 165.2, 139.0, 138.8, 127.9, 127.8, 127.3, 102.8, 59.6, 
57.5, 14.0; HRMS (ESI+) m/z calcd for C12H14N2O4S [M+H]
+ 283.0753, found 283.0786. 
 
SFC Separation: Chiralpak IA (250 mm x 4.6 mm), run time 6.08 min; Peak A: 2.57 min 
[α]D -8.1 (c = 0.16, CH2Cl2); Peak B: 3.08 min [α]D +9.0 (c = 0.13, CH2Cl2). 
 
 
2-68 
Ethyl 6-ethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylate 1,1-dioxide 
(2-68).  To a solution of thiadiazine 2-44 (0.871 g, 3.09 mmol) and ethanol (0.213 mL, 3.70 
mmol) in THF (20 mL) was added PPh3 (0.984 g, 3.72 mmol) and DBAD (0.853 g, 3.63 mmol).  
The reaction mixture was stirred at rt for 4.5 h, concentrated under reduced pressure, and purified 
by chromatography on SiO2 (15:85 to 3:7; EtOAc:hexanes) to give 2-68 (0.723 g, 75%) as a 
colorless solid: Mp 98.9-101.3°C (CH2Cl2); IR (ATR) 3197, 1661, 1609, 1171 cm
-1; 1H NMR 
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(acetone-d6, 400 MHz) δ 7.63 (s, 1 H), 7.39-7.35 (m, 2 H), 7.34-7.23 (m, 3 H), 6.95 (d, 1 H, J = 
7.6 Hz), 5.55 (d, 1 H, J = 7.7 Hz), 4.03, 3.97 (AB dq, 2 H, JAB = 10.8, 7.1 Hz), 3.73, 3.68 (AB 
dq, 2 H, JAB = 14.5, 7.2 Hz), 1.32 (t, 3 H, J = 7.2 Hz), 1.03 (t, 3 H, J = 7.1 Hz); 
13C NMR 
(acetone-d6, 100 MHz) δ 165.8, 142.6, 139.9, 129.0, 128.8, 128.4, 106.3, 60.4, 59.5, 45.6, 15.6, 
14.4; HRMS (ESI+) m/z calcd for C14H19N2O4S [M+H]
+ 311.1066, found 311.1069. 
 
 
2-69 
Ethyl 6-ethyl-2-methyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylate 1,1-
dioxide (2-69).  To a suspension of thiadiazine 2-68 (0.741 g, 2.39 mmol) and K2CO3 (1.01 g, 
7.27 mmol) in MeCN (24 mL) was added iodomethane (0.372 mL, 5.98 mmol).  The solution 
was stirred at rt for 2.5 h, then diluted with water (20 mL) and EtOAc (10 mL).  The organic 
layer was separated and the aqueous layer was extracted with EtOAc (2 x 10 mL).  The 
combined organic layers were washed with sat. aq. Na2SO3 (1 x 15 mL) and brine (1 x 15 mL), 
dried (Na2SO4), decanted, and concentrated under reduced pressure to give a yellow colored 
crude oil.  The crude mixture was purified by chromatography on SiO2 (15:85 to 2:8; 
EtOAc:hexanes) to give the dialkylated thiadiazine 2-69 (0.782 g, 100%) as a light yellow 
viscous oil:  IR (ATR) 2977, 1692, 1141, 1038 cm-1; 1H NMR (acetone-d6, 400 MHz) δ 7.70 (s, 
1 H), 7.34-7.17 (m, 5 H), 5.52 (s, 1 H), 4.10, 4.06 (AB dq, 2 H, JAB = 10.8, 7.1 Hz), 3.73 (q, 2 H, 
J = 7.2 Hz), 2.95 (s, 3 H), 1.32 (t, 3 H, J = 7.2 Hz), 1.12 (t, 3 H, J = 7.1 Hz); 13C NMR (acetone-
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d6, 100 MHz) δ 166.3, 141.6, 140.0, 128.8, 128.4, 128.1, 102.7, 67.0, 60.7, 46.0, 40.1, 15.8, 14.5; 
HRMS (ESI+) m/z calcd for C15H21N2O4S [M+H]
+ 325.1222, found 325.1236. 
 
 
2-70 
Ethyl 2,6-dimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylate 1,1-
dioxide (2-70).  To a suspension of thiadiazine 2-44 (2.390 g, 8.465 mmol) and K2CO3 (7.00 g, 
50.7 mmol) in MeCN (40 mL) was added iodomethane (2.65 mL, 42.6 mmol).  The solution was 
stirred at rt for 2.25 h, then diluted with water (50 mL) and EtOAc (50 mL).  The organic layer 
was separated and the aqueous layer was extracted with EtOAc (3 x 15 mL).  The combined 
organic layers were washed with sat. aq. Na2SO3 (1 x 25 mL), sat. aq. NaHCO3 (1 x 25 mL), and 
brine (1 x 25 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to give a 
light yellow sticky oil. The crude mixture was purified by chromatography on SiO2 (1:9 to 2:8; 
EtOAc:hexanes) to give 2-70 (2.620 g, 100%) as a light yellow oil: IR (ATR) 2977, 2932, 1691, 
1366 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.45 (s, 1 H), 7.34-7.25 (m, 5 H), 5.46 (s, 1 H), 4.15, 
4.11 (AB dq, 2 H, JAB = 10.9, 7.1 Hz), 3.28 (s, 3 H), 2.93 (s, 3 H), 1.15 (t, 3 H, J = 7.1 Hz); 
13C 
NMR (CDCl3, 100 MHz) δ 166.0, 142.1, 138.0, 128.1, 128.0, 127.8, 102.4, 66.4, 60.7, 39.8, 
36.8, 14.3; HRMS (ESI+) m/z calcd for C14H19N2O4S [M+H]
+ 311.1066, found 311.1103. 
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2-71 
6-Ethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylic acid 1,1-dioxide (2-
71).  To a suspension of ester 2-68 (0.250 g, 0.805 mmol) in EtOH (1.0 mL) was added in one 
portion 2 M KOH (4.0 mL, 8.0 mmol).  The reaction mixture was stirred at 80 °C for 4 h then 
cooled to rt, diluted with EtOAc (5 mL), and acidified with 5 M HCl (~ 2 mL).  The aqueous 
layer was extracted with EtOAc (3 x 5 mL). The organic layers were combined, dried (Na2SO4), 
decanted, and concentrated under reduced pressure to give acid 2-71 (0.222 g, 98%) as a yellow-
orange solid:  Mp 170.1-175.3 C (dec, CH2Cl2); IR (ATR) 3245, 2922, 1661, 1152 cm
-1; 1H 
NMR (acetone-d6, 400 MHz) δ 10.53 (bs, 1 H), 7.66 (s, 1 H), 7.40-7.37 (m, 2 H), 7.32-7.22 (m, 3 
H), 7.01 (d, 1 H, J = 7.5 Hz), 5.56 (d, 1 H, J = 7.5 Hz), 3.74, 3.69 (AB dq, 2 H, JAB = 14.4, 7.1 
Hz), 1.33 (t, 3 H, J = 7.2 Hz); 13C NMR (acetone-d6, 100 MHz) δ 167.0, 143.1, 139.9, 129.0, 
128.7, 128.3, 105.6, 59.2, 45.6, 15.6; HRMS (ESI-) m/z calcd for C12H13N2O4S [M-H]
- 281.0596, 
found 281.0609. 
 
 
2-72 
6-Ethyl-2-methyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylic acid 1,1-
dioxide (2-72).  To a solution of dialkylated thiadiazine 2-69 (2.69 g, 8.29 mmol) in EtOH (10 
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mL) was added in one portion 2 M KOH (43 mL, 85 mmol).  The reaction mixture was warmed 
to 90 °C and stirred for 5 h, cooled to rt, diluted with EtOAc (50 mL), cooled to 0 °C, and 
acidified with 5 M HCl (~ 17 mL).  The aqueous layer was extracted with EtOAc (3 x 20 mL).  
The organic layers were combined, washed with water (1 x 10 mL) and brine (1 x 10 mL), dried 
(Na2SO4), decanted, and concentrated under reduced pressure.  The crude product contained 
AcOH that was removed by evaporating with hexanes and CHCl3 to give the acid 2-72 (2.06 g, 
84%) as a light yellow powder:  Mp 156.7-158.6 C (dec, CH2Cl2); IR (ATR) 2969, 2563, 1668, 
1655, 1169, 1154 cm-1; 1H NMR (CDCl3, 500 MHz) δ 10.96 (bs, 1 H), 7.63 (s, 1 H), 7.37-7.26 
(m, 5 H), 5.41 (s, 1 H), 3.62 (q, 2 H, J = 7.2 Hz), 2.91 (s, 3 H), 1.33 (t, 3 H, J = 7.2 Hz); 13C 
NMR (CDCl3, 100 MHz) δ 171.9, 142.9, 137.8, 128.1, 128.0, 127.7, 100.1, 66.1, 45.9, 40.1, 
15.5; MS (ESI-) m/z 295 ([M-1]-, 100), 231 (-SO2, 85); HRMS (ESI
-) m/z calcd for C13H15N2O4S 
[M-H]- 295.0753, found 295.0795. 
 
 
2-73 
2,6-Dimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylic acid 1,1-
dioxide (2-73).  To a solution of dialkylated thiadiazine 2-70 (2.589 g, 8.343 mmol) in EtOH (10 
mL) was added in one portion 2 M KOH (41.5 mL, 83.0 mmol).  The reaction mixture was 
heated to 75 °C and stirred for 3.5 h.  The reaction mixture was cooled to rt, diluted with water 
(10 mL), and acidified with conc. aq. HCl (~5 mL).  The aqueous layer was extracted with Et2O 
(3 x 20 mL).  The combined organic layers were washed with brine (1 x 20 mL), dried (MgSO4), 
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filtered, and concentrated under reduced pressure.  The crude oil was placed under high vacuum 
for 6 h to give the desired acid 2-73 (2.063 g, 88%) as a light yellow solid:  Mp 158.2-160.9 C 
(dec, Et2O); IR (ATR) 3062, 2951, 2626, 2561, 1663, 1279, 1248 cm
-1; 1H NMR (CDCl3, 400 
MHz) δ 8.70 (bs, 1 H), 7.56 (s, 1 H), 7.37-7.27 (m, 5 H), 5.42 (s, 1 H), 3.26 (s, 1 H), 2.95 (s, 1 
H); 13C NMR (CDCl3, 100 MHz) δ 171.6, 144.4, 137.7, 128.2, 127.7, 100.2, 66.1, 40.3, 37.0; 
HRMS (ESI-) m/z calcd for C12H13N2O4S [M-H]
- 281.0596, found 281.0632. 
 
 
2-74 
tert-Butyl (2,6-dimethyl-1,1-dioxido-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazin-4-
yl)carbamate (2-74).  To a suspension of dimethyl thiadiazine carboxylate 2-73 (0.0770 g, 0.273 
mmol) in toluene (0.6 mL) was added Et3N (0.0840 mL, 0.598 mmol).  The mixture was 
degassed by FPT (3 x), backfilled with Ar, and treated with DPPA (0.0640 mL, 0.297 mmol). 
The reaction mixture was stirred at rt for 2 h, and heated to 95 °C for 1 h (during which time 
bubbling occurred for 30 min).  The mixture was then cooled to rt, treated with t-BuOH (0.200 
mL, 2.10 mmol) and heated to 100 °C for 3 h.  The reaction mixture was cooled to rt, diluted 
with EtOAc (5 mL), and washed with 1 M NaOH (1 x 5 mL).  The aqueous layer was extracted 
with EtOAc (3 x 5 mL).  The combined organic layers were washed with sat. aq. NaHCO3 (1 x 
10 mL) and brine (1 x 10 mL), dried (Na2SO4), filtered, and concentrated under reduced 
pressure.  The crude material was purified by chromatography on SiO2 (1:9 to 2:8; 
EtOAc:hexanes), dissolved in CHCl3 and concentrated under reduced pressure (3 x) to remove 
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trace EtOAc to give N-Boc amine 2-74 (21.5 mg, 22%) as a colorless solid:  Mp 124.7-126.6 C 
(CHCl3); IR (ATR) 3336, 2973, 1722 cm
-1; 1H NMR (CDCl3, 500 MHz) δ 7.45-7.37 (m, 5 H), 
6.69 (bs, 1 H), 5.08 (s, 1 H), 4.77 (s, 1 H), 3.10 (s, 3 H), 2.56 (s, 3 H), 1.36 (s, 9 H); 13C NMR 
(CDCl3, 125 MHz) δ 152.9, 135.2, 129.6, 129.5, 129.3, 122.2, 119.3, 81.0, 68.7, 38.7, 34.8, 28.3; 
HRMS (ESI+) m/z calcd for C16H23N3O4SNa [M+Na]
+ 376.1307, found 376.1346. 
 
 
2-75 
6-Ethyl-3-phenyl-N-(pyridin-2-ylmethyl)-3,6-dihydro-2H-1,2,6-thiadiazine-4-
carboxamide 1,1-dioxide (2-75).  To a solution of monoalkylated thiadiazine 2-71 (0.101 g, 
0.357 mmol), 2-pyridylmethylamine (0.445 mL, 0.428 mmol), EDCI (0.0756 g, 0.394 mmol), 
and DMAP (0.0267 g, 0.219 mmol) in CH2Cl2 (0.5 mL) was added DIPEA (0.0445 mL, 0.432 
mmol).  The reaction mixture was sealed under an atmosphere of Ar in a screw cap vial, stirred 
at rt for 15 h, quenched with sat. aq. NH4Cl (2 mL), diluted with EtOAc (5 mL), and separated.  
The aqueous layer was extracted with EtOAc (3 x 5 mL).  The organic layers were combined, 
washed with sat. aq. NaHCO3 (1 x 5 mL), water (1 x 5 mL), and brine (1 x 5 mL), dried 
(Na2SO4), decanted, and concentrated under reduced.  The crude solid was purified by 
chromatography on SiO2 (6:94; MeOH:CH2Cl2) to give amide 2-75 (0.0950 g, 72%) as a 
colorless solid:  Mp 157.5-157.8 C (CHCl3); IR (ATR) 3333, 3314, 3066, 1644, 1171 cm
-1; 1H 
NMR (acetone-d6, 400 MHz) δ 8.41 (ddd, 1 H, J = 4.8, 1.8, 0.9 Hz), 7.57 (td, 1 H, J = 7.6, 1.8 
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Hz), 7.53-7.48 (m, 1 H), 7.48-7.44 (m, 2 H), 7.41-7.40 (m, 1 H), 7.34-7.26 (m, 3 H), 7.15 (ddd, 1 
H, J = 7.4, 4.8, 0.8 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 6.92 (d, 1 H, J = 7.8 Hz), 5.77 (d, 1 H, J = 7.4 
Hz), 4.45, 4.36 (AB dd, 2 H, JAB = 16.2, 5.7 Hz), 3.64, 3.59 (AB dq, 2 H, JAB = 10.9, 7.2 Hz), 
1.30 (t, 3 H, J = 7.2 Hz); 13C NMR (acetone-d6, 100 MHz) δ 166.5, 159.5, 149.6, 139.5, 137.8, 
137.2, 129.4, 128.9, 128.7, 122.7, 121.7, 111.6, 59.7, 45.3, 45.2, 15.3; HRMS (ESI+) m/z calcd 
for C18H21N4O3S [M+H]
+ 373.1334, found 373.1348. 
 
 
2-76 
6-Ethyl-2-methyl-3-phenyl-N-(pyridin-2-ylmethyl)-3,6-dihydro-2H-1,2,6-
thiadiazine-4-carboxamide 1,1-dioxide (2-76).  To a vial containing acid 2-72 (0.0900 g, 0.304 
mmol) in CH2Cl2 (0.85 mL) was added PyBOP (0.173 g, 0.333 mmol), 2-pyrididylmethylamine 
(34.0 μL, 0.330 mmol), and DIPEA (0.110 mL, 0.632 mmol).  The reaction mixture was sealed 
under an atmosphere of Ar and stirred for 23 h at rt.  The reaction mixture was diluted with 
EtOAc (15 mL) and washed with sat. aq. NH4Cl (1 x 10 mL).  The aqueous layer was extracted 
with EtOAc (3 x 10 mL).  The combined organic layers were washed with sat. aq. NaHCO3 (1 x 
10 mL) and brine (1 x 10 mL), dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The crude oil was purified by chromatography on SiO2 (6:4; EtOAc:hexanes to 100% 
EtOAc) to give the amide 2-76 (0.100 g, 85%) as a colorless foam:  IR (ATR) 3307, 1638, 1357, 
1165 cm-1; 1H NMR (CDCl3, 500 MHz) δ 8.34 (d, 1 H, J = 4.8 Hz), 7.59 (dt, 1 H, J = 7.7, 1.8 
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Hz), 7.42-7.40 (m, 3 H), 7.34-7.26 (m, 3 H), 7.15-7.09 (m, 2 H), 6.62 (bs, 1 H), 5.52 (s, 1 H), 
4.51, 4.46 (AB dd, 2 H, JAB = 16.5, 4.7 Hz), 3.64 (dq, 2 H, J = 7.3, 1.8 Hz), 2.84 (s, 3 H), 1.35 (t, 
3 H, J = 7.2 Hz); 13C NMR (CDCl3, 125 MHz) δ 165.9, 156.0, 148.9, 137.5, 136.8, 136.7, 128.9, 
128.7, 128.5, 122.3, 122.0, 106.0, 66.5, 45.3, 44.6, 39.0, 15.5; HRMS (ESI+) m/z calcd for 
C19H23N4O3S [M+H]
+ 387.1491, found 387.1466. 
 
 
2-77 
6-Ethyl-N-(4-methoxybenzyl)-2-methyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-
4-carboxamide 1,1-dioxide (2-77).  To a solution of acid 2-72 (0.0974 g, 0.329 mmol), PyBOP 
(0.2052 g, 0.3944 mmol), and p-methoxybenzylamine (0.0520 mL, 0.398 mmol) in CH2Cl2 (0.9 
mL) was added DIPEA (0.125 mL, 0.718 mmol).  The reaction mixture was sealed under and 
atmosphere of Ar, stirred at rt for 23 h, concentrated under reduced pressure, and partitioned 
between EtOAc (10 mL) and water (10 mL).  The organic layer was washed with 1 M NaHSO4 
(2 x 5 mL), sat. aq. NaHCO3 (1 x 5 mL), and brine (1 x 10 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure.  The crude residue was purified by chromatography on 
SiO2 (2:8 to 1:1; EtOAc:hexanes) to give a light yellow oil that was dissolved in CHCl3 (3 x 10 
mL) and concentrated under reduced pressure to remove trace EtOAc to give amide 2-77 (0.114 
g, 83%) as a light yellow sticky foam:  IR (ATR) 3405, 3297, 2973, 2931, 1637, 1357, 1338 cm-
1; 1H NMR (CDCl3, 500 MHz) δ 7.39 (d, 1 H, J = 0.7 Hz), 7.39-7.32 (m, 5 H), 6.90 (d, 2 H, J = 
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8.7 Hz), 6.76-6.74 (m, 2 H), 5.41 (s, 1 H), 5.30 (t, 1 H, J = 5.1 Hz), 4.32, 4.23 (AB dd, 2 H, JAB = 
14.7, 5.8 Hz), 3.77 (s, 3 H), 3.62 (q, 2 H, J = 7.2 Hz), 2.77 (s, 3 H), 1.34 (t, 3 H, J = 7.2 Hz); 13C 
NMR (CDCl3, 125 MHz) δ 165.6, 159.1, 137.9, 136.4, 130.1, 128.98, 128.96, 128.9, 128.7, 
114.1, 105.8, 66.2, 55.4, 45.4, 43.4, 38.4, 15.5; HRMS (ESI+) m/z calcd for C21H26N3O4S 
[M+H]+ 416.1644, found 416.1648. 
 
 
2-78 
N-(2-(Dimethylamino)ethyl)-6-ethyl-2-methyl-3-phenyl-3,6-dihydro-2H-1,2,6-
thiadiazine-4-carboxamide 1,1-dioxide (2-78).  To a vial containing acid 2-72 (0.0900 g, 0.304 
mmol) in CH2Cl2 (0.85 mL) was added PyBOP (0.173 g, 0.333 mmol), N,N-dimethylethylene 
diamine (36.0 μL, 0.330 mmol), and DIPEA (0.110 mL, 0.632 mmol).  The reaction mixture was 
sealed under an atmosphere of Ar and stirred for 23 h at rt.  The reaction mixture was diluted 
with EtOAc (15 mL) and washed with sat. aq. NH4Cl (1 x 10 mL).  The aqueous layer was 
extracted with EtOAc (3 x 10 mL).  The combined organic layers were washed with sat. aq. 
NaHCO3 (1 x 10 mL) and brine (1 x 10 mL), dried (Na2SO4), filtered, and concentrated under 
reduced pressure.  The crude material was purified by chromatography on SiO2 (1:99 to 1:9; 
MeOH:CHCl3) to give amide 2-78 (0.0847 g, 76%) as a light yellow foam:  IR (ATR) 3420, 
3307, 2975, 1638, 1357, 1340 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.41-7.29 (m, 5 H), 7.37 (s, 1 
H), 6.04 (bs, 1 H), 5.45 (s, 1 H), 3.64 (q, 2 H, J = 7.3 Hz), 3.27-3.18 (m, 2 H), 2.79 (s, 3 H), 2.39, 
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2.52 (AB ddd, 2 H, JAB = 12.1, 6.6, 4.9 Hz), 2.06 (s, 6 H), 1.35 (3 H, J = 7.2 Hz); 
13C NMR 
(CDCl3, 125 MHz) δ 166.5, 137.7, 136.8, 128.9, 128.7, 128.5, 105.9, 66.3, 57.7, 45.4, 44.7, 38.5, 
37.0, 15.5; HRMS (ESI+) m/z calcd for C17H27N4O3S [M+H]
+ 367.1804, found 367.1797. 
 
 
2-79 
(6-Ethyl-2-methyl-1,1-dioxido-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazin-4-
yl)(morpholino)methanone (2-79).  To a vial containing acid 2-72 (0.0900 g, 0.304 mmol) in 
CH2Cl2 (0.85 mL) was added PyBOP (0.173 g, 0.333 mmol), morpholine (29.0 uL, 0.332 mmol), 
and DIPEA (0.110 mL, 0.632 mmol).  The reaction mixture was sealed under and atmosphere of 
Ar and stirred for 23 h at rt.  The reaction mixture was diluted with EtOAc (15 mL) and washed 
with sat. aq. NH4Cl (1 x 10 mL).  The aqueous layer was extracted with EtOAc (3 x 10 mL).  
The combined organic layers were washed with sat. aq. NaHCO3 (1 x 10 mL) and brine (1 x 10 
mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude reaction 
mixture was purified by chromatography on SiO2 (3:7 to 1:1; EtOAc:hexanes) to give amide 2-
79 (0.0933 g, 84%) as a colorless colorless powder:  Mp 115.7-116.8 C (CHCl3); IR (ATR) 
2969, 2923, 2852, 1623, 1610, 1357 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.37-7.32 (m, 5 H), 
6.56 (d, 1 H, J = 1.6 Hz), 5.68 (d, 1 H, J = 1.5 Hz), 3.62, 3.58 (AB dq, 2 H, JAB = 14.5, 7.2 Hz), 
3.54-3.47 (m, 2 H), 3.43-3.34 (m, 4 H), 3.34-3.27 (m, 2 H), 2.54 (s, 3 H), 1.34 (t, 3 H, J = 7.2 
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Hz); 13C NMR (CDCl3, 125 MHz) δ 167.6, 135.4, 134.2, 129.2, 129.1, 128.7, 109.8, 66.6, 66.5, 
45.2, 34.5, 15.3; HRMS (ESI+) m/z calcd for C17H24N3O4S [M+H]
+ 388.1307, found 388.1314. 
 
 
2-80 
6-Ethyl-N-methoxy-N,2-dimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-
carboxamide 1,1-dioxide (2-80).  To a round bottom flask containing acid 2-72 (0.9985 g, 3.369 
mmol), dimethylhydroxylamine hydrochloride (0.4413 g, 4.524 mmol), and PyBOP (2.073 g, 
3.984 mmol) was added CH2Cl2 (9.9 mL).  The solution was cooled to 0 °C and treated with 
DIPEA (2.05 mL, 11.8 mmol), slowly warmed to rt, and stirred for 23 h.  The reaction mixture 
was concentrated under reduced pressure and partitioned between EtOAc (40 mL) and water (20 
mL).  The organic layer was washed with 1 M NaHSO4 (2 x 20 mL), sat. aq. NaHCO3 (1 x 20 
mL), and brine (1 x 20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure.  
The crude residue was purified by chromatography on SiO2 (2:8 to 1:1; EtOAc:hexanes) to give 
a light yellow oil.  The oil was dissolved in CHCl3 (3 x 10 mL) and concentrated under reduced 
pressure to remove trace EtOAc to give 2-80 (1.026 g, 90%) as a light yellow sticky oil:  IR 
(ATR) 2977, 2936, 1627, 1163 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.36-7.31 (m, 5 H), 7.05 (d, 
1 H, J = 1.8 Hz), 5.92 (d, 1 H, J = 1.8 Hz), 3.65, 3.61 (AB dq, 2 H, JAB = 14.4, 7.2 Hz), 3.54 (s, 3 
H), 2.99 (s, 3 H), 2.43 (s, 3 H), 1.36 (t, 3 H, J = 7.2 Hz); 13C NMR (CDCl3, 125 MHz) δ 167.7, 
137.7, 136.1, 129.2, 128.7, 128.6, 108.4, 65.7, 61.1, 45.1, 34.0, 33.2, 15.5; HRMS (ESI+) m/z 
calcd for C15H22N3O4S [M+H]
+ 340.1331, found 340.1330. 
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2-81 
N-Methoxy-N,2,6-trimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-
carboxamide 1,1-dioxide (2-81).  To a solution of acid 2-73 (5.0772 g, 17.984 mmol), 
dimethylhydroxylamine hydrochloride (2.330 g, 23.89 mmol), PyBOP (11.306 g, 21.730 mmol) 
was added CH2Cl2 (51 mL) and stirred at rt for 5 min then cooled to 0 °C for 10 min.  The cooled 
solution was treated dropwise over 5 min with DIPEA (10.95 mL, 62.92 mmol) and slowly 
warmed to rt and stirred for 24.25 h.  The reaction mixture was diluted with EtOAc (150 mL) 
and water (100 mL). The organic layer was separated and washed with 1 M NaHSO4 (2 x 50 
mL), sat. aq. NaHCO3 (1 x 50 mL), and brine (1 x 50 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude material was purified by chromatography on 
SiO2 (2:8 to 1:1; EtOAc:hexanes) to give a light yellow oil that was dissolved in CHCl3 (100 
mL) and washed with 1 M NaHSO4 (2 x 50 mL), NaHCO3 (1 x 50 mL), and brine (1 x 50 mL), 
dried (Na2SO4), filtered, and concentrated under reduced pressure to give the amide 2-81 (5.500 
g, 94%) a light yellow oil:  IR (ATR) 2936, 1629, 1163 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
7.35-7.29 (m, 5 H), 6.96 (d, 1 H, J = 1.8 Hz), 5.91 (d, 1 H, J = 1.8 Hz), 3.53 (s, 3 H), 3.25 (s, 3 
H), 2.97 (s, 3 H), 2.46 (s, 3 H); 13C NMR (CDCl3, 100 MHz) δ 167.6, 139.2, 135.9, 129.2, 128.7, 
128.6, 108.7, 65.7, 61.1, 36.4, 34.0, 33.2; HRMS (ESI+) m/z calcd for C14H20N3O4S [M+H]
+ 
326.1175, found 326.1186. 
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2-82 
2,6-Dimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carbaldehyde 1,1-dioxide 
(2-82).  To a solution of Weinreb amide 2-81 (1.2654 g, 3.8890 mmol) in THF (26 mL) cooled to 
-78 °C was added dropwise LiAlH4 (1 M in Et2O, 7.80 mL, 7.80 mmol) over 5 min.  The 
reaction mixture was stirred for 2 h at -78 °C, warmed to 0 °C, stirred for 15 min, diluted with 
Et2O (80 mL), quenched with water (100 mL), and 1 M HCl (40 mL).  The phases were 
separated and the aqueous layer was extracted with Et2O (3 x 25 mL).  The combined organic 
layers were washed with brine (1 x 50 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure to give a light yellow oil.  The crude material was purified by chromatography 
on SiO2 (4:6 to 6:4; EtOAc:hexanes) to give the aldehyde 2-82 (0.7267 g, 70%) as a colorless 
foam:  IR (ATR) 1659, 1610, 1363, 1307, 1167 cm-1; 1H NMR (CDCl3, 400 MHz) δ 9.38 (s, 1 
H), 7.34-7.26 (m, 5 H), 7.13 (s, 1 H), 5.51 (s, 1 H), 3.35 (s, 3 H), 2.93 (s, 3 H); 13C NMR 
(CDCl3, 100 MHz) δ 187.7, 150.3, 136.4, 128.3, 127.7, 113.9, 64.8, 39.9, 37.2; HRMS (ESI
+) 
m/z calcd for C12H14N2O3S [M+H]
+ 267.0803, found 267.0815. 
 
 
2-83 
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4-((Cyclopropylamino)methyl)-2,6-dimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-
thiadiazine 1,1-dioxide (2-83).  To a solution of aldehyde 2-82 (0.0603 g, 0.226 mmol) in 
CH2Cl2 (0.28 mL) was added cyclopropylamine (0.0170 mL, 0.245 mmol) and Ti(i-PrO)4 (0.200 
mL, 0.676 mmol).  The reaction mixture was sealed under an atmosphere of Ar and stirred at rt 
for 21 h.  The reaction mixture was diluted with EtOAc (10 mL), quenched with brine (10 mL), 
and filtered through a pad of Celite®.  The organic layer was separated, and the aqueous layer 
was extracted with EtOAc (3 x 10 mL).  The organic layers were combined, washed with brine 
(1 x 10 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The oil was 
dried under high vacuum overnight to give the imine, isolated as a colorless foam, was taken on 
without purification. 
To a solution of imine (0.0691 g, 0.226 mmol) in MeOH (0.4 mL) and THF (0.4 mL) 
cooled to 0 °C was slowly added NaBH4 (0.0261 g, 0.690 mmol).  The reaction mixture was 
stirred at 0 °C for 15 min then warmed to rt.  After 1.5 h the reaction mixture was diluted with 
CH2Cl2 (10 mL), washed with 5% aq. K2CO3 (2 x 10 mL) and brine (1 x 10 mL), dried 
(Na2SO4), filtered, and concentrated under reduced pressure.  The crude oil was purified by 
chromatography through a short plug of SiO2 (2:8 to 1:1; EtOAc:hexanes w/ 2% Et3N) to give 
the amine 2-83 (0.0455 g, 65%) as a colorless solid:  Mp 87.2-88.2 °C (CHCl3); IR (ATR) 3308, 
2839, 1338, 1158, 755, 744 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.40-7.30 (m, 5 H), 6.03 (s, 1 
H), 4.74 (s, 1 H), 3.08 (s, 3 H), 2.94, 2.86 (AB d, 2 H, JAB = 13.7 Hz), 2.55 (s, 3 H), 2.00 (m, 1 
H), 1.41 (bs, 1 H), 0.41-0.32 (m, 1 H), 0.32-0.24 (m, 2 H), 0.12-0.02 (m, 1 H); 13C NMR (CDCl3, 
100 MHz) δ 137.0, 129.1, 128.8, 128.1, 122.1, 69.1, 50.4, 38.0, 34.5, 29.8, 6.7, 6.0; HRMS 
(ESI+) m/z calcd for C12H15N2O2S [M-C3H6N]
+ 251.0849, found 251.0841. 
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2-84 
4-(((4-Methoxybenzyl)amino)methyl)-2,6-dimethyl-3-phenyl-3,6-dihydro-2H-1,2,6-
thiadiazine 1,1-dioxide (2-84).  To a solution of aldehyde 2-82 (0.0603 g, 0.226 mmol) in 
CH2Cl2 (0.28 mL) was added 4-methoxybenzylamine (0.0320 mL, 0.245 mmol) and Ti(i-PrO)4 
(0.205 mL, 0.676 mmol). The reaction mixture was sealed under an atmosphere of Ar and stirred 
at rt for 24 h.  The reaction mixture was diluted with EtOAc (10 mL), quenched with water (10 
mL), stirred at rt for 5 min, and filtered through a pad of Celite®.  The organic layer was 
separated and the aqueous layer was extracted with EtOAc (3 x 10 mL).  The organic layers were 
combined and washed with brine (1 x 10 mL), dried (Na2SO4), filtered, concentrated under 
reduced pressure to give a light yellow oil that was dried under high vacuum for several hours to 
give the imine that was taken on without further purification. 
To a solution of imine in MeOH (0.9 mL) cooled to 0 °C was slowly added NaBH4 
(0.0261 g, 0.690 mmol).  The reaction mixture was stirred at 0 °C for 30 min and warmed to rt 
and stirred for 3.5 h.  The reaction mixture was diluted with CH2Cl2 (10 mL), washed with 5% 
aq. K2CO3 (2 x 10 mL) and brine (1 x 10 mL), dried (Na2SO4), filtered, and concentrated under 
reduced pressure.  The crude oil was purified by chromatography through a short plug of SiO2 
(4:6 to 1:1; EtOAc:hexanes w/ 2% Et3N) to give the amine 2-84 (0.0604 mg, 69%) as a light 
yellow oil:  IR (ATR) 3329, 2900, 2831, 1510, 1241, 1158 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
7.39-7.30 (m, 5 H), 7.12 (d, 2 H, J = 8.2 Hz), 6.82 (d, 2 H, J = 8.2 Hz), 6.04 (s, 1 H), 4.80 (s, 1 
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H), 3.79 (s, 3 H), 3.61, 3.51 (AB d, 2 H, JAB = 13.0 Hz), 3.09 (s, 3 H), 2.89, 2.85 (AB d, 2 H, JAB 
= 14.6 Hz), 2.58 (s, 3 H), 1.42 (bs, 1 H) 13C NMR (CDCl3, 100 MHz) δ 158.8, 137.1, 132.2, 
129.4, 129.1, 128.82, 128.77, 128.3, 121.8, 113.9, 69.1, 55.4, 52.2, 49.8, 38.0, 34.7; HRMS 
(ESI+) m/z calcd for C20H26N3O3S [M+H]
+ 388.1695, found 388.1707. 
 
N N
S MeMe
O O
Ph
HN
N
Me Me  
2-86 
(E)-4-((2,2-Dimethylhydrazono)methyl)-2,6-dimethyl-3-phenyl-3,6-dihydro-2H-
1,2,6-thiadiazine 1,1-dioxide (2-86).  To a solution of aldehyde 2-82 (0.5240 g, 1.968 mmol) 
and PTS (0.0398 g, 0.209) in benzene (4.9 mL) was added 1,1-dimethylhydrazine (0.230 mL, 
3.02 mmol).  The reaction mixture was stirred at rt for 14 h, heated to 65 °C for 2 h, heated to 
reflux for 1.5 h, treated with powdered 4Å MS (125 mg), heated at 75 °C for 1 h, cooled to rt, 
diluted with CH2Cl2 (15 mL), and washed with water (10 mL).  The aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL).  The organic layers were combined, washed with brine (1 x 10 mL), 
dried (Na2SO4), filtered, and concentrated under reduced pressure.  The crude mixture was 
purified by chromatography on SiO2 (2:8 to 4:6; EtOAc:hexanes) to give the hydrazone 2-86 
(0.320 g, 53%) as a light yellow foam:  IR (ATR) 1627, 1355, 1165, 1010 cm-1; 1H NMR 
(CDCl3, 500 MHz) δ 7.35-7.20 (m, 5 H), 6.89 (s, 1 H), 6.31 (s, 1 H), 5.41 (s, 1 H), 3.16 (s, 3 H), 
2.89 (s, 3 H), 2.65 (s, 6 H); 13C NMR (CDCl3, 125 MHz) δ 138.4, 131.8, 131.7, 128.6, 127.7, 
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127.4, 114.2, 66.9, 43.0, 38.9, 36.5; HRMS (ASAP+) m/z calcd for C14H21N4O2S [M+H]
+ 
309.1385, found 309.1369. 
 
 
2-96 
Ethyl 6-(pent-4-yn-1-yl)-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylate 
1,1-dioxide (2-96).  To a solution of thiadiazine 2-44 (1.446 g, 5.120 mmol) and pentyn-1-ol (2-
95) (0.572 mL, 6.15 mmol) in THF (30 mL) was added PPh3 (1.463 g, 5.523 mmol) and DBAD 
(1.304 g, 5.551 mmol).  The reaction mixture was stirred at rt for 5.3 h, concentrated under 
reduced pressure, and purified by chromatography on SiO2 (1:9 to 1:1; EtOAc:hexanes) to give 
2-96 (1.033 g, 58%) as a colorless oil:  IR (ATR) 3439, 3282, 1685, 1618, 1165, 1034 cm-1; 1H 
NMR (CDCl3, 500 MHz) δ 7.50 (d, 1 H, J = 0.9 Hz), 7.38-7.30 (m, 5 H), 5.55 (d, 1 H, J = 8.5 
Hz), 4.55 (d, 1 H, J = 8.5 Hz), 4.03, 3.96 (AB dq, 2 H, JAB = 10.9, 7.2 Hz), 3.73 (dt, 2 H, J = 
14.5, 7.1 Hz), 2.34 (td, 2 H, J = 6.8, 2.7 Hz), 2.06 (t, 1 H, J = 2.7 Hz), 1.97 (quint., 2 H, J = 6.9 
Hz), 1.00 (t, 3 H, J = 7.2 Hz); 13C NMR (CDCl3, 125 MHz) δ 165.2, 142.3, 138.3, 128.9, 128.7, 
127.6, 106.7, 82.6, 70.2, 60.5, 59.8, 49.2, 28.1, 15.6, 14.0; HRMS (ESI+) m/z calcd for 
C14H19N2O4S [M+H]
+ 311.1066, found 311.1069. 
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2-97 
Ethyl 2-methyl-6-(pent-4-yn-1-yl)-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-
carboxylate 1,1-dioxide (2-97).  To a suspension of thiadiazine 2-96 (1.009 g, 2.895 mmol) and 
K2CO3 (1.208 g, 8.738 mmol) in MeCN (14 mL) was added iodomethane (0.450 mL, 7.23 
mmol) over 5 min. The solution was stirred at rt for 3.5 h. The reaction mixture was diluted with 
water (25 mL) and EtOAc (25 mL). The organic layer was separated and the aqueous layer was 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with sat. aq. 
Na2SO3 (1 x 20 mL), sat. aq. NaHCO3 (1 x 20 mL), and brine (1 x 20 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude mixture was purified by 
chromatography on SiO2 (1:9 to 2:8; EtOAc:hexanes) to give 2-97 (1.027 g, 98%) as a colorless 
oil:  IR (ATR) 3286, 1692, 1622, 1366, 1161 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.57 (s, 1 H), 
7.33-7.26 (m, 5 H), 5.46 (s, 1 H), 4.16, 4.10 (AB dq, 2 H, JAB = 10.9, 7.2 Hz), 3.77, 3.70 (AB dt, 
2 H, JAB = 14.7, 6.3 Hz), 2.32 (dt, 2 H, J = 6.7, 2.6 Hz), 2.07 (t, 1 H, J = 2.4 Hz), 2.01-1.88 (m, 2 
H), 1.15 (t, 3 H, J = 7.2 Hz); 13C NMR (CDCl3, 125 MHz) δ 166.0, 141.3, 138.0, 128.1, 128.0, 
127.8, 102.2, 82.4, 70.2, 66.4, 60.7, 49.5, 39.6, 28.5, 15.5, 14.3; HRMS (ESI+) m/z calcd for 
C18H23N2O4S [M+H]
+ 363.1379, found 363.1400. 
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2-98 
2-Methyl-6-(pent-4-yn-1-yl)-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-carboxylic 
acid 1,1-dioxide (2-98).  To a solution of dialkylated thiadiazine 2-97 (0.9339 g, 2.577 mmol) in 
EtOH (3.5 mL) and THF (3 mL) was added in one portion 2 M KOH (13.0 mL, 26.0 mmol).  
The reaction mixture was warmed to 85 °C and stirred for 3.5 h.  The reaction mixture was 
cooled to rt and extracted with Et2O (1 x 20 mL). The organic layer was extracted with 2 M 
KOH (1 x 20 mL).  The aqueous layer was cooled in an ice bath and acidified with conc. aq. HCl 
(~6 mL).  A colorless precipitate formed and the slurry was extracted with Et2O (3 x 20 mL).  
The combined organic layers were washed with brine (1 x 10 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure to give acid 2-98 (0.7386, 86%) as a light yellow solid:  Mp 
152.5-153.8 C (dec., Et2O); IR (ATR) 3292, 2930, 2554, 1663, 1616, 1165 cm
-1; 1H NMR 
(CDCl3, 500 MHz) δ 7.69 (s, 1 H), 7.34-7.26 (m, 5 H), 5.41 (s, 1 H), 3.82-3.75 (m, 1 H), 3.74-
3.67 (m, 1 H), 2.94 (s, 3 H), 2.30 (dt, 2 H, J = 6.8, 2.6 Hz), 2.07 (t, 1 H, J = 2.6 Hz), 1.99-1.85 
(m, 2 H); 13C NMR (CDCl3, 125 MHz) δ 171.6, 143.7, 137.7, 128.2, 128.1, 127.7, 99.9, 82.2, 
70.5, 66.1, 49.9, 40.2, 28.4, 15.4; HRMS (ESI+) m/z calcd for C16H19N2O4S [M+H]
+ 335.1066, 
found 335.1064. 
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2-99 
N-Methoxy-N,2-dimethyl-6-(pent-4-yn-1-yl)-3-phenyl-3,6-dihydro-2H-1,2,6-
thiadiazine-4-carboxamide 1,1-dioxide (2-99).  To a solution of acid 2-98 (0.3432 g, 1.026 
mmol), dimethylhydroxylamine hydrochloride (0.1326 g, 1.359 mmol), PyBOP (0.6440 g, 1.238 
mmol) in CH2Cl2 (2.9 mL) cooled to 0 °C was added DIPEA (0.625 mL, 3.59 mmol).  The 
reaction mixture was slowly warmed to rt, stirred for 23 h, and diluted with EtOAc (15 mL) and 
water (15 mL).  The aqueous layer was separated and extracted with EtOAc (3 x 10 mL).  The 
organic layers were combined, washed with 1 M NaHSO4 (2 x 10 mL), sat. aq. NaHCO3 (1 x 20 
mL), and brine (1 x 20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure.  
The crude residue was purified by chromatography on SiO2 (2:8 to 1:1; EtOAc:hexanes) to give 
a light yellow oil.  The oil was dissolved in CHCl3 and concentrated under reduced pressure (3 x 
10 mL) to give the Weinreb amide 2-99 (0.3548 g, 92%) as a light yellow oil:  IR (ATR) 3284, 
2934, 1635, 1631, 1359, 1158 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.37-7.29 (m, 5 H), 7.10 (d, 1 
H, J = 1.6 Hz), 5.91 (d, 1 H, J = 1.5 Hz), 3.73, 3.68 (AB dt, 2 H, JAB = 14.5, 7.1 Hz), 356 (s, 3 
H), 2.99 (s, 3 H), 2.46 (s, 3 H), 2.32 (dt, 2 H, J = 6.8, 2.6 Hz), 2.03 (t, 1 H, J = 2.6 Hz), 1.95 
(pentet, 2 H, J = 6.9 Hz); 13C NMR (CDCl3, 125 MHz) δ 167.6, 138.3, 136.1, 129.1, 128.6, 
128.5, 107.9, 82.5, 70.1, 65.8, 61.1, 49.2, 34.3, 33.3, 28.6, 15.5; HRMS (ESI+) m/z calcd for 
C18H24N3O4S [M+H]
+ 378.1488, found 378.1501. 
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2-100 
2-Methyl-6-(pent-4-yn-1-yl)-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine-4-
carbaldehyde 1,1-dioxide (2-100). To a solution of Weinreb amide 2-99 (0.7689 g, 2.037 
mmol) in THF (13.5 mL) cooled to -78 °C was added dropwise LiAlH4 (1 M in Et2O, 4.20 mL, 
4.20 mmol) over 5 min.  The reaction mixture was stirred for 2 h at -78 °C.  The reaction mixture 
was warmed to 0 °C for 15 min, diluted with Et2O (20 mL), and quenched with water (5 mL).  
The aqueous layer was diluted with water (30 mL), acidified with 1 M HCl (~10 mL), the layers 
were separated, and the aqueous layer was extracted with Et2O (2 x 20 mL), CH2Cl2 (1 x 20 mL), 
and EtOAc (1 x 20 mL).  The combined organic layers were washed with brine (1 x 10 mL), 
diluted with EtOAc (~40 mL), dried (MgSO4), filtered, and concentrated under reduced pressure.  
The crude solid was purified by chromatography on SiO2 (2:8 to 6:4; EtOAc:hexanes) to give the 
desired aldehyde 2-100 (0.4899 g, 76%) as a colorless foam:  IR (ATR) 3239, 2936, 1663, 1618, 
1353, 1338, 1161 cm-1; 1H NMR (CDCl3, 400 MHz) δ 9.39 (s, 1 H), 7.34-7.25 (m, 6 H), 5.51 (s, 
1 H), 3.88, 3.79 (AB dt, 2 H, JAB = 14.6, 7.3 Hz), 2.91 (s, 3 H), 2.35 (dt, 2 H, J = 6.4, 2.6 Hz), 
2.10 (t, 1 H, J = 2.6 Hz), 2.04-1.91 (m, 2 H); 13C NMR (CDCl3, 100 MHz) δ 187.8, 149.8, 136.4, 
128.27, 128.25, 127.7, 113.6, 82.3, 70.7, 64.8, 50.0, 39.8, 28.2, 15.3; HRMS (ASAP+) m/z calcd 
for C16H19N2O3S [M+H]
+ 319.1119, found 319.1117. 
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2-101 
(E)-4-((2,2-Dimethylhydrazono)methyl)-2-methyl-6-(pent-4-yn-1-yl)-3-phenyl-3,6-
dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (2-101).  To a suspension of aldehyde 2-100 (0.3040 
g, 0.9548 mmol) in benzene (2.35 mL) was added PTS (0.0186 g, 0.0978 mmol) and 1,1-
dimethylhydrazine (0.110 mL, 1.45 mmol).  The aldehyde did not dissolve and CH2Cl2 (1 mL) 
was added to increase solubility.  The reaction mixture was stirred at rt for 14 h, heated to 65 °C 
for 2 h, then the reaction flask was equipped with a dean-stark trap, heated at reflux for 1.5 h, 
treated with powdered 4A MS (200 mg), and stirred for 2.5 h at 85 °C.  The reaction was 
incomplete and treated with PTS (0.0228 g, 1.20 mmol) and 1,1-dimethylhydrazine (0.110 mL, 
1.45 mmol), heated to 80 °C for 3 h, cooled to rt, diluted with CH2Cl2 (10 mL), filtered, and 
washed with water (1 x 10 mL).  The aqueous layer was extracted with CH2Cl2 (3 x 5 mL).  The 
combined organic layers were washed with brine (1 x 10 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure to give hydrazone 2-101 (0.2020 g, 59%) as a light yellow 
oil:  IR (ATR) 3284, 2952, 1631, 1448, 1351, 1161, 1016 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
7.34-7.20 (m, 5 H), 6.92 (s, 1 H), 6.43 (s, 1 H), 5.42 (s, 1 H), 3.63 (t, 2 H, J = 6.9 Hz), 2.87 (s, 3 
H), 2.65 (s, 6 H), 2.32 (dt, 2 H, J = 6.8, 2.5 Hz), 2.04 (t, 1 H, J = 2.6 Hz), 1.93 (pentet, 2 H, J = 
6.9 Hz); 13C NMR (CDCl3, 100 MHz) δ 138.4, 132.2, 130.7, 128.5, 127.7, 127.3, 113.1, 83.0, 
69.8, 66.7, 48.7, 43.0, 39.1, 28.3, 15.6; HRMS (ESI+) m/z calcd for C18H24N4O2S [M+H]
+ 
361.1698, found 361.1722. 
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4.4 CHAPTER 3 EXPERIMENTAL PART 
General Notes for Equilibrium Experiments by 1H NMR: 
 All experiments were performed with a delay time (d1) of 5 s and the spin off on 
a Bruker Avance 500 mHz NMR.  Samples were auto tuned and matched (atma), auto shimmed 
(topshim), and calibrated to CD2Cl2 (δ 5.32).  Each sample was analyzed three consecutive times 
at each time point to account for variations due to manual integration. 
 
Experimental set up for equilibrium study for enone 3-98 and thiophenyl adduct 3-
104. 
 
Reaction Base ΔG 
3-98 to 3-104 Et3N ≤ −4.6 kcal/mol 
3-98 to 3-104 DBU ≤ −4.6 kcal/mol 
3-104to 3-98 Et3N +1.8 ± 0.03 kcal/mol 
3-104to 3-98 DBU ≤ −3.8 kcal/mol 
 
For 3-98 to 3-104 using Et3N as a base: 
To a solution of enone 3-98 (0.0290 g, 0.0840 mmol) in CD2Cl2 (0.75 mL) was added 
thiophenol (10.0 μL, 96.6 μmol) and Et3N (1.0 μL, 8.5 μmol).  The solution was transferred to an 
 148 
NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 
1H NMR at 12, 23, and 38 h while monitoring the ratio of 3-98 (δ 5.95 (dd)) and 3-104 (minor 
diastereomer: δ 4.29 (app. t); 4.22 (app. t), major diastereomer:  δ 4.17 (dd)). The ratio of 3-
104:3-98 was > 50:1.  Keq = ≥ 2.6 x 10
3 and ΔG = ≤ −4.6 kcal/mol.  The dr of 3-104 was 
observed to be 2.7 to 1 (3-104a to 3-104b) from the peaks for minor diastereomer: δ 4.29 (app. t, 
0.5 H); 4.22 (app. t, 0.5 H), major diastereomer:  δ 4.17 (dd, 1 H). 
 
For 3-98 to 3-104 using DBU as a base: 
To a solution of enone 3-98 (0.0290 g, 0.0840 mmol) in CD2Cl2 (0.75 mL) was added 
thiophenol (10.0 μL, 96.6 μmol) and Et3N (1.0 μL, 6.7 μmol).  The solution was transferred to an 
NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 
1H NMR at 10 and 23 h while monitoring the ratio of 3-98 (δ 5.95 (dd)) and 3-104 (minor 
diastereomer: δ 4.30 (app. t); 4.23 (app. t), major diastereomer:  δ 4.18 (m)). The ratio of 3-
104:3-98 was > 50:1.  Keq = ≥ 2.6 x 10
3 and ΔG = ≤ −4.6 kcal/mol.  The dr of 6 was observed to 
be 1.6 to 1 (3-104a to 3-104b) from the peaks for minor diastereomer: δ 4.30 (app. t, 0.5 H); 4.23 
(app. t, 0.5 H), major diastereomer:  δ 4.18 (m, 1 H). 
 
For 3-104 to 3-98 using Et3N as a base: 
To a solution of thiophenol adduct 3-104 (0.0128 g, 0.0281 mmol) in CD2Cl2 (0.75 mL) 
was added Et3N (4.2 μL, 3.0 μmol).  The solution was transferred to an NMR tube, flushed with 
argon, capped, and sealed with parafilm.  The solution was analyzed by 1H NMR at 10, 24, and 
30 h while monitoring the ratio of 3-104 (minor diastereomer: δ 4.29 (app. t); 4.22 (app. t), major 
diastereomer:  δ 4.17 (dd)) to 3-98 (δ 5.95 (dd)).  The ratio of 3-98:3-104 was 1:4.3.  Keq = 5.0 ± 
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0.2 x 10-2 and ΔG = 1.8 ± 0.03 kcal/mol.  The dr of 3-104 was observed to be 1.8 to 1 (3-104a to 
3-104b) from the peaks for minor diastereomer: δ 4.29 (app. t, 0.5 H); 4.22 (app. t, 0.5 H), major 
diastereomer:  δ 4.17 (dd, 1 H). 
 
For 3-104 to 3-98 using DBU as a base: 
To a solution of thiophenol adduct 3-104 (0.0128 g, 0.0281 mmol) in CD2Cl2 (0.75 mL) 
was added DBU (4.5 μL, 3.0 μmol).  The solution was transferred to an NMR tube, flushed with 
argon, capped, and sealed with parafilm.  The solution was analyzed by 1H NMR at 10, 24, and 
30 h while monitoring the ratio of 3-104 (minor diastereomer: δ 4.30 (app. t); 4.23 (app. t), major 
diastereomer:  δ 4.18 (m)) to 3-98 (δ 5.95 (dd)).  The ratio of 3-98:3-104 was > 50:1.  Keq = ≥ 6.3 
x 102 and ΔG = ≤ −3.8 kcal/mol. 
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Experimental set up for equilibrium study for enone 3-99 and thiophenyl adduct 3-
105. 
 
Reaction Base ΔG 
3-99 to 3-105 Et3N −4.1 ± 0.06 kcal/mol 
3-99 to 3-105 DBU −4.0 ± 0.02 kcal/mol 
3-105 to 3-99 Et3N +1.0 ± 0.001 kcal/mol 
3-105 to 3-99 DBU ≤ −3.8 kcal/mol 
 
For 3-99 to 3-105 using Et3N as a base: 
To a solution of enone 3-99 (0.0247 g, 0.0550 mmol) in CD2Cl2 (0.3 mL) was added 
thiophenol (0.100 mL, 0.0633 mmol, 0.633 M in CD2Cl2) and Et3N (0.10 mL, 5.0 μmol, 0.050 M 
in CD2Cl2).  The solution was transferred to a J-Young NMR tube, flushed with argon, and 
sealed.  The solution was analyzed by 1H NMR for 13 d while monitoring the ratio of 3-99 (δ 
6.10 (app t, 1 H)) and 3-105 (minor diastereomer: δ 7.99-7.95 (m, 2 H); major diastereomer: 
7.71-7.67 (m, 2 H)). After 150 h the ratio of 3-105:3-99 was 22:1.  Keq = 1.0 ± 0.09 x 10
3 and ΔG 
= −4.1 ± 0.06 kcal/mol.  The dr of 3-105 was observed to be 2.6 to 1 from the peaks for minor 
diastereomer: δ 7.99-7.95 (m, 2 H), major diastereomer:  δ 7.71-7.67 (m, 2 H).  The relative 
stereochemistry of the diastereomers could not be determined. 
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For 3-99 to 3-105 using DBU as a base: 
To a solution of enone 3-99 (0.0247 g, 0.0550 mmol) in CD2Cl2 (0.3 mL) was added 
thiophenol (0.100 mL, 0.0633 mmol, 0.633 M in CD2Cl2) and DBU (0.10 mL, 5.0 μmol, 0.050 
M in CD2Cl2).  The solution was transferred to a J-Young NMR tube, flushed with argon, and 
sealed.  The solution was analyzed by 1H NMR for 14 d while monitoring the ratio of 7 (δ 6.10 
(app t, 1 H)) and 3-105 (minor diastereomer: δ 7.99-7.95 (m, 2 H); major diastereomer: 7.71-7.67 
(m, 2 H)). After 150 h the ratio of 3-105:3-99 was 21:1.  Keq = 9.1 ± 0.3 x 10
2 and ΔG = −4.0 ± 
0.02 kcal/mol.  The dr of 3-105 was observed to be 2.1 to 1 from the peaks for minor 
diastereomer: δ 7.99-7.95 (m, 2 H), major diastereomer:  δ 7.71-7.67 (m, 2 H).  The relative 
stereochemistry of the diastereomers could not be determined. 
 
For 3-105 to 3-99 using Et3N as a base: 
To a solution of the major diastereomer of the thiophenol adduct 3-105 (0.0157 g, 0.0280 
mmol) in CD2Cl2 (0.75 mL) was added Et3N (4.2 μL, 3.0 μmol).  The solution was transferred to 
an NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed 
by 1H NMR at 24 h while monitoring the ratio of 3-105 (minor diastereomer: δ 7.98-7.94 (m, 2 
H); major diastereomer: 7.71-7.67 (m, 2 H)) to 7 (δ 6.10 (app. t)).  The ratio of 3-99:3-105 was 
1:2.3.  Keq = 1.8 ± 0.004 x 10
-1 and ΔG = 1.0 ± 0.001 kcal/mol.  The dr of 3-105 was observed to 
be 6.7:1 from the peaks for minor diastereomer: δ 7.98-7.94 (m, 2 H); major diastereomer: 7.71-
7.67 (m, 2 H). 
 
For 3-105 to 3-99 using DBU as a base: 
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To a solution of the major diastereomer of the thiophenol adduct 3-105 (0.0126 g, 0.0225 
mmol) in CD2Cl2 (0.6 mL) was added DBU (3.5 μL, 2.4 μmol).  The solution was transferred to 
an NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed 
by 1H NMR at 8 and 22 h while monitoring the ratio of 3-105 (minor diastereomer: δ 7.98-7.94 
(m, 2 H); major diastereomer: 7.71-7.67 (m, 2 H)) to 7 (δ 6.10 (app. t)).  The ratio of 3-99:3-105 
was ≥ 50:1.  Keq = ≥ 6.1 x 10
2 and ΔG = ≤ −3.8 kcal/mol. 
 
Experimental set up for equilibrium study for enone 3-92 and thiophenyl adduct 3-
93. 
 
Reaction Base ΔG 
3-92 to 3-93 Et3N ≤ −4.6 kcal/mol 
3-92 to 3-93 DBU ≤ −4.6 kcal/mol 
3-93b to 3-92 Et3N +3.4 ± 0.1 kcal/mol 
3-93b to 3-92 DBU ≤ −2.6 kcal/mol 
 
For 3-92 to 3-93 using Et3N as a base: 
To a solution of enone 3-92 (0.012 g, 0.0485 mmol) in CD2Cl2 (0.45 mL) was added 
thiophenol (5.7 μL, 55.8 μmol) and Et3N (0.61 μL, 4.4 μmol).  The solution was transferred to an 
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NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 
1H NMR at 6, 10, and 22 h while monitoring the ratio of 3-92 (δ 6.96 (d)) and 3-93 (δ 5.70-5.62 
(m)).  The ratio of 3-93:3-92was > 50:1.  Keq = ≥ 2.8 x 10
3 and ΔG = ≤ −4.6 kcal/mol.  The dr of 
3-93 was observed to be 3.8 to 1 (3-93a to 3-93b) from the methyl ester peaks at δ 3.70 (s) and 
3.68 (s). 
 
For 3-92 to 3-93 using DBU as a base: 
To a solution of enone 3-92 (0.0120 g, 0.0485 mmol) in CD2Cl2 (0.45 mL) was added 
thiophenol (5.7 μL, 55.8 μmol) and DBU (0.65 μL, 4.4 μmol).  The solution was transferred to 
an NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed 
by 1H NMR at 6, 10, and 22 h while monitoring the ratio of 3-92 (δ 6.96 (d)) and 3-93 (δ 5.70-
5.62 (m)).  The ratio of 3-93:3-92was < 50:1.  Keq = ≥ 2.8 x 10
3 and ΔG = ≤ −4.6 kcal/mol.  The 
dr of 3-93 was observed to be 2.7 to 1 (3-93a to 3-93b) from the methyl ester peaks at δ 3.70 (s) 
and 3.68 (s). 
 
For 3-93b to 3-92 using Et3N as a base: 
To a solution of ketone 3-93b (0.0060 g, 0.017 mmol, minor diastereomer 3-93b) in 
CD2Cl2 (0.45 mL) was added Et3N (2.5 μL, 0.018 mmol).  The solution was transferred to an 
NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 
1H NMR at 19 and 24 h while monitoring the ratio of 3-93b (δ 5.70-5.62 (m)) and 3-92 (δ 6.98 
(dd)).  The ratio of 3-92: 3-93b was 1:17.1.  Keq = 3.3 ± 0.7 x 10
-3 and ΔG = +3.4 ± 0.1 kcal/mol.  
The dr of 3-93 was observed as a single diastereomer (3-93b). 
 
 154 
For 3-93b to 3-92 using DBU as a base: 
To a solution of ketone 3-93b (0.0083 g, 0.023 mmol, minor diastereomer 3-93b) in 
CD2Cl2 (0.620 mL) was added DBU (3.7 μL, 0.025 mmol).  The solution was transferred to an 
NMR tube, flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 
1H NMR at 19 and 24 h while monitoring the ratio of 3-93b (δ 5.70-5.62 (m)) and 3-92 (δ 5.76-
5.71 (m)).  The ratio of 3-92:3-93b was >12.4:1.  Keq = ≥ 84 and ΔG = ≤ − 2.6 kcal/mol. 
 
Experimental set up for equilibrium study for enone 3-95 and thiophenyl adduct 3-
94. 
 
 
Reaction Base ΔG 
3-95 to 3-94 Et3N ≤ −4.6 kcal/mol 
3-95 to 3-94 DBU ≤ −4.6 kcal/mol 
3-94a to 3-95 Et3N +2.3 ± 0.03 kcal/mol 
3-94b to 3-95 DBU −2.9 ± 0.2 kcal/mola 
aduring reaction 3-94 to 3-95 with DBU enone 3-95 is 
observed as a 2.5:1 mixture of diastereomers (epimerization 
α to ketone). 
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For 3-95 to 3-94 using Et3N as a base: 
To a solution of enone 3-95 (0.0133 g, 0.0533 mmol) in CD2Cl2 (0.3 mL) was added 
thiophenol (0.100 mL, 61.3 μmol, 0.613 M in CD2Cl2) and Et3N (0.100 mL, 4.80 μmol, 0.0480 
M in CD2Cl2).  The solution was transferred to an NMR tube, flushed with argon, capped, and 
sealed with parafilm.  The solution was analyzed by 1H NMR at 9 and 22 h while monitoring the 
ratio of 3-95 (δ 5.91 (dd)) and 3-94 (δ 4.02 (dd, major diastereomer) and 3.98 (dd, minor 
diastereomer).  The ratio of 3-94:3-95 was > 50:1.  Keq = ≥ 2.8 x 10
3 and ΔG = ≤ −4.6 kcal/mol.  
The dr of 3-94 was observed to be 3.6 to 1 from the peaks at δ 4.02 (dd) and 3.98 (dd). 
 
For 3-95 to 3-94 using DBU as a base: 
To a solution of enone 3-95 (0.0133 g, 0.0533 mmol) in CD2Cl2 (0.3 mL) was added 
thiophenol (0.100 mL, 61.3 μmol, 0.613 M in CD2Cl2) and DBU (0.100 mL, 4.80 μmol, 0.0480 
M in CD2Cl2).  The solution was transferred to an NMR tube, flushed with argon, capped, and 
sealed with parafilm.  The solution was analyzed by 1H NMR at 12 and 22 h while monitoring 
the ratio of 3-95 (δ 5.91 (dd)) and 3-94 (δ 4.02 (dd, major diastereomer) and 3.98 (dd, minor 
diastereomer).  The ratio of 3-94:3-95 was > 50:1.  Keq = ≥ 2.8 x 10
3 and ΔG = ≤ −4.6 kcal/mol.  
The dr of 3-94 was observed to be 3.5 to 1 from the peaks at δ 4.02 (dd) and 3.98 (dd). 
 
For 3-94 to 3-95 using Et3N as a base: 
To a solution of ketone 3-94 (0.0083 g, 0.023 mmol, major diastereomer) in CD2Cl2 (0.6 
mL) was added Et3N (3.4 μL, 0.025 mmol).  The solution was transferred to an NMR tube, 
flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 1H NMR at 
23 h while monitoring the ratio of 3-94 (δ 4.02 (dd, major diastereomer) and 3.98 (dd, minor 
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diastereomer) and 3-95 (δ 3.89 (app. t)).  The ratio of 3-95: 3-94 was 1:6.7.  Keq = 2.1 ± 0.1 x 10
-
2 and ΔG = +2.3 ± 0.03 kcal/mol.  The dr of 3-94 shifted from a single isomer to a ratio of 3.1:1. 
 
For 3-94 to 3-95 using DBU as a base: 
To a solution of ketone 3-94 (0.0069 g, 0.019 mmol, minor diastereomer) in CD2Cl2 
(0.45 mL) was added DBU (3.0 μL, 0.020 mmol).  The solution was transferred to an NMR tube, 
flushed with argon, capped, and sealed with parafilm.  The solution was analyzed by 1H NMR at 
23 h while monitoring the ratio of 3-94 (δ 3.98 (app. t)) and 3-95 (δ 5.95 (dd) and 5.91 (dd) 
epimers).  The ratio of 3-95:3-94 was 15.8:1.  Keq = 140 ± 40 and ΔG = −2.9 ± 0.2 kcal/mol.  
During the reaction enone 3-95 was epimerized to a 2.5:1 mixture of diastereomers and the 
position alpha to the ester. 
 
 
3-98 
(2S,3aR,7aR)-1-Benzyl 2-methyl 3a-hydroxy-6-oxo-3,3a,7,7a-tetrahydro-1H-indole-
1,2(2H,6H)-dicarboxylate (3-98).169, 172 The enone 3-98 was prepared according to the literature 
to give 3-98 (11.04 g, 71%) as a pale orange foam:  1H NMR (CDCl3, 400 MHz, 1:2 mixture of 
rotamers) δ 7.39-7.26 (m, 5 H), 6.82 (d, 0.66 H, J = 10.3 Hz), 6.80 (d, 0.33 H, J = 10.3 Hz), 6.02 
(d, 0.33 H, J = 10.3 Hz), 6.01 (d, 0.66 H, J = 10.3 Hz), 5.21 (d, 1 H, J = 12.2 Hz), 5.10 (d, 0.66 
H, J = 12.2 Hz), 5.01 (d, 0.33 H, J = 12.1 Hz), 4.58-4.51 (m, 1.33 H), 4.48-4.42 (m, 0.66 H), 
3.85 (s, 2 H), 3.56 (s, 1 H), 3.27 (dd, 0.33 H, J = 16.6, 6.4 Hz), 3.05 (dd, 0.66 H, J = 16.6, 6.4 
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Hz), 2.60-2.50 (m, 1 H), 2.31 (d, 0.33 H, J = 14.2 Hz), 2.29 (d, 0.66 H, J = 14.3 Hz), 2.19 (d, 
0.66 H, J = 16.6 Hz), 2.16 (d, 0.33 H, J = 16.6 Hz). 
 
 
3-99 
(2S,3aR,7aR)-1-Benzyl 2-methyl 3a-(benzoyloxy)-6-oxo-3,3a,7,7a-tetrahydro-1H-
indole-1,2(2H,6H)-dicarboxylate (3-99).169 To solution of alcohol 3-98 (1.000 g, 2.896 mmol), 
benzoic anhydride (1.021 g, 4.513 mmol), and DMAP (0.0367 g, 0.300 mmol) in CH2Cl2 (14 
mL) was added pyridine (1.15 mL, 14.22 mmol).  The light yellow solution was heated to reflux 
for 17 h, treated with DMAP (44.3 mg, 0.363 mmol), and heated for 26 h.  The reaction was not 
complete yet and more DMAP (101.2 mg, 0.828 mmol) was added, the reaction was stirred at 
reflux for an additional 21 h, quenched with 10% aq. HCl (50 mL), and extracted with CHCl3 (3 
x 20 mL).  The combined organic layers were washed with 1 M HCl (2 x 50 mL), sat. aq. 
NaHCO3 (1 x 50 mL) and brine (1 x 50 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure.  The crude oil was purified by chromatography on SiO2 (1:4 to 2:3; 
EtOAc:hexanes) to give benzyolated compound 3-99 (0.9027 g, 69 %) as a colorless foam:  1H 
NMR (CD2Cl2, 500 MHz, 1:1 mixture of rotamers) δ 7.94-7.91 (m, 2 H), 7.63-7.58 (m, 1 H), 
7.48-7.44 (m, 2 H), 7.38-7.36 (m, 2 H), 7.36-7.39 (m, 3 H), 7.05 (d, 0.5 H, J = 10.5 Hz), 7.01 (d, 
0.5 H, J = 10.4 Hz), 6.10 (app t, 1 H, J = 10.6 Hz), 5.20 (AB d, 0.5 H, JAB = 12.3 Hz), 5.16 (AB 
d, 0.5 H, JAB = 12.4 Hz), 5.11 (AB d, 0.5 H, JAB = 12.4 Hz), 5.03 (AB d, 0.5 H, JAB = 12.7 Hz), 
5.01 (dt, 1 H, J = 10.1, 1.1 Hz), 4.72 (dd, 0.5 H, J = 9.8, 1.4 Hz), 4.66 (dd, 0.5 H, J = 9.5, 1.9 
Hz), 3.59 (s, 1.5 H), 3.40 (s, 1.5 H), 3.83 (ddd, 0.5 H, J = 16.8, 6.7, 0.6 Hz), 3.22 (ddd, 0.5 H, J = 
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16.7, 6.7, 0.7 Hz), 3.08 (dt, 0.5 H, J = 6.2, 1.5 Hz), 3.05 (dt, 0.5 H, J = 6.3, 1.6 Hz), 2.75 (dd, 0.5 
H, J = 14.3, 9.5 Hz), 2.69 (dd, 0.5 H, J = 14.5, 9.9 Hz), 2.50 (dd, 0.5 H, J = 16.7, 9.9 Hz), 2.42 
(dd, 0.5 H, J = 16.7, 10.4 Hz); 13C NMR (CDCl3, 100 MHz, 1:1 mixture of rotamers) δ 195.0, 
194.9, 171.4, 170.8, 165.5, 165.3, 154.2, 153.9, 145.0, 144.1, 136.1, 135.9, 133.9, 133.8, 130.3, 
130.0, 129.9, 129.8, 129.39, 129.36, 128.8, 128.6, 128.53, 128.45, 128.4, 128.3, 84.0, 82.8, 68.0, 
67.6, 62.0, 61.4, 58.6, 58.4, 52.7, 52.5, 42.9, 41.6, 39.6, 38.8. 
 
 
3-101 
(2S,7aR)-1-Benzyl 2-methyl 6-oxo-7,7a-dihydro-1H-indole-1,2(2H,6H)-dicarboxylate 
(3-101). To a suspension of diene 3-84 (0.8048 g, 2.444 mmol) and activated 4Å MS (0.850 g) in 
CH2Cl2 (10.4 mL) cooled to 0 °C was added NMO (0.4069 g, 3.011 mmol) and TPAP (0.0275 g, 
0.0783 mmol).  The black suspension was warmed to rt and stirred for 17.5 h.  By TLC the 
reaction was incomplete so NMO (0.0917 g, 0.678 mmol) was added, the reaction was stirred at 
rt for 26 h, filtered through a pad of SiO2, washed with EtOAc, and concentrated under reduced 
pressure.  The crude residue was purified by chromatography on SiO2 (1:4 to 1:3: 
EtOAc:hexanes) to give ketone 3-101 (0.5636 g, 67%) as a light yellow oil:  IR (ATR) 2952, 
1745, 1705, 1670, 1405, 1348, 1204 cm-1; 1H NMR (CDCl3, 400 MHz, 1:1 mixture of rotamers) 
δ 7.37-7.29 (m, 5 H), 7.20 (d, 1 H, J = 9.8 Hz), 7.19 (d, 1 H, J = 9.8 Hz), 6.09 (d, 0.5 H, J = 9.2 
Hz), 6.07 (d, 0.5 H, J = 9.2 Hz), 5.28-5.15 (m, 2.5 H), 5.12-4.98 (m, 1.5 Hz), 3.75 (s, 1.5 H), 
3.65 (dd, 0.5 H, J = 15.8, 5.7 Hz), 3.52 (s, 1.5 H), 3.40 (dd, 0.5 H, J = 15.8, 5.6 Hz), 2.49 (dd, 0.5 
H, J = 12.5, 3.1 Hz), 2.45 (dd, 0.5 H, J = 12.6, 3.2 Hz); 13C NMR (CDCl3, 100 MHz, 1:1 mixture 
of rotamers) δ 196.8, 196.7, 169.8, 169.6, 154.8, 154.0, 138.5, 138.4, 137.4, 136.9, 136.04, 
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135.99, 135.9, 131.5, 131.1, 128.7, 128.6, 128.5, 128.4, 128.32, 128.27, 122.8, 122.4, 68.7, 68.3, 
67.9, 67.4, 62.2, 61.4, 52.8, 52.6, 45.8, 44.9; HRMS (ESI+) m/z calcd for C18H17NO5Na [M+Na]
+ 
350.1004, found 350.0992. 
 
 
 3-104a 3-104b 
(2S,3aS,4S,7aR)-1-Benzyl 2-methyl 3a-hydroxy-6-oxo-4-(phenylthio)octahydro-1H-
indole-1,2-dicarboxylate (3-104a) and (2S,3aS,4R,7aR)-1-benzyl 2-methyl 3a-hydroxy-6-
oxo-4-(phenylthio)octahydro-1H-indole-1,2-dicarboxylate (3-104b).  To a round bottom flask 
was added enone 3-98 (0.150 g, 0.434 mmol) in CH2Cl2 (3.9 mL) was added thiophenol (0.051 
mL, 0.50 mmol) and Et3N (0.005 mL, 0.04 mmol) and stirred at rt for 16.5 h.  The crude reaction 
mixture was concentrated under reduced pressure and purified by chromatography on SiO2 (1:4 
to 1:2; EtOAc:hexanes) to give the thiol addition product 3-104a and 3-104b (0.1544 g, 79%) as 
a colorless foam and an inseparable 2.3:1 (3-104a:3-104b) mixture of diastereomers:  IR (ATR) 
3433, 3057, 2951, 1702, 1404, 1346, 1113, 736, 693 cm-1; 1H NMR (CD2Cl2, 300 MHz, 1:1 
mixture of rotamers, peaks for major diastereomer 3-104a) δ 7.52-7.45 (m, 2 H), 7.38-7.27 (m, 8 
H), 5.19 (m, 2 H), 5.01 (app d, 1 H, J = 12.3 Hz), 4.54-4.47 (m, 1 H), 4.16 (dd, 1 H, J = 11.8, 5.3 
Hz), 3.78 (s, 1.5 H), 3.61 (s, 1.5 H), 3.50 (dt, 1 H, J = 11.4, 4.2 Hz), 3.17 (dd, 0.5 H, J = 16.4, 5.3 
Hz), 3.00 (dd, 0.5 H, J = 16.4, 5.2 Hz), 2.71-2.45 (m, 3 H), 2.45-2.14 (m, 2 H); 13C NMR 
(CDCl3, 125 MHz, 1:1 mixture of rotamers, mixture of diastereomers) δ 206.9, 206.7, 205.6, 
204.8, 175.1, 174.7, 174.5, 174.2, 155.25, 154.86, 136.8, 136.7, 134.1, 134.0, 133.62, 133.51, 
133.3, 129.9, 129.7, 129.0, 128.9, 128.7, 128.50, 128.48, 81.2, 80.5, 80.1, 68.0, 67.9, 67.8, 65.9, 
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65.6, 65.2, 64.6, 60.8, 59.7, 59.6, 58.4, 58.3, 53.3, 53.1, 51.65, 51.4, 45.0, 44.9, 44.6, 44.0, 43.8, 
43.0, 42.9, 42.8, 42.2, 40.9, 37.2, 36.7; HRMS (ESI+) m/z calcd for C24H26NO6S [M+H]
+ 
456.1475, found 456.1568. 
 
 
3-105 
(2S,3aS,7aR)-1-Benzyl 2-methyl 3a-(benzoyloxy)-6-oxo-4-(phenylthio)octahydro-1H-
indole-1,2-dicarboxylate (3-105).  To a solution of enone 3-99 (0.0762 g, 0.170 mmol) and 
thiophenol (0.020 mL, 0.20 mmol) was added Et3N (0.0035 mL, 0.025 mmol) and stirred at rt for 
10 h.  The reaction mixture was concentrated under reduced pressure and purified by 
chromatography on SiO2 (1:4; 1:2; 2:3; EtOAc:hexanes) to give thiol addition product 3-105 as 
an unassigned mixture of diastereomers.  Major diastereomer (0.0597 g, 63 %) and minor 
diastereomer (0.0273 g, 29%, containing trace 3-99): Major diastereomer:  IR (ATR) 2951, 1746, 
1705, 1282, 1094 cm-1; 1H NMR (CDCl3, 400 MHz, 3:1 mixture of rotamers) δ 7.72-7.67 (m, 2 
H), 7.55-7.48 (m, 1 H), 7.38-7.27 (m, 9 H), 7.04-6.94 (m, 3 H), 5.18 (d, 0.75 H, J = 12.3 Hz), 
5.15 (d, 0.25 H, J = 14.4 Hz), 5.07 (dd, 0.75 H, J = 12.2, 6.2 Hz), 5.00-4.85 (m, 2.25 H), 4.68 (d, 
0.25 H, J = 8.9 Hz), 4.59 (d, 0.75 H, J = 9.0 Hz), 3.58, (s, 0.75 H), 3.30 (s, 2.25 H), 3.24 (app d, 
1.5 H, J = 4.5 Hz), 3.18 (dd, 0.25 H, J = 15.6, 6.5 Hz), 2.97 (app d, 0.25 H, J = 15.5 Hz), 2.92-
2.82 (m, 2 H), 2.67-2.57 (m, 1 H), 2.48-2.37 (m, 1 H); 13C NMR (CD2Cl2, 100 MHz, major 
rotamer) δ 206.0, 172.4, 166.2, 155.5, 136.8, 134.0, 133.9, 130.1, 129.6, 129.1, 129.0, 128.7, 
128.5, 90.4, 67.8, 63.9, 59.0, 52.8, 46.2, 43.4, 43.1, 37.1; HRMS (ESI+) m/z calcd for 
C31H29NO7SNa [M+Na]
+ 582.1557, found 582.1551. Minor diastereomer:  IR (ATR) 2951, 
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1752, 1705, 1702, 1405, 1277, 1245, 1094 cm-1; 1H NMR (CDCl3, 400 MHz, 3:2 mixture of 
rotamers) δ 7.99-7.94 (m, 2 H), 7.60-7.55 (m, 1 H), 7.47-7.34 (m, 7 H), 7.34-7.23 (m, 5 H), 5.27-
5.17 (m, 1.6 H), 5.06 (d, 0.4 H, J = 12.1 Hz), 4.96 (t, 0.6 H, J = 6.4 Hz), 4.86 (t, 0.4 H, J = 7.8 
Hz), 4.66-4.62 (m, 1.4 H), 4.57 (d, 0.6 H, J = 9.0 Hz), 4.49 (dd, 0.6 H, J = 16.8, 7.6 Hz), 3.33 (s, 
1.2 H), 3.30-3.25 (m, 1.4 H), 3.14 (s, 1.8 H), 2.87-2.78 (m, 1 H), 2.70-2.57 (m, 2.6 H), 2.40 (dd, 
0.4 H, J = 16.6, 7.4 Hz); 13C NMR (CD2Cl2, 100 MHz, 3:2 mixture of rotamers) δ 205.6, 204.9, 
171.9, 171.3, 166.1, 166.0, 154.8, 154.7, 136.9, 134.5, 134.4, 134.1, 133.0, 132.7, 130.5, 130.4, 
130.3, 129.9, 129.1, 129.0, 128.8, 128.63, 128.57, 89.0, 88.2, 68.1, 67.8, 62.4, 61.6, 58.6, 58.4, 
52.7, 49.5, 49.3, 45.1, 43.8, 42.5, 38.3, 37.0; HRMS (ESI+) m/z calcd for C31H29NO7SNa 
[M+Na]+ 582.1557, found 582.1553. 
 
 
3-92 
(2S,31S,7aS,10aR)-Methyl 8-oxo-1,2,31,4,7,7a,8,10a-octahydroazepino[3,2,1-
hi]indole-2-carboxylate (3-92).169 The enone 3-92 was prepared according to the literature to 
give enone 3-92 as a light yellow oil:  1H NMR (CDCl3, 400 MHz) δ 6.98 (dd, 1 H, J = 9.8, 1.9 
Hz), 5.99 (dd, 1 H, J = 9.8, 2.9 Hz), 5.80-5.74 (m, 1 H), 5.59 (ddd, 1 H, J = 8.4, 5.2, 2.3 Hz), 
4.01 (dd, 1 H, J = 8.4, 6.0 Hz), 3.71 (s, 3 H), 3.62-3.55 (m, 2 H), 3.30 (dd, 1 H, J = 17.6, 6.0 Hz), 
2.94 (ddd, 1 H, J = 12.4, 7.2, 2.0 Hz), 2.78-2.69 (m, 1 H), 2.60 (dt, 1 H, J = 12.3, 8.3 Hz), 2.59-
2.51 (m, 1 H), 2.18 (dd, 1 H, J = 16.2, 8.1 Hz), 1.81 (td, 1 H, J = 11.8, 5.9 Hz); 13C NMR 
(CD2Cl2, 125 MHz) δ 200.7, 174.4, 148.5, 130.5, 129.5, 128.6, 65.2, 63.2, 51.4, 50.4, 47.4, 37.2, 
32.2, 24.2. 
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 3-93a 3-93b 
(2S,31R,7aS,10R,10aS)-Methyl 8-oxo-10-(phenylthio)-1,2,31,4,7,7a,8,9,10,10a-
decahydroazepino[3,2,1-hi]indole-2-carboxylate (3-93a) and (2S,31R,7aS,10S,10aS)-methyl 
8-oxo-10-(phenylthio)-1,2,31,4,7,7a,8,9,10,10a-decahydroazepino[3,2,1-hi]indole-2-
carboxylate (3-93b).  To a solution of enone 3-92 (0.0604 g, 0.244 mmol) in CH2Cl2 (2.2 mL) 
was added thiophenol (29.0 μL, 0.283 mmol) and Et3N (5.5 μL, 39 μmol).  The solution was 
stirred at rt for 3 h, concentrated under reduced pressure and purified by chromatography on SiO2 
(0:1; 5:95; 1:9; 1:4; to 1:1; EtOAc:hexanes) to the major diastereomer 3-93a (0.0553 g, 63%) as 
a colorless solid and the minor diastereomer 3-93b (0.0198 g, 23%) as a light yellow oil:  Major 
diastereomer 3-93a:  Mp 142.5-143.6 °C (dec., CHCl3); IR (ATR) 3014, 2962, 2898, 2811, 1728, 
1694, 1193, 1152, 734 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.39-7.36 (m, 2 H), 7.31-7.28 (m, 2 
H), 7.26-7.23 (m, 1 H), 5.72-5.66 (m, 1 H), 5.57-5.52 (m, 1 H), 4.04 (dd, 1 H, J = 8.9, 5.1 Hz), 
3.83 (dd, 1 H, J = 10.8, 7.4 Hz), 3.78-3.70 (m, 1 H), 3.74 (s, 3 H), 3.62-3.55 (m, 1 H), 3.32 (ddt, 
1 H, J = 17.8, 5.8, 1.8 Hz), 2.95 (dd, 1 H, J = 11.6, 7.4 Hz), 2.69 (ddd, 1 H, J = 16.2, 3.3, 0.9 
Hz), 2.65-2.58 (m, 1 H), 2.61 (dd, 1 H, J = 16.1 , 5.7 Hz), 2.52 (tdd, 1 H, J = 10.4, 8.4, 3.9 Hz), 
2.41 (dt, 1 H J = 12.9, 8.7 Hz), 2.24 (ddd, 1 H, J = 12.9, 10.2, 5.0 Hz), 2.03 (dd, 1 H, J = 15.6, 
8.4 Hz); 13C NMR (CDCl3, 125 MHz) δ 210.8, 174.5, 134.6, 132.3, 129.7, 129.3, 127.9, 127.5, 
63.9, 61.2, 54.4, 51.7, 48.5, 46.0, 44.7, 42.3, 30.5, 25.9; HRMS (ESI+) m/z calcd for C20H24NO3S 
[M+H]+ 358.1471, found 358.1461.  Minor diastereomer 3-93b:  IR (ATR) 3018, 2947, 2915, 
1728, 1702, 1437, 1199 cm-1; 1H NMR (CD2Cl2, 500 MHz) δ 7.44 (dd, 2 H, J = 8.1, 1.6 Hz), 
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7.36-7.29 (m, 3 H), 5.65 (ddd, 1 H, J = 10.1, 10.1, 1.1 Hz), 5.52 (m, 1 H), 3.98 (dd, 1 H, J = 8.9, 
5.4 Hz), 3.68 (s, 3 H), 3.51 (m, 1 H), 3.47 (dd, 1 H, J = 10.1, 7.6 Hz), 3.34-3.24 (m, 2 H), 2.80 
(dd, 1 H, J = 11.7, 7.6 Hz), 2.75 (dd, 1 H, J = 16.5, 5.9 Hz), 2.64 (dt, 1 H, J = 13.2, 8.3 Hz), 
2.53-2.44 (m, 1 H), 2.33 (dd, 1 H, J = 16.4, 9.5 Hz), 2.05-1.94 (m, 2 H), 1.74 (ddd, 1 H, J = 13.1, 
10.3, 5.3 Hz); 13C NMR (CD2Cl2, 125 MHz) δ 200.1, 164.5, 123.4, 122.6, 119.5, 119.1, 117.9, 
117.8, 54.8, 53.4, 43.6, 41.4, 38.2, 36.9, 35.4, 33.6, 23.0, 15.7; HRMS (ESI+) m/z calcd for 
C20H24NO3S [M+H]
+ 358.1471, found 358.1459. 
 
 
3-94a 
(2S,31R,7aS,10R,10aS)-Methyl 8-oxo-10-(phenylthio)dodecahydroazepino[3,2,1-
hi]indole-2-carboxylate (3-94a).169 To a solution of thioether 3-93a (0.0553 g, 0.155 mmol) in 
CH2Cl2:EtOH (1:4; 4.3 mL) was added Wilkinson's catalyst (0.0317 g, 0.0343 mmol).  The 
suspension was stirred under an atmosphere of H2 (Balloon) at rt for 14 h and concentrated under 
reduced pressure to give red oil.  The crude oil was purified by chromatography on SiO2 (0:1; 
5:95; 1:9: 15:85; 1:4; EtOAc:hexanes) to give 3-94a (34.2 mg, 62%) as a light red-orange solid:  
Mp 135.3-136.4 °C (dec., CHCl3); IR (ATR) 2917, 2902, 2820, 2848, 1726, 1689, 1431, 1202, 
1167, 749, 695 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.36 (d, 2 H, J = 7.4 Hz), 7.28 (d, 2 H, J = 
7.2 Hz), 7.22 (app. t, 1 H, J = 7.3 Hz), 4.03 (dd, 1 H, J = 8.1, 6.5 Hz), 3.79 (dd, 1 H, J = 10.9, 7.4 
Hz), 3.72 (s, 3 H), 3.74-3.68 (m, 1 H), 2.85 (dt, 1 H, J = 14.7, 3.2 Hz), 2.81-2.76 (m, 1 H), 2.66 
(dd, 1 H, J = 11.3, 7.8 Hz), 2.63-2.57 (m, 2 H), 2.42 (ddt, 1 H, J = 11.0, 7.8, 3.8 Hz), 2.33 (dt, 1 
H, J = 12.5, 8.0 Hz), 2.15 (ddd, 1 H, J = 12.3, 10.8, 6.3 Hz), 1.96-1.89 (m, 1 H), 1.79-1.70 (m, 1 
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H), 1.67-1.57 (m, 2 H), 1.46-1.37 (m, 1 H), 1.32-1.22 (m, 1 H); 13C NMR (CDCl3, 125 MHz) δ 
211.7, 175.4, 134.7, 132.2, 129.2, 127.4, 63.7, 61.2, 56.4, 51.7, 47.5, 45.8, 45.0, 42.6, 30.9, 
30.41, 3.38, 27.0, ; HRMS (ESI+) m/z calcd for C20H26NO3S [M+H]
+ 360.1628, found 360.1612. 
 
 
3-95 
(2S,31S,7aS,10aR)-Methyl 8-oxo-1,2,31,4,5,6,7,7a,8,10a-decahydroazepino[3,2,1-
hi]indole-2-carboxylate (3-95).169 To a solution of ketone 3-94a (0.0219 g, 0.0610 mmol) in 
CH2Cl2 (1.85 mL) was added DBU (10.0 μL, 0.0669 mmol).  The solution placed under an Ar 
atmosphere, stirred at rt for 2 h, concentrated under reduced pressure, and purified by 
chromatography on SiO2 (1:9 to 2:3; EtOAc:hexanes) to give enone 3-95 (9.5 mg, 63%) as a 
light yellow oil:  1H NMR (CD2Cl2, 400 MHz) δ 6.96 (d, 1 H, J = 9.7 Hz), 5.91 (dd, 1 H, J = 9.7, 
2.2 Hz), 3.89 (app. t, 1 H, J = 7.9 Hz), 3.68 (s, 3 H), 3.50 (dd, 1 H, J = 10.0, 6.1 Hz), 2.94-2.78 
(m, 2 H), 2.72-2.63 (m, 2 H), 2.52 (dt, 1 H, J = 11.8, 7.2 Hz), 1.97-1.91 (m, 1 H), 1.79-1.66 (m, 3 
H), 1.64-1.56 (m, 1 H), 1.52-1.40 (m, 1 H), 1.39-1.27 (m, 1 H). 
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